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Abstract 
Acute lung injury (ALI) is a severe inflammatory lung disease with high mortality.  
Previous studies revealed several important concepts in ALI, including cellular 
interaction between lung-marginated leukocytes and pulmonary endothelium, and 
decompartmentalisation of soluble mediators.  However, there are inherent 
limitations within both in vivo and in vitro models to identify the detailed mechanism 
underlying these concepts.  In this PhD project, we attempted to address these 
unanswered questions, using an in situ isolated perfused mouse lung (IPL). 
 
Specifically, we aimed to 1) develop, characterise, and optimise the mouse IPL 
model; 2) investigate soluble and cellular aspects of two models of ALI that are 
particularly amenable to study using the IPL, namely ventilator-induced lung injury 
(VILI) and ischaemia-reperfusion injury. 
 
From a physiological viewpoint, VILI consists of 2 primary components, high-stretch 
and atelectasis.  Modelling atelectasis-related injury in vivo is difficult due to negative 
pleural pressure.  We took advantage of the zero pleural pressure of open-chest IPL 
system to develop an atelectasis-related VILI model.  Comparison of this 
‘atelectrauma’ and a high-stretch ‘volutrauma’ model demonstrated that both cause 
lung oedema and pulmonary inflammation, but the inflammatory impact was different 
between them.  Volutrauma, but not atelectrauma, facilitated systemic cytokine 
release, in which lung-marginated monocytes seem to play an important role.  This 
finding in the VILI model drove us to further investigate the role of these monocytes 
in an ischaemia-reperfusion model, which is clinically highly relevant and simulates a 
lung transplantation setting.  Our results suggested that lung-marginated monocytes 
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may also contribute to develop ischaemia-reperfusion injury, potentially involving 
TNF upregulation. 
 
Through this PhD project, we have successfully developed a technically very 
challenging mouse IPL model.  We utilised the unique features of the IPL to develop 
experimental models that we believe will be strong tools to fill the gap between in 
vivo physiological significance and in vitro mechanistic understanding. 
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1.  Introduction 
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1.1. Acute lung injury/Acute respiratory distress syndrome 
1.1.1. Definitions and epidemiology 
Acute lung injury (ALI), or its severe form acute respiratory distress syndrome 
(ARDS), is a major cause of the mortality and morbidity in the intensive care unit 
(ICU).  The pathological manifestation of ALI/ARDS was first reported in 1967 (1), 
and was described as “acute onset of tachypnoea, hypoxaemia, and loss of 
compliance after a variety of stimuli”.  The basic pathological concept has not 
changed much since this initial report, but due to a wide disparity in the definition, the 
incidence of ALI/ARDS has hugely varied among reports.  In 1994, ALI/ARDS criteria 
were proposed at the American European Consensus Committee (AECC) on ARDS 
(2) which has been widely used to diagnose ALI/ARDS (Table 1-1). 
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Acute Lung Injury Acute Respiratory Distress Syndrome 
Acute onset 
Bilateral infiltrates on chest radiographs 
Pulmonary artery wedge pressure < 18mmHg if measured, or absence of left 
atrial hypertension 
PaO2/ FiO2 (P/F) ratio < 300mmHg P/F ratio < 200mmHg 
 
Table 1-1  American European Consensus Committee definition of Acute Lung Injury and 
Acute Respiratory Distress Syndrome 
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Several papers criticised the AECC consensus because it included many 
patients with heterogeneous aetiologies and varying levels of severity (3, 4).  Villar 
and colleagues pointed out that alteration of ventilator settings including positive 
end-expiratory pressure (PEEP) and fraction of inspired oxygen (FiO2) can 
dramatically change the PaO2/FiO2 (P/F) ratio.  Because ventilator settings are not 
standardised in the AECC definition, dependence on the degree of oxygenation to 
classify patients as ALI or ARDS is highly questionable.  Thus the current AECC 
criteria may lead to great inaccuracies when estimating ALI incidence (5).  Since the 
somewhat arbitrary terminological difference between ALI and ARDS probably does 
not reflect true pathological difference, as seen in this AECC criteria, I will use the 
word ALI in general to encompass both ALI and ARDS in this thesis. 
Subjective interpretation of the chest X-ray may contribute to variable 
diagnosis of ALI (6, 7), and daily clinical practice is also changing.  For instance, the 
Swan-Ganz Catheter (SGC), used for measuring pulmonary artery wedge pressure 
(PAWP), was a popular method employed to assess the cardio-respiratory status of 
critically ill patients.  However, recent clinical studies have demonstrated that SGC 
use does not improve patient outcome (8), and as a result, it is now rare to 
determine PAWP. 
Despite these criticisms, the simplicity of the criteria has allowed clinicians to 
gain some idea of ALI incidence and begin carrying out interventional trials.  Using 
the criteria, the incidence of ALI in the US was estimated at 56-82 per 100,000 
population/year resulting in approximately 75,000 deaths per year (9).  In contrast, 
MacCallum et al. showed the incidence of ALI in Europe and Australia to be less, at 
17-34 per 100,000 (10).  The discrepancy between these data may be ascribed to 
the variability of the current diagnosis criteria.  Ferguson et al. reported the sensitivity 
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and specificity of 3 ALI criteria to detect patients with the typical pathological ALI 
finding of diffuse alveolar damage (DAD) (11).  While the AECC criteria tended to 
have a better sensitivity, the specificity was worse than the other two criteria, Delphi 
scoring (12) and Murray’s lung injury score (13).  Delphi scoring uses strict 
hypoxaemia criteria (P/F ratio ≤ 200 with PEEP ≥ 10) and recognised risk factors for 
ALI to identify the patients, whereas Murray’s score uses respiratory mechanics data 
(when available) and the number of lung areas radiologically consolidated to 
diagnose ALI.  In October 2011, the new ‘Berlin Definition’ was announced at the 
European Society of Intensive Care Medicine meeting (Table 1-2) (14).  The new 
Berlin defintiion dealt with the above criticism by requesting enough PEEP to judge 
the P/F ratio.  The PAWP criteria has been removed from the new definition. 
Finally, it is worth pointing out that there do remain some arguments about the 
concept of ALI itself, because it encompasses various different aetiologies; hence 
the all-in-one name may create a misconcept that there is a uniform pathophysiology 
in ALI (15).  I will discuss this issue in the final chapter. 
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 Mild Moderate Severe 
Timing 
Acute onset within 1 week of a known clinical insult or 
new/worsening respiratory symptoms 
Radiographical 
Abnormalities 
Bilateral opacities – not fully explained by effusions, lobar/lung 
collapse, or nodules 
Origin of 
oedema 
Respiratory failure not fully explained by cardiac failure or fluid overload 
Need objective assessment (eg. echocardiography) to exclude 
hydrostatic oedema if no risk factor present 
Hypoxaemia 
 
200 < P/F ratio ≤ 300mmHg 
with PEEP/CPAP ≥ 5 cmH2O 
100 < P/F ratio ≤ 200mmHg 
with PEEP ≥ 5cmH2O 
P/F ratio ≤ 100mmHg 
with PEEP ≥ 5cmH2O 
 
Table 1-2  Berlin definition of Acute Respiratory Distress Syndrome 
PEEP: positive continuous end-expiratory pressure 
CPAP: continuous positive airway pressure  
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1.1.2. Pathogenesis 
Aetiology 
ALI can arise from a range of aetiologies including both pulmonary insults (e.g. 
pneumonia and acid aspiration) and extra-pulmonary insults (e.g. trauma and 
sepsis).  Although various causes of ALI result in similar pathologies at the late 
stages of the disease, evidence indicates that the pathophysiology of early ALI may 
differ according to the nature of the primary insult (16, 17).  Gattinoni and colleagues 
showed that although the elastance of the whole respiratory system was similarly 
deranged between pulmonary/extrapulmonary ALI, the main cause of the elastance 
increase was different between these two types of ALI.  ALI from extrapulmonary 
insult caused an increase in the chest wall elastance while ALI of pulmonary insult 
caused consolidation, and the response to PEEP was better (reduced elastance of 
the total respiratory system) in patients with extrapulmonary ALI (16).  Ferguson et 
al. showed that pulmonary ALI may develop more rapidly than extrapulmonary ALI 
(18).  It has also been demonstrated that ALI resulting from direct pulmonary insult 
may have a worse outcome (19), although recent meta-analysis opposes this idea 
(20). 
The influence of ethnicity and race on the development and outcome of ALI 
has been superficially investigated, with papers showing better clinical outcome from 
ALI in White-American patients over Hispanic (21) or African-American (22).  In 
recent years, genetic influence has become a hot topic and several candidate genes 
have been implicated in the development of ALI.  For instance, Glavan et al. recently 
identified 4 single nucleotide polymorphisms in FAS gene (FAS is a peptide involved 
in apoptotic cell death), which were associated with increased risk for developing ALI 
(23).  In another example, the human angiotensin-converting enzyme gene contains 
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a restriction fragment length polymorphism consisting of insertion/deletion (I/D) of a 
287 base pair, and the DD genotype has been reported to increase the risk for ALI 
(24, 25).  However, such genetic data require careful interpretation as there are 
pitfalls including publication bias and underpowered studies (26).  Other patient 
characteristics, such as alcohol abuse, may also increase the risk of developing ALI 
(27).  In addition, the presence of air leakage within the first 2 days, organ 
dysfunction, lower serum pH, immune-incompetence (e.g. steroid use, AIDS, cancer) 
and age, were also identified as risk factors for the death of ALI patients (28).  
Interestingly, there is evidence that underweight patients may be susceptible to ALI, 
while obese patients are somewhat protected (29), although other studies do not 
support the protective effect of obesity (30, 31).  Similarly type 2 diabetic patients 
may also be at lower risk for developing ALI (32, 33).  This effect might be ascribed 
to cytokines released from adipocytes, termed adipokines.  The level of leptin (one of 
these adipokines) is increased in patients with obesity and type II diabetes, probably 
due to leptin resistance (34).  Leptin resistance was shown to be protective in 
hyperoxia-induced experimental ALI (35). 
 
Clinical presentations 
ALI displays a rapid onset (in many cases, within 12-48 hours after the initial insults) 
with an increasing need for oxygen.  Because of respiratory distress, patients often 
need mechanical ventilation as a supportive therapy.  Approximately 20-30% of ALI 
patients have P/F ratio: 200 – 300, and 20-50% within this patient group progress to 
P/F ratio < 200 (a defined characteristic of ARDS) within 7 days (9, 28).  The patient 
outcome is usually determined by day 8-10, by which stage half of the patients are 
dead or have been extubated (36).  Approximately 10% of patients are ventilated for 
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more than 1 month.  In terms of mortality, respiratory failure only accounts for 10-
20% of deaths among ALI patients while more than 50% is ascribed to sepsis with 
multiple organ dysfunction syndrome (MODS), with another 20-30% of deaths due to 
co-existing neurological diseases (37-39). 
Radiographically, ALI presents as bilateral opacification of the lung area in 
chest X-ray and was thought to develop homogeneously. However, computed 
tomography (CT) studies revealed that the collapsed lesion is unevenly distributed in 
the lungs of ALI patients, and the remaining inflatable lung size is substantially 
decreased, a phenomenon often termed ‘baby lung’ (40).  At the supine position, the 
concentrated densities are primarily seen in the most dependent regions (41), and 
this uneven distribution of collapse contributes to ventilation-perfusion mismatch and 
increases the risk of regional over-stretch in the ALI lung. 
 
Histological findings 
Histologically, ALI is typically characterised by a sequence of diffuse inflammation 
within the lung parenchyma, known as DAD.  The progression of DAD is divided into 
three stages; exudative (early), proliferative (subacute), and fibrotic (late) (42).  The 
exudative phase is characterised by hyaline membrane formation along alveolar 
ducts and septa as well as interstitial/alveolar lung oedema.  Following 1-2 weeks of 
the exudative phase, the proliferative stage commences and features proliferation of 
fibroblasts and type II epithelial cells.  The fibrotic stage is characterised by an 
increase in collagenous interstitial tissue, known as a honeycomb lesion.  These 
consequences are not necessarily progressive; sometimes the processes recover or 
stop at any stage.  Occasionally a lung biopsy is needed to make a correct 
diagnosis, as ALI can present itself as a different pathology such as acute 
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eosinophilic pneumonia and acute fibrinous and organising pneumonia.  Eosinophilic 
pneumonia, in particular, should not be missed, as it is generally responsive to 
steroid therapy (43). 
 
Systemic effect and patient outcome 
Mortality rate of ALI patients over the past decade is a controversial topic.  While the 
mortality from ALI has decreased since the first report in the 1960s, it remains high 
and is estimated at 40% of ALI patients (9, 44).  There is a consensus among 
several papers that showed a decrease in mortality up to the early 1990s (45-47).  
However, in terms of the trend of mortality since 1994 to 2006, two recent systematic 
reviews demonstrated opposing results (44, 48), depending on the inclusion criteria 
and database used.  Importantly, as described above, the key factors of ALI-related 
mortality are not associated with respiratory failure, but with sepsis and MODS (49).  
Therefore, the improved outcome may be ascribed in large part to the improvement 
of supportive therapy for these diseases, rather than any improvement of specific 
management strategies for ALI.  There have been various attempts to predict 
prognosis from physiological parameters (e.g. APACHE II, P/F ratio) and biological 
markers (e.g. TNF, IL-6, DcR3).  Among them, TNF and surfactant protein B might 
be the best prognostic markers, according to a recent meta-analysis by Ware et al. 
(50). 
Even if patients survive ALI, the level of morbidity is also significant.  In a 
young patient population, Herridge et al. reported that loss of 18% body weight, due 
to muscle weakness and fatigue, was seen at the time of discharge from the hospital 
(51).  In addition, some respiratory functions such as diffusion capacity of the lungs 
for carbon monoxide (DLCO) were decreased even after 12 months from the onset 
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of the disease.  The same authors have recently published 5-year outcomes (52) 
and showed deterioration in DLCO and 6-minutes walk tests even after 5 years.  Not 
only physiological parameters, but quality of life is also affected in survivors of ALI.  
Health-related quality of life after 6 months from ALI is poorer than the healthy 
reference populations (53), and the survivors of other critical diseases such as 
trauma or sepsis (54). 
 
1.1.3. Treatment 
Pharmacotherapy 
Many pharmacological agents have been studied in an attempt to decrease the 
mortality of ALI, but unfortunately none of the drugs tested have proved effective (55, 
56).  Exogenous repletion of surfactant has been shown to be effective in neonatal 
respiratory distress syndrome (RDS) (57), but not in adults (58, 59).  In clinical trials 
by Spragg and colleagues, oxygenation was improved and the inflammation marker 
IL-6 was decreased in lavage and plasma by exogenous surfactant repletion, but the 
effects tended to decline within a day (59, 60).  These results may indicate that 
surfactant deficiency in ALI is a consequence of other pathological changes, 
whereas the immature lung develops RDS due to a primary deficit in surfactant 
production.  Investigations into the use of inhaled vasodilators to improve the 
ventilation-perfusion (V/Q) mismatch in injured lungs have been carried out.  
However, while both inhaled nitric oxide (NO) (61) and aerosolised prostacyclin (62) 
improved oxygenation, they failed to show any mortality benefits.  Oxygenation may 
be a surrogate marker that does not reflect the actual lung tissue damage, hence 
these approaches to improve oxygenation may not be as effective as expected.  
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Reactive oxygen species (ROS) have been implicated in ALI (63), since decreased 
endogenous antioxidants and increased lipid-derived and nitrogen-derived oxidants 
are seen in ALI patients (64-66).  However, anti-oxidant therapy including N-
acetylcysteine has failed to show clinical benefit (67-69).  The use of beta-2 agonists 
has also sparked interest in potentially improving alveolar fluid clearance, prevention 
of neutrophil sequestration, early cytokine release, and surfactant impairment (70).  
However large randomised clinical trials using both systemic (71, 72) and pulmonary 
applications (73) have failed to show improvement in patient outcome. 
Among the various anti-inflammatory drugs tested, glucocorticosteroids were 
considered to be the ideal candidate for treating ALI because they can reduce the 
expression of numerous cytokines as well as preventing excessive collagen 
deposition.  Unfortunately, preventive application (74-76), both early (77) and late 
(78) stage application of steroids, administered at both low (78-80) and high (74-77) 
doses, have also failed to show clinical benefit.  After a series of clinical trials, the 
current evidence suggests that glucocorticosteroids should not be used for the 
treatment of ALI at any stage (81).  However, some clinicians still insist low-dose 
steroid should be beneficial if a proper regimen is identified (82, 83).  Why steroid 
treatment has failed to show mortality benefit is not yet clear.  While the expected 
acute side effects including secondary infection and hyperglycaemia are not obvious 
(77, 82), long-term follow-up indicated that use of steroid was associated with 
prolonged muscle weakness and impaired functional status (51).  Evidence also 
suggested that macrophage migration inhibitory factor (MIF) was increased in ALI 
patients, which may deactivate intra-alveolar cortisol (84), potentially contributing to 
the steroid resistance in ALI patients. 
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There are still potential candidates being investigated for the treatment of ALI 
such as statin (85) and mesenchymal stem cells as anti-inflammatory agents (86), 
but to date, no definitive pharmacological treatments have been established. 
 
Supportive therapies 
Fluid management is one of the major supportive therapies employed in the ICU.  
The conservative fluid approach can theoretically ameliorate pulmonary oedema at 
the expense of non-pulmonary organ perfusion.  A large randomised controlled trial 
has been carried out to address whether this leads to improved patient outcome, but 
the conservative fluid approach failed to reduce mortality, despite reducing ventilator 
free-days and length of ICU stay (87). 
In terms of nutritional support, eicosanoids including prostaglandins and 
leukotrienes are implicated in many inflammatory diseases including ALI (88, 89), 
and the phospholipid composition of plasma membranes are important in the 
regulation of eicosanoid-mediated inflammatory responses.  Whereas both omega-3 
(n-3) and omega-6 (n-6) fatty acids produce eicosanoids, n-3 fatty acid only slowly 
stimulates eicosanoid receptors and competes with n-6 fatty acid, which causes 
vigorous inflammatory response via eicosanoid receptor stimulation (90, 91). 
Therefore, the n-3 fatty acid is considered to be anti-inflammatory, and a recent 
clinical trial showed a protective effect of n-3 fatty acid for septic patients (92).  
However, a large randomised clinical trial by ARDSNet has recently demonstrated 
that supplementation of n-3 fatty acid to enteral nutrition was not beneficial, and even 
showed worse outcomes for ALI patients, in terms of ventilator-free days and 60-
days mortality (93). 
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Prone positioning may improve the homogeneous inflation of alveolar lung 
units and ventilator-perfusion (V/Q) mismatch (94).  Gattinoni and colleagues have 
been pursuing the clinical benefit of prone positioning for many years, but the results 
of major clinical trials have not shown mortality benefits, despite improvements in 
oxygenation (95-97).  Recent subgroup analysis highlights the potential benefit of 
prone positioning in the most severely ill patients (98), but currently there is no clear 
evidence to support the routine use of prone positioning. 
Ventilation strategies would be discussed in the next section ‘ventilator-
induced lung injury’. 
 
 
1.2. Ventilator-induced lung injury 
1.2.1. Overview of ventilator-induced lung injury 
In the early 1950s, the endemic poliomyelitis in Denmark was successfully treated 
using positive pressure ventilation with a dramatic decrease in mortality from 90% to 
25%, although this required 1,500 medical and dental students in total to manually 
ventilate more than 300 patients with tracheostomy (99, 100).  This demonstrated 
the need for mechanical ventilators, which we now use as daily clinical practice. 
In the current era, the major use of mechanical ventilation in ICUs is to treat 
patients with ALI.  Although mechanical ventilation is indispensable for these 
patients, it affects lung function in various ways.  For instance, the insertion of an 
endotracheal or tracheostomy tube enables pathogens to freely access the lower 
airway and result in pneumonia, known as ventilator-associated pneumonia (101, 
102).  Even without such an infection, mechanical ventilation per se causes or 
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exacerbates ALI, a concept known as ventilator-associated lung injury or ventilator-
induced lung injury (VILI) (103-105).  The fact that ‘injurious’ ventilation can rapidly 
cause endothelial and epithelial injury in the lung and physiological derangements, 
even without any other insults, has been known for many years based on animal 
models (106-108).  The clinical benefits of so-called ‘lung protective’ ventilation, 
involving the use of a low tidal volume and high PEEP, were initially reported in the 
late 1990s (109), and supported by a large randomised controlled trial by ARDSNet 
(36) and a recent systematic review (110).  Indeed, modification of the ventilation 
strategy is the only supportive therapy/treatment that has consistently shown 
mortality benefit in major trials.  Esteban et al. showed that the international clinical 
practice regarding ventilation settings has indeed changed since this beneficial effect 
of protective ventilation was revealed (111).  In 2004 compared with 1998, clinicians 
used lower tidal volume and higher PEEP. 
The concept of the protective ventilation strategy was a paradigm shift in the 
way patients are ventilated.  Historically, the primary aim of mechanical ventilation 
was to normalise patients’ pathological status, represented by the arterial blood gas 
profile; i.e. pH, pO2, pCO2.  However, to achieve this, large tidal volumes were 
frequently required, which led to VILI.  The protective ventilation strategy decreases 
the mechanical stress of the lung potentially at the expense of pCO2 control, a 
concept known as permissive hypercapnia.  Some literature has in fact reported a 
direct beneficial effect of hypercapnic acidosis via inhibition of neutrophil recruitment, 
reduction of NF-kappa B activation, and attenuation of free radical production (112-
114).  However, hypercapnia per se (i.e. increased pCO2 without pH decrease) may 
not be harmless or protective (115).  Nichol and colleagues investigated the effect of 
buffered hypercapnia by inducing chronic hypercapnia (3 days) in a rat infectious ALI 
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model.  The buffered hypercapnia impaired epithelial wound healing and 
exacerbated the lung injury (116). 
The definition of ventilator ‘induced’ lung injury is not as clear as ALI, because 
it is often difficult to ascribe the lung injury solely to mechanical ventilation in clinical 
settings.  The histological findings in VILI are in fact similar to ALI; including alveolar 
haemorrhage, alveolar neutrophil infiltration, alveolar macrophage and type II 
pneumocyte proliferation, interstitial congestion and thickening, interstitial 
lymphocyte infiltration, emphysematous change, and hyaline membrane formation 
(107, 117).  In 1999, an ATS Consensus Committee attempted to address this issue 
by using two terms, VILI and ventilator-associated lung injury (VALI) (118).  They 
defined VILI as ALI induced by mechanical ventilation in animal models, whereas ALI 
in patients receiving mechanical ventilation was defined as VALI (119).  Despite such 
a controversy behind the definition of VILI, there is little doubt that mechanical 
ventilation can cause or exacerbate ALI.  Because the basic concept is the same in 
these two terms, I use the word VILI in general to encompass the concept of 
experimental VILI and clinical VALI in this thesis. 
 
1.2.2. Proposed pathophysiologies in VILI 
Overstretch of lung units - barotrauma and volutrauma 
The fact that inappropriate artificial ventilation can cause lung injury was first 
described by a Scottish surgeon in the early 18th century (104).  Two centuries later, 
a concept of VILI was truly established by the seminal paper by Webb and Tierney 
(108), who showed that high-pressure ventilation caused haemorrhagic pulmonary 
oedema in previously healthy rats, while application of PEEP with the same high 
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peak pressure attenuated this lung injury.  Several aspects of mechanical ventilation 
have been proposed as injurious.  Originally, VILI was mainly attributed to physical 
disruption of the epithelial/endothelial barrier due to excessive pressure, a concept 
known as barotrauma.  This concept was later challenged by Dreyfuss and 
colleagues, who proposed a different mechanism that higher tidal volume and the 
consequent over-stretch of the alveolar units is more important in VILI, known as 
volutrauma (120).  They showed that high airway pressure with low tidal volume (by 
strapping the chest wall) did not cause lung injury.  Furthermore, lung injury 
developed even if a negative pressure strategy was used to produce high tidal 
volume ventilation.  These results clearly demonstrated the airway pressure is not 
the sole reason for developing VILI (121). 
Since this clarification of the pathophysiology of VILI, the term barotrauma is 
now used as a synonym for air leaks, defined as any extrusion of air outside the 
tracheobronchial tree, including pneumothorax, pneumomediastinum, 
pneumopericardium, pulmonary interstitial oedema, and subcutaneous emphysema 
(122).  A recent international cohort study showed that 2.9% of ventilated patients 
(ventilated >12h) develop barotrauma, and it preferentially develops in the patients 
with underlying pulmonary disease such as asthma and ALI (123).  Incidence and 
risk factors of volutrauma is inherently difficult to investigate clinically, as separating 
the volutrauma from developing ALI is challenging (118). 
These two concepts (barotrauma and volutrauma) are not independent; the 
importance of tidal volume in VILI can be rephrased as that of transpulmonary 
pressure, rather than airway pressure.  In fact, there is a linear relationship between 
the transpulmonary pressure and lung volume, known as stress-strain relationship.  
From a viewpoint of bioengineering, the forces developing into the lung structure that 
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produces the transpulmonary pressure can be defined as stress, and the lung 
deformation (compared to its resting status) caused by tidal inflation can be defined 
as strain (124).  The lung stress-strain relationship is linear, until the strain/stress 
reaches a certain point where the biomaterial (lung alveoli) approaches its elastic 
limit.  Below that point, strain and stress are linked by the formula: <stress> = K × 
<strain>, where K is the specific elastance.  The specific elastance is considered to 
be similar between ALI patients and healthy humans (125).  In most cases, instead 
of measuring stress and strain, conventional surrogate markers (plateau pressure 
and tidal volume normalised for ideal body weight, for stress and strain respectively) 
are used.  Gattinoni and colleagues claim that these surrogate markers are not good 
representatives and recommend the use of an oesophageal probe for measuring the 
pleural pressure to calculate the transpulmonary pressure.  Since the specific 
elastance is almost constant as described above, we may be able to estimate the 
strain from the stress even if we do not use CT to measure functional residual 
capacity (FRC) (125).  The same research group recently showed that strain and 
stress are in fact the critical determinants of VILI; pig lungs developed significant VILI 
only when the applied strain was greater than 1.5-2.0 times the FRC (126). 
 Although we have changed our clinical practice and are now using lower tidal 
volume, volutrauma is still a major problem for ventilated ALI patients because of the 
nature of the injured lungs.  Computed tomography (CT) of ALI patients revealed that 
the lung is non-homogeneously injured and the aeration status of each alveolar unit 
is very different (127-129); including over-inflated, normally aerated, poorly aerated, 
or completely collapsed alveolar units.  Interestingly, Gattinoni and colleagues 
demonstrated that it was the volume of normally aerated lung regions that correlated 
with lung compliance rather than that of poorly aerated or collapsed lung regions, 
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thus the decreased compliance of injured lungs may be due to the small normally-
aeratable lung volume rather than the stiffened tissue due to oedema (41).  The 
same group also estimated the weight of normally aerated tissue in adult ALI 
patients as 300-500g (41), which is similar to that of 5-6 year old children, leading to 
the theory known as ‘baby lung’ (40).  Because of the non-homogeneous nature of 
the injured lung, normally aerated regions receive most of the insufflated gas, 
meaning that even use of a usually ‘non-injurious ventilation’ strategy results in 
delivery of a relatively high tidal volume to the normally aerated lung units, causing 
VILI to the ‘baby lung’.  Theoretically, lung recruitment manoeuvres (RMs) are useful 
to attenuate the regional over-inflation by preventing the collapse of normally 
aeratable lung regions.  Another benefit of RMs relates to the half-atelectatic regions, 
where the lung tissue is injured by a different mechanism, known as atelectrauma. 
  
Repetitive opening and collapse of lung units – atelectrauma 
Ventilated patients are subject to atelectasis for various reasons (130).  90% of 
patients with general anaesthesia were found to develop atelectasis (131) and this 
happens with both intravenous and inhalational anaesthesia (132-134).  For 
instance, when the FiO2 is raised, increased concentration of alveolar oxygen greatly 
facilitates the gas movement from alveoli to blood and may exceed the actual gas 
inflow in poorly ventilated lung zones, causing the phenomenon called resorption 
atelectasis (130, 135).  Other factors included in the development of atelectasis in 
ventilated patients are relatively low tidal volume and endotracheal suctioning to 
remove sputum (136).  Such collapsed lung units may produce additional stresses 
during mechanical ventilation and cause atelectrauma.  Local stress between 
aerated units and neighbouring collapsed units can exceed more than 100cmH2O 
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when lungs are ventilated with 30cmH2O of transpulmonary pressure (137).  Half-
atelectatic lung units may also be exposed to repetitive collapse and re-opening 
during ventilation, resulting in epithelial shear stress.  This shear stress theory 
originally came from findings in neonatal RDS, where the lack of surfactant due to 
prematurity makes it difficult to expand the lung. Nilsson demonstrated that 
mechanical ventilation of newborn rabbits induced bronchiolar epithelial injury within 
5 minutes and this was attenuated by applying either natural surfactant or PEEP, 
suggesting that the irregular aeration may cause epithelial shear stress and injury 
(138).  In line with this, Muscedere et al. demonstrated epithelial injury when isolated 
non-perfused adult rat lungs were ventilated with zero PEEP (ZEEP), suggesting a 
similar mechanism applies to ALI (139).  Repetitive opening and collapse of lung 
units can occur because of increased thickness of the fluid lining the airways and 
surfactant deactivation due to co-existing pulmonary diseases (140-142). 
Experimental findings by Nieman and colleagues also supported this theory 
by visually demonstrating alveolar instability (i.e. Large changes in alveolar size 
during each respiratory cycle) in surfactant deactivated adult pig lungs using 
intravital microscopy (143-145), although another paper using similar techniques 
opposed this idea and proposed heterogeneous regional over-expansion as the 
main mechanism of atelectrauma (146).  It is however not straightforward to interpret 
such studies, as visualisation usually needs open-chest and/or negative suction 
pressure within the intrapleural space, which changes the normal lung physiology.  
Even if these problems are solved, presence of a coverslip on the subpleural regions 
constrains the movement of the alveoli; hence the kinetics of alveoli is inherently 
different from the rest of the lung (147). 
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Tsuchida and colleagues indicated the localisation of shear stress-induced 
epithelial injury using surfactant-depleted rats.  They depleted surfactant by saline 
lavage and subsequently applied injurious ventilation (low PEEP and high tidal 
volume) to the rats.  This resulted in atelectasis and histological distal airway injury in 
the dependent regions, while both distal airway and alveolar injury developed in the 
non-atelectatic, non-dependent regions (148).  Based on the results, they suggested 
that the injury in the non-dependent regions was caused by over-stretch due to baby 
lung phenomenon, while shear stress can also cause lung injury, with the main 
localisation at distal airway.  Other findings from in vivo (149, 150) and in vitro 
models (151, 152) of collapse and reopening also support the hypothesis that the 
shear stress mainly affects distal airway.  Taskar et al. showed negative end-
expiratory pressure and surfactant deactivation in rabbits resulted in alveolar 
collapse, intra-alveolar oedema, hyaline membranes, intra-alveolar haemorrhage, 
bronchiolar epithelial necrosis, and recruitment of granulocytes to the airspace, 
suggesting both alveoli and bronchiolar epithelium can be injured by atelectasis 
(140).  One study reported that an in vivo atelectrauma model induced endothelial 
blebbing, suggesting that atelectrauma might even involve endothelial shear stress 
(153), but this finding has not been confirmed by others (and a later study by the 
same authors (154) indicated their in vivo atelectrauma model may be hypoxia-
induced).  Collectively, these data suggest that atelectrauma primarily involves 
epithelial injury due to shear stress (with the main affected regions likely to be distal 
airway), but it might also involve the pulmonary endothelium and alveoli. 
The beneficial effects of lung volume maintenance in mechanical ventilation 
was initially proposed in high-frequency oscillatory (HFO) ventilation experiments 
(155-157), and later also in controlled mandatory ventilation (CMV) (158).  There are 
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two main methods to decrease atelectasis during mechanical ventilation; RMs and 
increased PEEP (159, 160), use of which is clinically known as open lung strategy 
(161, 162).  RMs are accomplished either by sustained inflation (SI) or temporal 
increase of PEEP (163).  Although there have been some concerns over the safety 
and efficacy of RMs (164, 165), a recent systematic review showed the RM protocols 
used in clinical trials (i.e. peak pressure of 30-50cmH2O for 20-50 seconds), were 
safe and effective to improve oxygenation by reducing the anatomical shunt (166).  
However, this and other systematic reviews have contrastingly demonstrated RMs 
did not improve mortality (166, 167). 
Adequate PEEP is also needed to prevent derecruitment and sustain the 
effect of RMs (163, 168).  The protective effects of high PEEP in animal models of 
ALI were experimentally demonstrated many years ago (108, 121), but the 
mechanism was not clear until the role of atelectasis in VILI became apparent.  The 
weight of the injured lung is increased by oedema and thus more dependent regions 
of the lung may be compressed and collapsed (169), although this ‘compression 
theory’ has been challenged by Hubmayr et al., who insisted the weight of chest wall 
and mediastinum are more important than the lung weight per se (170).  Several 
studies by Gattinoni and colleagues using CT encouraged clinicians to use high 
PEEP to counterbalance the superimposed pressure from the wet lung (169, 171).  
However, despite the clear importance of PEEP in animal models, the ‘open lung 
ventilation strategy’ by high PEEP per se did not show a significant clinical impact in 
large randomised controlled trials carried out by ARDSNet (172) and other groups 
(162, 173, 174). 
Several reasons have been suggested to explain why high PEEP was not 
successful in large-scale clinical trials.  There is a concern that high PEEP may 
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induce adverse haemodynamic effects (175, 176).  These are considered to be due 
to the decrease of systemic venous return secondary to the increased pleural 
pressure (177) and increased afterload of the right ventricle leading to right 
ventricular failure (178).  These factors can decrease the cardiac output and result in 
poor organ perfusion.  More importantly, the concept of ‘optimal PEEP’ has not yet 
been well defined.  Previous clinical trials determined PEEP based on either FiO2 
required to achieve target oxygenation (36, 172), or static pressure-volume (P-V) 
curve (109, 164).  The static P-V curve of ALI patients often shows two inflection 
points (Fig 1.1).  The lower inflection point (LIP) may represent the pressure/volume, 
where lung units are recruited, whereas the upper inflection point (UIP) may reflect 
the point where all alveoli approach becoming over-stretched and thus potentially 
damaged.  Based on the theory that ideal ventilation should avoid both atelectrauma 
and volutrauma, tidal ventilation should take place between the LIP and UIP; hence it 
was proposed that the ‘optimal PEEP’ should be set just above the LIP (179).  
However, the concept of LIP has been challenged (170, 180), as LIP may not mean 
the opening point of most airways (181, 182) and this pressure does not always 
lessen lung injury (183). 
Further attempts have been made to improve the optimal PEEP protocol; e.g. 
monitoring pleural pressure using an oesophageal probe (184).  Overall however, 
meta-analyses and systematic reviews investigating the usefulness of PEEP have 
proved inconclusive (166, 174, 185-187).  Collectively, current evidence has not 
shown that the open lung strategy is clearly beneficial to ventilated patients, although 
experimental data strongly suggest atelectasis can induce or exacerbate VILI. 
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Figure 1-1  Pressure-curve derived from a patient with Acute Lung Injury. 
During the inflation, there are two inflection points; lower inflection point and upper inflection point. 
FRC: functional residual capacity 
LIP: lower inflection point 
UIP: upper inflection point. 
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Inflammation in the lung - biotrauma 
Historically, the mechanisms of VILI mainly focused on physical aspects.  Following 
a number of publications showing the role of neutrophils in the genesis of ALI in the 
early 1980s (188-190), Kawano and Bryan first demonstrated that neutrophil 
depletion by nitrogen mustard attenuated VILI in a surfactant depleted rabbit model, 
suggesting inflammation can modify the course of VILI (191).  In 1994, Imai and 
colleagues showed that HFO was associated with decreased mediator release 
(compared to CMV), including platelet-activating factor and thromboxaneB2 into 
lavage samples from ventilated rabbits (192).  These experiments indicated that 
inflammatory cellular and/or soluble mediators affect the development of VILI, 
although it was unclear whether the lung per se has an ability to produce such 
mediators.  Ex vivo isolated lung preparations were used to address this question.  
Tremblay et al. ventilated isolated non-perfused rat lung with different ventilation 
strategies, and showed that the most injurious strategy (high tidal volume and ZEEP) 
increased the concentration of both inflammatory and anti-inflammatory cytokines in 
lavage fluid including TNF, macrophage inflammatory protein-2 (MIP-2; mouse IL-8 
homologue), IFN-gamma, and IL-10, together with the increased expression of c-fos 
mRNA (193).  Uhlig and colleagues used a mouse isolated perfused lung system 
and demonstrated that the lung can secrete various mediators including TNF, IL-6, 
keratinocyte chemoattractant (KC; another mouse IL-8 homologue), and monocyte 
chemotactic protein-1 (MCP-1) into the pulmonary circulation via NF-kB signalling 
pathway (194, 195).  Such supportive evidence together with clinical evidence that 
protective ventilation reduces cytokines in plasma and lavage samples from patients 
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(196) led to the proposal that these inflammatory mediators could be responsible for 
developing VILI, known as the biotrauma theory (197). 
Since then, several arguments have been raised about the critical role of 
biotrauma in developing VILI (198-200).  One of the points in this argument was 
based on the inconsistency of cytokine production.  For instance, Wilson et al. 
showed that intra-alveolar TNF was increased after 2 hours from the initiation of 
high-stretch ventilation, at which time the respiratory mechanics was not changed.  
However, after another hour of ventilation (a total of 3 hours), TNF was no longer 
detectable in the intra-alveolar space but pulmonary oedema had developed (201).  
These data suggest that the detectable mediators are different, depending on the 
timing of sampling (202-204).  Another argument relates to the sequence of 
chemoattractive mediators, which is a subset of cytokines and known as chemokines, 
and cellular recruitment.  Traditionally, it was considered that production of 
chemokines was the upstream event within the lung in response to injurious 
ventilation, and these mediators subsequently recruit leukocytes to the lung (205), 
resulting in inducing or exacerbating tissue damage (206, 207).  However, other 
evidence indicated that injurious ventilation may directly cause permeability change, 
independent of traditional chemokines.  For instance, neutrophil margination can 
occur earlier than detectable increases in intra-alveolar chemokines (208), and 
genetic abrogation of cytokine signalling pathways showed attenuation of pulmonary 
oedema without changing the neutrophil sequestration (209). 
The cellular source of these lung-borne mediators is also intriguing, but a 
complex issue.  Traditionally, alveolar macrophages (210, 211) and neutrophils (212) 
have been considered to produce these mediators, and lung parenchymal cells were 
regarded as bystanders.  In line with this idea, depletion of alveolar macrophages 
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has been shown to attenuate the pulmonary oedema and cytokine production in rat 
and mouse VILI models (213, 214).  However, alveolar epithelial cells (215, 216), 
fibroblasts (217), and pulmonary microvascular endothelium (218) have also been 
reported to produce cytokines including IL-8, TNF, and IL-6, making it complicated to 
identify the cellular source of these mediators. 
The number of candidate mediators responsible for this biotrauma is 
continuously increasing, including monocytes (219), lipid-derived mediators (220-
224), coagulation factors (225-227), reactive oxygen species (228-231), and 
prototypic hormones such as angiotensin-converting enzyme (232, 233).  One of the 
arguments against the biotrauma hypothesis is that most of these mediators might 
be a consequence, rather than the cause, of VILI.  In order to address this 
complicated causal relationship, a recent review by Jaecklin and Kavanagh 
proposed to use Koch’s postulates (originally formulated in 1884), of which the basic 
concept is still valid to identify pathogens (234, 235).  They proposed that the 
candidate mediators should fulfill the criteria; 1) Circulating factors increased by 
injurious ventilation, but not by non-injurious ventilation; 2) Soluble candidate 
mediators are derived from the lung and can be identified in the circulation; 3) 
Exogenous application of the mediators induce injury in healthy lungs; 4) Increased 
candidate mediators found in lung injury caused by the transfer of circulating fluid 
(236).  They pointed there had been no study to clearly address the last two 
postulates, and based on this understanding, the same authors demonstrated that 
transfer of effluate from isolated perfused lungs that had received injurious 
ventilation can induce lung injury within recipient lungs ventilated with non-injurious 
settings (237). 
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Inflammatory propagation in VILI 
Patients with ALI often die from MODS rather than acute respiratory failure, hence 
understanding the roles and mechanisms of this inflammatory propagation from lung 
to other organs is crucial in the management of ventilated patients with ALI.  
Historically, deteriorated blood gas profile including hypercapnia and hypoxaemia, 
and altered cardiac output by mechanical ventilation were considered to be central in 
the development of these organ injuries (238), however evidence indicates that 
mechanical ventilation plays a role in this inflammatory propagation.  Recent 
progress in understanding the biotrauma mechanism highlighted the role of 
biological mediators in MODS following VILI.  As discussed above, lungs produce 
multiple mediators such as IL-8 and TNF in response to a variety of stimuli (193-
195).  These mediators not only cause inflammation within the lung itself, but also 
can propagate inflammation to extrapulmonary organs. 
Clinical evidence suggested a correlation between the levels of plasma pro-
inflammatory cytokines and the development of MODS.  Ranieri et al. retrospectively 
analysed the patient data from the ARDSNet trial (36), and found that MODS (using 
the criteria (239) proposed by Knaus et al.) was increased in the patients received 
conventional (higher tidal volume) ventilation and plasma IL-6, TNF, IL-1beta, and IL-
8 were correlated with the number of failing organs (240).  Later studies showed 
similar correlation between MODS and IL-6, IL-8, sTNFR1, and sTNFR2 (241, 242).  
Although these data have implicated the role of these plasma cytokines in 
developing MODS, clinical evidence of the direct causal relationship between plasma 
cytokines and MODS is still lacking (243).  Animal studies also supported this theory.  
For instance, Imai and Slutsky showed kidney and liver dysfunction with apoptotic 
cells in those organs using a rabbit VILI model.  In that paper, they also showed the 
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plasma from rabbits receiving injurious ventilation caused apoptosis in kidney tubular 
cell line in a soluble FAS ligand (sFasL) dependent manner, suggesting the role of 
sFasL in developing MODS following VILI.  In fact, they also showed the correlation 
between plasma sFasL and kidney dysfunction in patients with ALI (244). 
The spillage of lung-borne mediators is often explained by a mechanism 
known as decompartmentalisation.  This theory proposed that the spill-over of the 
lung-borne mediators occurs through 2 processes; 1) increase of the mediators 
within the alveolar space (mainly produced by epithelium and alveolar macrophages) 
by insults including acid aspiration, infection, or mechanical ventilation; 2) loss of 
alveolar-capillary barrier function causes the spillage of these intra-alveolar 
mediators.  Tutor et al. first showed the proof of concept for this 
decompartmentalisation theory, by demonstrating spillage of intratracheally-applied 
recombinant TNF into the circulation following chemically induced endothelial barrier 
dysfunction (245).  Kurahashi et al. showed that alveolar epithelial injury was also an 
important factor determining whether intra-alveolar inflammatory mediators induced 
by P. aeruginosa instillation spread into the systemic circulation, leading to septic 
shock (246).  Later papers implicated the role of injurious ventilation in 
decompartmentalisation.  Indeed, mechanical ventilation has been described as the 
‘engine’ of systemic inflammation, leading directly to the dissemination of a local 
inflammation to the rest of the body.  Chiumello et al. ventilated HCl-treated rats with 
various ventilator settings and found that their injurious ventilation protocol (high tidal 
volume and zero PEEP for 4 hours) caused significant TNF and MIP-2 increases 
both in plasma and lung lavage fluid, compared to protective ventilation protocol (low 
tidal volume and PEEP), suggesting the injurious ventilation is involved in not only 
exacerbating the local inflammation, but also inflammatory propagation in VILI (247).  
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Haitsma and colleagues ventilated LPS-treated rats with two different ventilation 
protocols and showed that the injurious ventilation (higher tidal volume and zero 
PEEP) induces loss of compartmentalisation of TNF, and this 
decompartmentalisation was attenuated by exogenous surfactant pretreatment (248, 
249).  In line with this experimental evidence, Stuber et al. showed in ALI patients 
that the switch from protective ventilation to injurious ventilation rapidly (within an 
hour) increased cytokines both in the alveolar and intravascular space, and return 
from injurious to protective ventilation again rapidly decreased the plasma cytokine 
concentration, but not the lavage cytokine concentration (250).  Evidence from 
animal models suggested such decompartmentalisation mechanisms also apply to 
bacterial agents.  Murphy et al. showed that endotoxin was spread by injurious 
ventilation in rabbits (251), and others showed pulmonary-to-systemic bacterial 
translocation caused by injurious ventilation (252, 253). 
Despite the popularity (and simplicity) of the concepts, the 
decompartmentalisation paradigm should be interpreted in light of current evidence.  
In in vivo situations, it is not often clear where the increased cytokines are coming 
from.  They could be from the intra-alveolar space as the decompartmentalisation 
paradigm proposes, but could be also from the pulmonary intravascular space.  
Differentiating such simultaneous cytokine production from intra-alveolar and 
intravascular space and the cytokine increases in both compartments due to 
decompartmentalisation is difficult in vivo.  It is also notable that the 
decompartmentalisation theory was often based on the translocation of exogenous 
agents, however such recombinant agents can behave differently compared to 
endogenous counterparts.  In fact, evidence indicates that intra-alveolar cell 
populations are not the only cellular sources of the stretch-induced cytokines.  It has 
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been acknowledged for many years that mechanical ventilation causes injury not 
only to the epithelium, but also pulmonary endothelium (107), suggesting VILI is a 
‘whole-lung’ event where both intra-alveolar and intra-vascular components are 
stretched.  Later experimental evidence also supported this theory.  Kuebler et al. 
using in situ isolated perfused lung (IPL) showed that high-stretch ventilation 
activates the PI3K/Akt/eNOS pathway in pulmonary endothelium, resulting in NO 
production (254).  Miyao et al. showed that high-stretch within IPL upregulates cell 
adhesion molecules on pulmonary endothelium including ICAM-1 and VCAM-1, 
which are involved in the entrapment of leukocytes at the pulmonary microcirculation 
(255).  A recent publication by Hegeman et al. also found similar upregulation of 
endothelium-specific cell adhesion molecules following high-stretch (256).  In line 
with this, in vitro evidence also showed that pulmonary endothelial cells produced IL-
8 in response to high-stretch (218). 
Collectively, current evidence strongly suggests the role of plasma cytokines 
in MODS following VILI.  However, the propagation mechanism may not be simply 
explained by the current decompartmentalisation paradigm.  Since MODS is a critical 
determinant of the mortality in ALI patients, it is important to further elucidate the 
inflammatory propagation mechanism. 
 
Mechanotransduction 
The concept of barotrauma/volutrauma and atelectrauma are not independent from 
that of biotrauma, because the biological reactions in response to ventilation are 
initiated by mechanical stress.  There are a number of proposed mechanisms by 
which physical stress may result in an inflammatory response (257).  When the 
stress exceeds the structural limit of basement membrane, cell integrity is destroyed 
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and eventually these necrotic cells release various intracellular components such as 
stored chemokines, cytosol proteins, and nuclear proteins, a concept known as 
stress failure (257-259).  These intracellular components indicate damage of the 
cells and can stimulate the immune system via pattern recognition receptors 
including toll-like receptors; thus these intracellular factors are often termed damage-
associated molecular patterns (DAMP). 
Even if the structural integrity is maintained, unphysiologcal stress can induce 
biological signals via mechanosensors, a mechanism collectively termed 
mechanotransduction.  For instance, Parker and colleagues reported that a stretch-
activated ion channel Transient Receptor Potential Vanilloid 4 (TRPV4), which is 
also involved in the endothelial permeability increase by hypotonic stress, heat, and 
metabolites of arachidonic acid, was related to the acute permeability increase in 
VILI via endothelial calcium entry (260, 261).  Other proposed mechanisms of 
mechanotransduction in VILI include conformation changes in extracellular matrix-
integrin-cytoskeleton complex (262), intracellular junction such as adherens junctions 
(263, 264), and modifying gene expression by changing the nuclear pore size (265).  
Various signalling molecules have been implicated downstream of these pathways 
such as c-fos (193) and MAP kinases (266), and the consequent events further 
downstream include apoptosis, pulmonary inflammation, and repair (267). 
 
Oxygen stress in the lung - hyperoxia 
Many clinicians suspect application of pure oxygen and the resultant hyperoxia may 
be deleterious.  In line with this, the current clinical British Thoracic Society guideline 
recommends FiO2 should be regulated to aim for target oxygen saturation of 94-98% 
(268).  Despite the popularity of this concept, the clinical evidence about the toxicity 
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of pure normobaric oxygen is scarce, with only a few old studies showing no or a 
little permeability increase after several days of pure oxygen exposure (269, 270).  In 
contrast, hyperoxia has been long known to cause fatal lung injury to most mammals 
via the production of ROS (271) and in vitro experiments using human cells showed 
inflammatory responses following hyperoxia (272).  Clinically, a systematic review 
indicated the potential usefulness of room air over 100% oxygen in neonatal 
resuscitation (273).  Because pure oxygen application also induces other side effects 
including resorption atelectasis and increased V/Q mismatch due to the decrease of 
hypoxic pulmonary vasoconstriction (274), hyperoxia tends to be avoided in clinical 
settings. 
 
1.2.3. Treatments for VILI 
Since the concept of VILI was established, the pathophysiological understanding of 
VILI has been dramatically progressed due to the translational research.  Based on 
the mechanisms described above, there are three major theoretical approaches to 
minimise VILI; protective ventilation strategy, biological interventions, and “don’t 
ventilate”, i.e. lung resting therapy.  As discussed above, only the protective 
ventilation strategy has been proven to be clearly beneficial to patients so far (36, 
109, 164), an effect ascribed mainly to limiting tidal volume.  Use of other ventilation 
techniques including partial liquid ventilation (275, 276), HFO (277) and airway 
pressure release ventilation (APRV) have also been proposed in an attempt to 
minimise the VILI, but the mortality benefits have not yet been established (167).  A 
recent large clinical trial indicated the mortality benefits of early and short 
administration of a neuromuscular blocking agent, without showing long-term muscle 
weakness (278).  The beneficial effects of the agents may be because it facilitates 
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use of a protective ventilation strategy by minimising the patient-ventilator interaction 
and allowing for the accurate adjustment of tidal volume and PEEP. 
Extracorporeal membrane oxygenation (ECMO) is theoretically an ideal 
approach to prevent VILI as it allows the lungs to completely avoid being ventilated.  
ECMO is essentially the respiratory equivalent of cardiac bypass, exchanging the 
oxygen and carbon dioxide outside the body.  However, this lung resting therapy has 
a high incidence of complications such as haemorrhagic complications in half of 
patients with influenza-related ALI (279), and did not show benefit in an earlier 
clinical trial (280).  A recent clinical trial in an ECMO centre showed a promising 
result for H1N1 influenza related ALI (281), suggesting that centralised care and 
expertise are needed to maximise the beneficial effects from ECMO (282). 
Past clinical trials often showed a discrepancy between improved respiratory 
outcomes (e.g. oxygenation) and a negative overall benefit (e.g. mortality).  That 
may be ascribed to the fact that most patients with ALI die from MODS rather than 
acute respiratory failure, hence reducing the biotrauma by protective ventilation 
and/or therapeutic intervention including anti-inflammatory drugs may be more 
important from this aspect.  Nevertheless, the current evidence indicates that none of 
the drugs, including corticosteroids, have been effective to reduce mortality.  
Substantial negative results in large clinical trials of ALI and VILI have taught 
researchers the difficulty of clinical trials and that we have to be more cautious to 
immediately extrapolate experimental results to clinical trials (4, 283, 284), as many 
potential mediators of injury may be ‘shadows’ rather than the actual causative 
agents of VILI.  Rigorously selecting the candidate agents and carefully considering 
the actual sequence and mechanisms of biotrauma are critically needed (236), 
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before rushing to clinical trials and ending up with many more negative results (87, 
93, 172). 
 
 
1.3. Ischaemia-reperfusion related lung injury 
1.3.1. Clinical relevance of ischaemia-reperfusion related lung injury 
One particular aetiology of ALI is lung ischaemia and reperfusion.  Insufficient blood 
perfusion (ischaemia) causes deprivation of essential elements such as oxygen and 
accumulation of end-metabolic products.  It has now become apparent that not only 
ischaemia, but also the re-establishment of the blood flow can further induce cellular 
damage, known as reperfusion injury.  Although reperfusion restores the ischaemic 
tissue to normal status after a short period of ischaemia, reperfusion can cause 
cellular death and/or inflammation after longer periods of ischaemia.  These 
processes are collectively termed ischaemia-reperfusion (I/R) injury (285).  
Pulmonary I/R injury is involved in pulmonary embolism, cardiac surgery (cardio-
pulmonary bypass), and a very typical example is seen in the lung transplantation 
setting. 
Lung transplantation is the ultimate treatment for various end-stage lung 
diseases including pulmonary arterial hypertension, cystic fibrosis, and chronic 
obstructive pulmonary disease (286).  Although the initial attempts at lung 
transplantation were made in 1960s’ (287), life expectancy did not extend beyond 
months until breakthroughs were made in the 1980s’.  The most important of these 
was arguably development of effective immunosuppressants (principally 
cyclosporine A (288)), following which the number of lung transplantations has 
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gradually increased and now reaches more than 3,000 per year worldwide (289).  
However, the median survival length for adult lung recipients is still around 5 years, 
while recipients of other organs (heart, kidney, liver) enjoy a half-life of around 10 
years (290). 
One of the major complications of lung transplantation is I/R injury, which is 
now clinically defined as primary graft dysfunction (PGD) and arises from inevitable 
procedures in lung transplantation; harvesting the lung by resecting from the natural 
blood supply, warm or cold ischaemia, manipulating the organs, and reperfusion of 
the graft (291).  PGD represents the net result of these insults and is defined as non-
cardiogenic pulmonary oedema within 72 hours of transplantation (292).  The 
definition and grading system of PGD was proposed by the International Society for 
Heart and Lung Transplantation (ISHLT) in 2005 (Table 1-3)(291), and is similar to 
the AECC definition of ARDS.  Based on the definition, the incidence of PGD was 
estimated as 10% of all the transplantation recipients (293).  Mortality of the most 
severe Grade 3 PGD has been revealed to be about 30% and 40% at 30-days and 
1-year post-transplant, respectively - significantly higher than the other grades by 5-7 
times (294).  PGD also affects the long-term pulmonary function (295) and is 
associated with increased risk for bronchiolitis obliterans syndrome in later stages 
(296).  In this thesis, I use the word ‘lung I/R injury’ in general to encompass the 
clinical PGD and experimental I/R injury. 
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Grade P/F ratio Chest X-ray 
0 > 300 Normal 
1 > 300 
Diffuse allograft infiltrates 2 200-300 
3 < 200 
 
Table 1-3  International Society for Heart and Lung Transplantation grading system for Primary 
Graft Dysfunction 
Grade 0 is defined as normal, and the other grades (1-3) are defined as Primary Graft Dysfunction 
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The risk factors for PGD are ascribed to not only the recipient, but also donor 
factors such as head trauma, female gender, and older age (293, 297-299).  Fisher 
et al. collected bronchoalveolar lavage samples from the prospective organ donors 
to determine the effect of neutrophils on the genesis of PGD.  They found that higher 
levels of IL-8 and neutrophils were associated with the development of severe PGD 
and early recipient mortality, suggesting that the donor infection/inflammation may be 
involved in PGD, even when the infection is subclinical (severe obvious infection 
makes lungs ineligible for lung transplantation) (300).  Subclinical infection may be 
present in up to 50% of organ donors and correlate with the poorer outcome 
because of immunological dysfunction and bacterial translocation (301-303). 
 As a consequence of the improvement in the safety of the lung 
transplantation, clinical use has increased, and waiting lists have lengthened.  
Alternative approaches to address the imbalance of supply and demand in lung 
transplant, including living donor lobar transplantation (304) and easing the lung 
donor selection criteria have been also attempted (305, 306).  Nonetheless, the 
shortage of donor organs is currently a major problem worldwide, and the US and 
European data showed 10-15% of patients on the waiting list die before they reach 
to the transplantation procedure (307).  One of the main reasons for this donor 
shortage is because 70-80% of donor lungs are judged as unsuitable for 
transplantation (308, 309).  Lungs may become injured before and after death of the 
donor by several mechanisms including neurogenic pulmonary oedema, infection, 
aspiration, and pulmonary embolism, and these insults often make the lungs 
unsuitable for actual transplantation (310, 311).  Historically, standard selection 
criteria for assessment of lung donors included normal oxygenation (P/F >300 with 
PEEP of 5cmH2O and pure oxygen), clear chest X-ray, length of intubation (< 2 
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days), age (< 55 years old), negative lavage positive gram stain, and smoking history 
(<20 pack-years).  Although most of these criteria have been revised and removed, 
most clinicians believe P/F ratio is a critical marker for measuring the pulmonary 
function, which should be rarely affected by other factors (305).  However, with acute 
cardiogenic/neurogenic pulmonary oedema, the real oxygenation ability can be 
underestimated and ‘borderline’ lungs may be judged as unsuitable for 
transplantation.  These impairments could be easily reversible, and the lung can 
recover normalised function very quickly, if the parenchyma is not yet injured and the 
lung is taken away from the influence of left ventricular failure or huge bursts of 
neurogenic mediators.  To overcome this problem, an ex vivo lung perfusion (EVLP) 
system has been successfully developed to assess lung function without the effect of 
circulatory factors (312).  Recently the application of EVLP has been extended to 
more therapeutic approaches, using a hyperosmolar solution to recondition the lungs 
by absorbing the extravascular lung water, resulting in reviving some lungs that were 
initially judged as unsuitable for transplantation (313-315).  Currently, this cutting-
edge EVLP technique is being used at a small number of hospitals and has been 
shown to be beneficial (315-317). 
 
1.3.2. Pathophysiology of lung I/R injury 
Ischaemia 
One of the important points that distinguishes lung I/R from other organ I/R injury is 
the role of hypoxia.  In extrapulmonary organs, lack of blood supply inevitably leads 
to lack of oxygen supply, and the hypoxia is a major deleterious mechanism of I/R 
(318).  However, lung cells can gain oxygen from the airways.  In line with this idea, 
evidence indicated that the lung ATP content in a rat IPL model was unchanged 
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during the ischaemia period when ventilated with normal air (319), but such 
‘normoxic ischaemia’ still produced lung injury via the cessation of endothelial shear 
stress and resultant activation of flow-sensitive ion channels, and xanthine oxidase-
related ROS production (319-324).  If the real situation during the lung ischaemia is 
normoxic rather than anoxic, models using anoxic gas ventilation, which have been 
frequently used in the past literature (325-328), may tend to distort the real life 
phenomenon; hence caution is required when we interpret these findings (329).  In 
fact, anoxia leads to accumulation of xanthine and degradation of ATP, which in turn 
leads to ROS generation after restoration of the oxygen supply (330, 331). 
During the course of ischaemia, the temperature is also an important factor. 
To prevent the autolytic response by proteases, cooling the lung is used in clinical 
settings.  However, cold ischaemia changes the activity of enzymes and chemical 
equilibration, resulting in the impairment of various intracellular mechanisms.  For 
instance, hypothermia facilitates membrane permeability to calcium and the 
alteration of intracellular calcium concentration and pH affects the intracellular 
buffering capacity and may ultimately cause cellular damage (332).  Hypothermia 
also leads to the slow removal of waste molecules and low activity of intracellular 
and membrane-bound enzymes, most of which can be decreased by half with every 
10oC decrease in temperature (332).  Aiming to balance the pros and cons, a 
warmer temperature such as 10-15oC was proposed to be beneficial compared to 
4oC (333), however others opposed the idea and 4oC is common clinical practice at 
the moment (334, 335). 
 
Reperfusion 
	   58	  
Although the disease processes start in the ischaemia phase, the physiological 
changes mainly become evident in the reperfusion period (331).  Reperfusion 
introduces various factors including leukocytes, as well as removing and spreading 
the products from damaged cells.  As a result, lung injury develops through the 
interaction between damaged cells and mediators/leukocytes in blood, and 
extrapulmonary injury may also develop by spreading the damage signals and 
injurious mediators initiated within the lung. 
In experimental models, reperfusion injury is mainly produced by two 
mechanisms; ROS and inflammation.  ROS damages cells through lipid 
peroxidation, damaging DNA, and inactivating many proteins.  Several generators of 
ROS are known in the lung including mitochondria, activated xanthine oxidase, 
NADPH oxidase system, NOS, and neutrophils (329).  In this regard, Fisher and 
colleagues suggested distinct pathways of ROS production in anoxia-reoxygenation 
and ischaemia-reperfusion.  They indicated that xanthine oxidase was mainly 
involved in the reoxygenation injury, whereas NADPH oxidase inhibition by 
diphenyliodinium (DPI) attenuated the reperfusion injury (322, 330), indicating a 
modest role of the ATP degradation agent xanthine (which is mainly induced by 
hypoxia) in the genesis of lung I/R injury. 
In terms of the cellular factors of inflammation, the main research focus of 
leukocyte involvement has been recipient neutrophils (336-341) and (in the case of 
transplantation) donor alveolar macrophages (325, 327, 339, 342).  Fiser et al. 
reported a bi-phasic pattern of I/R injury, where early I/R was dependent on resident 
alveolar macrophages, while lymphocytes and neutrophils play a role in the late 
stage of I/R (339).  Regarding soluble inflammatory mediators, a large case-control 
study in the US reported that significantly higher levels of MCP-1 and interferon 
	   59	  
gamma-induced protein 10 (IP-10) were seen in the patients with PGD, compared to 
non-PGD recipients (343).  IL-8 may also be associated with the development of 
PGD (337).  TNF has been implicated in I/R injury since TNF knockout mice were 
shown to develop less lung I/R injury (344).  Other pathological mechanisms of 
reperfusion injury may include the complement system (345, 346), surfactant 
deactivation due to atelectasis during the ischemia period and the subsequent 
reexpansion of the alveolar units (347, 348), and red blood cell transfusion (349). 
 
1.3.3. Prevention and treatments of lung I/R injury 
As discussed above, numerous clinical factors such as cold ischaemic storage and 
subclinical donor infection, and various pathological mechanisms have been 
identified as contributing to the pathogenesis of PGD.  Therefore, prevention and 
treatments of lung I/R injury include general supportive therapies and specific 
interventions targeting a specific mechanism.  Since PGD is a predictable disease 
(i.e. we know when PGD develops), previous research has mainly focused on 
prevention rather than treatment. 
 
Prevention 
To date, the main research focus of PGD has been the technical improvement of 
lung preservation techniques to prevent PGD.  Such techniques include 
considerations of temperature, reperfusion procedure, components of preservation 
solution, and ventilation setting during organ transport.  These protocols are often 
not standardised and frequently changed due to the very rapid technical progress in 
this area; thus there have been only a few randomised controlled trials to seek the 
best method for prevention of PGD (350).  Organ preservation has changed during 
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the last 10 years and now the dominance of extracellular-type preservation solutions 
(e.g. Perfadex) over intracellular-type preservation solutions (e.g. Euro-Collins 
solution), in terms of preventing PGD, has been established (351).  Inhaled NO has 
theoretical benefits including pulmonary vasodilation and decreased leukocyte 
adhesion and platelet aggregation within the lung via increased intracellular cGMP 
production.  However, 2 clinical trials of NO application to recipients have not shown 
benefits in preventing PGD (352, 353).  Other randomised controlled trials, including 
soluble complement receptor-1 inhibitor injection to recipients for antagonising C5a-
related reperfusion injury (354) and platelet-activating factor (PAF) blocker 
administration to recipients to attenuate pro-inflammatory reactions, have similarly 
failed to prevent PGD (355, 356). 
As described above, EVLP was originally developed to assess the lung 
function ex vivo (312), and is now expanding its application to the reconditioning of 
donor lungs (315).  Since the EVLP also allows us to manipulate the lung (e.g. apply 
drugs into the perfusion circuit during the EVLP procedure) before implanting to 
recipients, it may provide an opportunity to develop novel therapies such as 
transfecting anti-inflammatory genes into the lung during EVLP (357). 
Brief ischaemic episodes followed by reperfusion can induce tolerance to 
further ischaemic damage, a mechanism known as ischaemic preconditioning (358, 
359).  Ischaemic preconditioning has been tested in animal models and shown to be 
beneficial (360-362), but there has been no clinical trial to test preconditioning for 
preventing PGD due to the complexity of inducing such a short ischaemia to the lung 
which has dual blood supply (i.e. pulmonary and bronchial circulation) whereas this 
technique may be effective in other clinical settings including liver resection and 
coronary artery bypass (363, 364). 
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Experimentally, there are other candidates for the prevention of PGD.  For 
instance, intratracheal anti-IL-8 antibody administration attenuated rabbit I/R injury 
together with a reduction in neutrophil infiltration (340).  Depletion of alveolar 
macrophages has also been shown to be effective to prevent PGD (325, 327), 
although these studies utilised anoxia-reoxygenation injury. 
 
Supportive therapy 
Supportive treatments are essentially similar to those for ALI, including protective 
ventilation to prevent VILI and avoiding excessive fluid administration.  ECMO use 
has been proposed for refractory hypoxia or the intraoperative setting, but the results 
are still controversial and inconclusive (365-369), perhaps due to difficulty in the 
management of ECMO (350).  Surfactant therapy has shown promising results in 
animal studies (370-372), and a small uncontrolled clinical trial showed 100% 19-
months survival rate (373), but further investigation is needed to confirm this pilot 
study. 
 
Specific therapy 
Clinical evidence suggested several potential candidates for the specific treatment of 
PGD.  Despite negative results in the prevention of PGD, inhaled NO may improve 
outcomes of PGD patients (374-376), but the overall result is conflicting so far (377) 
and the effect may be transient (378).  In the treatment of severe PGD, low-dose 
prostaglandin E1 (PGE1) infusion might be helpful (379-381).  However, these 
agents have not been tested in large randomised clinical trials yet, thus the evidence 
is not strong enough to recommend the routine use of these agents.  There are other 
candidates which have been proposed as effective from experimental findings, 
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including anti-oxidant agents (322, 330, 341) and blocking agents for transcriptional 
factors (NF-kappa B and AP-1) (382-384), but these have not yet been translated 
into clinical trials. 
 
 
1.4. Lung-marginated leukocytes 
1.4.1. Leukocyte kinetics in marginated pool of leukocytes 
Leukocytes are key component cells within the immune system.  During foetal 
development, leukocytes are mainly produced by liver and spleen.  After delivery, the 
main site producing blood shifts to bone marrow, where almost all the leukocytes are 
produced and matured under physiological conditions.  After the mature leukocytes 
are released from bone marrow, they either circulate in the blood (and as such are 
termed the circulating pool) or attach to the endothelium (and are termed as 
members of the marginated pool) (385, 386). 
The main site of the marginated pool is considered to be within the solid 
organs.  The spleen stores large number of leukocytes (especially lymphocytes) 
within its microcirculation (387, 388).  Evidence suggests that the lung also stores 
large number of leukocytes within its microcirculation (389, 390), potentially 
exceeding the size of the circulating pool (386), and lung has frequently been used 
for investigation of the kinetics of such a marginated pool.  The majority of such 
studies have been based on radioisotope techniques, where radioisotope-labelled 
leukocytes were injected (385, 391-395).  These studies revealed that the lung may 
have the biggest marginated pool in the body, although some researchers argued 
there is a species difference in the size of the lung marginated pool, and that in 
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healthy human lung it might be rather modest (396, 397).  It also has to be 
considered that the radiolabelling procedures can substantially change cellular 
features.  Recently, intravital microscopic examination has been used for kinetic 
analysis within the pulmonary microcirculation and revealed leukocyte margination is 
prominent not only in alveolar capillaries, but also in pulmonary arterioles and 
venules (398, 399). 
The roles of leukocytes in the marginated pool are not entirely clear.  They 
may work as a stock of leukocytes, which can be recruited to the circulating pool 
immediately.  This possibility was described in the early 20th century (by histological 
examination of rabbit lung), as “It may be that the bone marrow is the birthplace of 
leukocytes and the spleen their ultimate tomb, while the blood is their means of 
transit, the lung may serve as a weekend at the seaside” at a lecture to the Royal 
College of Physicians in London in 1910 (254).  Subsequent studies revealed that 
higher cardiac output (e.g. epinephrine injection, exercise) (393, 395, 400-402), 
steroid (402-404), or Muller manoeuvre (405) releases leukocytes from the 
marginated pool, while bacterial infection (e.g. LPS) (402), histamine (406), or 
Valsalva manoeuvre (405) increases the number of leukocytes in the marginated 
pool. 
Although much progress have been made in understanding immune 
mechanisms, less is known about the immune response within the vasculature, 
termed intravascular immunity (407), although this may play a crucial role to prevent 
bacterial dissemination and protect the host.  In this context, leukocytes in the 
marginated pool could play a sentinel role.  In most vascular beds, leukocyte 
recruitment occurs via four steps during the development of inflammation – rolling, 
adhesion, intraluminal crawling, and transmigration.  In response to infection or 
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injury, leukocytes first tether to the blood vessel endothelium and start rolling along 
the endothelium in a selectin-mediated manner, before firmly arresting at injured 
organs via an integrin-mediated interaction (408).  Thereafter, leukocytes start 
random crawling on the endothelial surface before transmigration across the 
endothelium (409, 410).  The leukocytes in the marginated pool may behave 
similarly (except transmigration) under normal physiological conditions and play a 
key role in intravascular immunity (as described below). 
However, the mechanisms underlying leukocyte recruitment may be different 
within the lung and liver, as selectin blockade did not reduce leukocyte recruitment in 
these organs (411-413).  In the lung, mechanical factors may be involved in this 
trapping mechanism (390, 391).  Doerschuk and colleagues showed that neutrophils 
and monocytes are in fact larger than the diameter of most lung capillaries, therefore 
they always have to deform themselves to pass through the pulmonary circulation 
(414), whereas erythrocytes rapidly deform themselves and smoothly pass through 
the pulmonary microcirculation (415, 416).  The retention time of leukocytes 
generally lasts less than a second, but occasionally exceeds 1 minute (399, 417).  
The same research group also demonstrated that leukocyte retention within the lung 
capillary depends on the stiffness of leukocytes, which is increased by stimuli 
including steroids and infection (394, 414).  In the liver, other adhesion molecules 
including CD44 and serum derived hyaluronan-associated protein have been 
implicated in leukocyte recruitment (418, 419). 
 
1.4.2. Leukocyte subsets within the marginated pool 
Several populations of leukocytes are located in the vasculature to detect and 
respond to infection.  Evidence suggested that a large number of neutrophils adhere 
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to postcapillary venules of the cremaster muscle and the majority of these adherent 
neutrophils crawl randomly along the endothelium, but eventually detach without any 
other stimuli (410).  Recent research has shown that these intravascular neutrophils 
can trap bacteria via the generation of neutrophil extracellular traps (420, 421). 
Using an intravital microscopy technique, Auffray et al. observed that a subset 
of murine monocytes crawled throughout the capillary in the absence of inflammation 
(422).  Recent studies indicated that there are at least two functionally distinct 
subtypes of monocytes in rodents and humans (423), which has increased interest in 
monocyte research.  In the mouse, ‘immature’ Gr-1 high and ‘mature’ Gr-1 low 
subsets have been identified (Gr-1 (Ly6C/G) is a cell surface granulocyte marker, 
any functional significance of which is as yet unknown).  Immature Gr-1 high 
monocytes migrate into local sites of inflammation and injury and have been termed 
the ‘inflammatory’ subset.  On the other hand, mature Gr-1 low monocytes can enter 
into the tissues and differentiate into tissue macrophages (424), and are hence 
termed the ‘resident’ subset (Fig 1.2).  Humans also have similar functionally distinct 
monocyte subsets, defined as ‘inflammatory’ CD14high/CD16- subset and ‘resident’ 
CD14+/CD16+ subset (423).  In the above study by Auffray, the Gr-1 low ‘resident’ 
monocyte subset was shown to patrol the microcirculation in a LFA-1 dependent 
manner and extravasate into the tissues in response to peritoneal bacterial 
stimulation (422).  These patrolling role of Gr-1 low monocytes was later also shown 
in brain tissue (425). 
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Figure 1-2  Development and functions of monocyte subsets in mice. 
Gr-1 high monocytes are released from bone marrow into circulating blood.  Some Gr-1 high 
monocytes are considered to be recruited to the inflamed tissue (and may differentiate into 
macrophages) and play a role in pathogen clearance and would healing.  Gr-1 high monocytes can 
also differentiate within the circulation into Gr-1 low monocytes, which subsequently enter the tissues 
and replenish tissue-resident macrophages and dendritic cells.  Based on these known characteristics 
of each subset, Gr-1 high monocytes and Gr-1 low monocytes are often termed ‘inflammatory’ and 
‘resident’ monocytes, respectively. 
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Macrophages are also seen within the intravascular space of particular 
organs.  Kupffer cells mobilise along the liver sinusoidal cells and play an important 
role as a gatekeeper in the liver, where many foreign substances derived from the 
food in the gastrointestinal tract are filtered (426, 427).  In some species including 
sheep and pigs, lungs have pulmonary intravascular macrophages (PIM).  In species 
that have PIM, most particulate matter and LPS is captured within the lung, whereas 
species lacking PIM capture particulate matter and LPS within the liver and spleen 
(428).  Warner et al. found that sheep (which has PIM) captured most of the bacterial 
agents, including P. aeruginosa (429) and LPS (430), at lungs and developed ALI, 
whereas rat (which does not have PIM) captured them mainly at liver and cause liver 
inflammation at early stage (429, 430), suggesting correlation between the site of 
bacterial uptake and the site of primary inflammation.  In line with this, depleting PIM 
has been shown to attenuate ALI in these animals that have PIM (431).  Humans, 
mice, and rats do not have PIM under normal condition (432-434), but mononuclear 
phagocytes were shown to be recruited in pathological conditions including liver 
disease and sepsis in laboratory animals (435-437), and human (438-440).  These 
recruited mononuclear phagocytes in the lung may act as PIM and contribute to 
increased pulmonary susceptibility to other insults, leading to ALI (435-437). 
Lymphocytes reside in the intravascular space and one of the major subsets 
of the intravascular lymphocytes is invariant natural killer T (iNKT) cells, which co-
express NK receptors and T cell antigen receptors and represent up to 30% of liver 
lymphocytes (441).  In the liver, iNKT cells localise within the liver sinusoids with 
Kupffer cells, which present antigens to the iNKT cells (442).  Geissman et al. 
demonstrated that the liver iNKT cells randomly crawl within liver sinusoids and 
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continuously patrol within these vessels (443).  In the lung, iNKT cells have been 
implicated in the development of I/R injury via the production of interleukin-17 (444). 
In summary, previous investigations about leukocytes in the marginated pool 
focused on their localisation, size, and kinetics.  Recent technical advances, in 
particular imaging techniques, made it possible to investigate such a dynamic 
environment (i.e. intravascular space) and emerging evidence indicates that the 
leukocytes in marginated pool play a key role in intravascular immunity.  The lung 
may contain a very large marginated pool, however the roles of these cells have not 
yet been well clarified. 
 
1.4.3. Monocyte-endothelial interaction in lung 
Using in vivo mouse models, we have previously demonstrated that monocytes were 
recruited to the lung during systemic endotoxaemia.  These newly-recruited ‘lung-
marginated monocytes’ expressed higher levels of membrane-associated TNF and 
they activated pulmonary endothelial cells in a direct cell contact-dependent manner, 
suggesting a role of monocyte-endothelial interaction (445).  We recently further 
pursued the monocyte subset, origin, and long-term kinetics of these monocytes, 
and consequential effects of this recruitment.  We found that a large number of Gr-1 
high ‘inflammatory’ subset monocytes were recruited from the bone marrow pool to 
the lung microvasculature after subclinical endotoxaemia (earlier than the peak of 
neutrophil margination), and that half of these monocytes rapidly left the lung within 
another 2 hours (446).  Interestingly, when the monocyte margination was maximal, 
the lungs were sensitised to subsequent stimuli including yeast infection (446) and 
injurious ventilation (219), and this ‘priming’ effect was abrogated by monocyte 
depletion.  Intravascular labelling techniques and histological examination revealed 
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that the majority of newly-recruited monocytes were present within the pulmonary 
microvasculature at the time of the second insults in the above experiments (446).  
Based on these backgrounds, we have hypothesised that the newly-recruited 
monocytes act like PIM, and increase susceptibility to additional stimuli, via the 
interaction between lung-marginated monocytes and pulmonary endothelium. 
Leukocyte-endothelial interaction is important not only for the sequential 
events of leukocyte transmigration, but also the synergistic activation of both cell 
types during the development of inflammation.  In this context, in vitro co-culture 
models have revealed several roles and mechanisms.  For instance, neutrophils are 
polarised through the endothelial interaction (447), whereas calcium influx is 
facilitated in endothelium by interaction with neutrophils (448).  In the case of 
monocyte-endothelial interaction, higher expression of mediators has been found in 
IL-8, MCP-1, tissue factor, and cyclooxygenase-2 (COX-2) (449-451).  These co-
culture experiments are often carried out using human umbilical vein endothelial 
cells, but endothelial cells have different site-specific characteristics (452, 453).  For 
instance, all pulmonary capillary endothelia express angiotensin-converting enzyme, 
while only 10% of systemic endothelium have the enzyme (454).  Pulmonary 
capillary endothelium contains large numbers of caveolae, and uniquely binds to a 
lectin from Griffonia simplicifolia, which specifically interacts with alpha-galactose 
(455).  We have recently demonstrated that the co-culture of pulmonary endothelium 
and monocytes induced the production of several mediators including inducible nitric 
oxide synthase (iNOS), COX-2, and IL-6 from monocytes, suggesting that monocyte-
endothelial interaction also induces synergistic effects within the lung.  The 
synergistic effects were mediated via the p38/MK2 pathway and more pronounced in 
the Gr-1 high inflammatory monocytes (456). 
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Collectively, our recent findings provided evidence relating to the critical role 
of interaction between lung-marginated inflammatory monocytes and endothelium in 
developing ALI.  Since the previous research has mainly focused on neutrophils, 
further elucidation of the monocyte-endothelial interaction in the context of ALI may 
give an insight to develop novel therapies targeting this interaction. 
 
 
1.5. Isolated perfused lung 
1.5.1. Overview of IPL 
Isolated perfused lung (IPL) is an in situ experimental lung model, which was 
developed some time ago to investigate the non-respiratory pulmonary function (457, 
458).  In the early days, the main use of IPL was limited to toxicology studies, 
pharmacokinetics studies, and characterisation of the pulmonary circulation (459-
461), whereas investigations in respiratory mechanics were often carried out using 
isolated, but non-perfused lung (462, 463).  Since the biotrauma hypothesis was 
highlighted in VILI, the number of IPL experiments for inflammatory research has 
increased (194, 464, 465) to clarify the role of the lung per se in the context of ALI.  
Because extrapulmonary factors substantially modulate the systemic inflammatory 
response, the removal of such extrapulmonary effects in IPL is theoretically a strong 
tool to elucidate the specific molecular mechanism within the lung. 
IPL involves the perfusion (with physiological buffer and protein) and 
ventilation of the entire lung.  By carrying out perfusion and ventilation properly, the 
lung is maintained as a complete organ with its many cellular and humoral 
interactions among the resident cells, and therefore it is more realistic and 
	   71	  
physiological than in vitro cell culture.  Compared to in vivo models, IPL provides 
more flexibility and the ability to use tools such as drugs (including potentially toxic 
agents) on the lungs without confounding effects on other organs.  Physiological 
parameters including pulmonary arterial pressure (PAP), which is not technically 
easy to measure in vivo, are easily monitored in IPL.  Historically, large animals have 
been used for IPL preparation, but recent technical developments made it possible to 
set up mouse IPL, making genetic/immunological intervention easier (194). 
 Limitations of IPL include the necessity of surgical procedure to set up the 
preparation; thus the life span of IPL is usually up to several hours because of the 
somewhat unphysiological condition.  The physiology of IPL is different from the in 
vivo situation for various reasons including the loss of bronchial circulation and 
perhaps most importantly, the loss of pleural pressure.  During the closed chest 
condition, negative pleural pressure prevents the lung units from collapse at the end-
expiratory phase and maintains some lung volume, known as functional residual 
capacity (FRC).  Since IPL experiments are conducted under open-chest condition, 
the pleural pressure is equal to the atmospheric pressure (‘zero’ pleural pressure), 
making the lungs more susceptible to collapse. 
 
1.5.2. Utilisation of IPL for ALI research 
Application for VILI research 
As discussed in the previous section, the role and mechanism of atelectasis-related 
VILI has not been well clarified.  One of the difficulties of the investigation of 
atelectrauma arises due to the difficulty of modelling this in animals.  For instance, 
atelectasis can increase the resistance of pulmonary circulation and therefore cause 
right ventricular dysfunction (130).  It is also difficult to create significant atelectasis 
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in healthy lungs, because the transpulmonary pressure at end-expiration during 
mechanical ventilation is still positive due to the elastic recoil of the rib cage and 
negative pleural pressure.  Therefore, most previous atelectrauma models 
incorporated pre-injury (139, 144, 148), relatively high tidal volume (193, 466), or 
both (467) to amplify the lung injury, making mechanistic analyses difficult. 
We planned to take advantage of IPL system, in which the chest is open to 
atmospheric pressure and the transpulmonary pressure at end-expiration becomes 
zero and thus the lung volume becomes less than the closing volume (where the 
small airways start to collapse), to develop the atelectasis without any other insults.  
Since the in vivo high-stretch model has been already developed in our laboratory 
(201), and mouse high-stretch model in IPL has been reported (194, 195), the 
comparison of an atelectrauma model and the high-stretch model should give us 
novel insights about the distinct pathophysiology of the two different aetiologies of 
VILI. 
Historically, isolated ‘non-perfused’ lung was used to prove that lung has an 
ability to produce cytokines in response to mechanical stretch (193), however the 
interpretation of such experiments was not straightforward because of the model-
related side effects such as accumulated metabolites and ischaemic effects. In this 
regard, IPL allows us to address the above criticisms over the use of non-perfused 
lung.  IPL is also useful to clearly define what the lung as an organ would produce 
and release into pulmonary veins and then to systemic circulation, because it is 
intrinsically difficult to analyse the lung inflammatory output in the intact system.  The 
simultaneous analysis of the lung-borne cytokines secreted to the circulation and 
intra-alveolar cytokines might give us some clues to investigate the inflammatory 
propagation mechanisms. 
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Application for investigating the role and mechanism of lung-marginated monocytes 
As described in the previous section, our laboratory has successfully shown the 
important role of lung-marginated monocytes and their interaction with pulmonary 
endothelium in ALI using in vivo mouse model and in vitro co-culture models.  
However, in order to further elucidate the mechanisms behind the cellular interaction, 
we faced model-related intrinsic problems.  In the case of the in vivo experiments, 
there were difficulties excluding systemic effects caused by treatment used and 
technical complexity.  For instance, we used clodronate-loaded liposomes to deplete 
monocytes in the in vivo LPS-VILI 2-hit model (219).  While the systemic injection of 
this agent is compartmentalised within the intravascular space, this treatment 
depletes other intravascular macrophages including Kupffer cells.  In order to 
overcome this limitation, we investigated two time points between the injection of 
clodronate-liposomes and the application of VILI; 1) 24 hours, at which all the 
monocytes are depleted; 2) 48 hours, when only Gr-1 high monocytes start to be 
repopulated (468).  Because the lung injury was attenuated at 24 hours, but less so 
at 48 hours, we concluded the priming effect was due to Gr-1 high monocytes rather 
than e.g. Kupffer cells.  However, we could not exclude the possibilities that the 
circulating monocytes may play a role rather than the lung-marginated monocytes, or 
that some unidentified off-target effects of clodronate-liposomes at 48 hours may 
have affected the results.  As such, in vivo investigations of direct cellular contacts 
within a particular organ are inevitably complicated by systemic effects. 
 
 
	   74	  
1.6. Hypothesis and aims 
Based on the background, we hypothesised that lung-marginated leukocytes play a 
key role in the development of pulmonary oedema and inflammatory propagation in 
ALI.  In particular we predicted that this may be more important for aetiologies of ALI 
involving insults to the intravascular space, including overstretch and ischaemia-
reperfusion.  To address this, we planned to develop an in situ mouse IPL model in 
this PhD project to address unanswered questions in the previous research 
including: 
1) The differential role and mechanism of high-stretch induced and atelectasis-
related VILI. 
2) The propagation mechanisms of inflammation in VILI. 
3) The role and mechanism of lung-marginated leukocytes in ALI. 
 
We chose the mouse because of the availability of various immunological 
tools and potential knockout mice experiments.  Regarding VILI, we intended to take 
advantage of the open-chest ‘zero pleural pressure’ IPL model to develop an 
atelectrauma model for investigating the distinct pathophysiology between 
volutrauma and atelectrauma.  In terms of the propagation mechanisms, IPL allows 
us to clearly define the systemic release of the lung-borne mediators together with 
the local mediator production in the intra-alveolar space.  For the investigation of the 
role and mechanism of lung-marginated monocytes, IPL should be a useful bridge 
between the in vivo physiological significance and in vitro mechanistic insights.  
Specifically, we aimed to; 
1) Develop, characterise, and optimise the mouse IPL system. 
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2) Compare the difference between atelectrauma and volutrauma in terms of 
disease progression and cytokine production. 
3) Investigate the role of lung-marginated leukocytes in the development of ALI. 
 
 
1.7. Overview of the thesis 
The overall structure of the thesis takes the form of 7 chapters, including this 
introductory chapter.  Chapter 2 presents the materials and methods used for the 
project. 
 
The result section is composed of four themed chapters.  The third chapter begins by 
describing the optimisation and characterisation of the mouse isolated perfused lung 
system, and also demonstrates that mouse lung contains a very substantial number 
of leukocytes within its microcirculation, which we term ‘lung-marginated leukocytes’. 
Chapter 4 is concerned with the development of a unique atelectasis-related 
ventilator-induced lung injury (VILI) model, and describes its pathophysiological 
difference from the high-stretch induced VILI model. 
Chapter 5 focuses on the role and mechanism of lung-marginated monocytes’ 
within the two developed VILI models.  I show that the lung-marginated monocytes 
seem to be particularly important in the development of high-stretch induced VILI. 
In chapter 6, I further explore the role of lung-marginated monocytes in more 
clinically relevant setting, transplant-related ischaemia-reperfusion induced lung 
injury. 
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The final chapter draws upon the entire thesis in order to reappraise some of the 
current paradigms, discuss the clinical implications, and identify areas for further 
research. 	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2. Material and methods 
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2.1. Mouse isolated perfused lung 
Animals 
All procedures followed the Animals (Scientific Procedures) Act 1986, United 
Kingdom.  Male C57BL6 mice (Charles River Laboratories, Margate, UK) aged 8 to 
12 weeks (20-30g) were used for all the experiments.  Animals had free access to 
food and water. 
 
IPL system setting 
The mouse IPL system (Isolated Perfused Lung Size 1 Type 839; Hugo-Sachs 
Elektronik, March-Hugstetten, Germany) consists of three circuits; perfusion circuit, 
respiratory circuit, and thermostatic circuit, and is illustrated in Fig 2.1.  Fig 2.2 
shows the schema of the perfusion circuit. 
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Figure 2-1  Photograph of the in situ mouse Isolated Perfused Lung system. 
The lungs were ventilated via the respiratory circuit, which consists of (1) the connection part, which 
directly connects to the endotracheal tube, (2) a pressure transducer used to measure the tracheal 
pressure, (3) a pneumotachometer used to determine the flow rate of the inspired gas, (4) a humidifier 
and (5) a Y-piece which was connected to our custom-made jet ventilator, within which (6) a solenoid 
valve regulated the air flow.  The lungs were perfused via the perfusion circuit, which consists of (7) a 
pulmonary artery cannula, (8) a venous drainage cannula, (9) a bubble trap, (10) a heat exchanger, 
(11) a reservoir and (12) a peristaltic pump.  The circuit type was switched between non-recirculating 
or recirculating by clamping (13) the 3-way connectors and the perfusion pressure is monitored by 
(14) a pressure transducer connected to one of the side ports of the stainless steel cannulae.  The 
lung and perfusate are warmed by the thermostatic circuit in which distilled water is heated and flows 
through (15) the plexiglass chamber, which in turn warms the perfusate (at the heat exchanger) and 
the lung.  Temperature and humidity levels are maintained by (16) the water-warmed plexiglass lid. 
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Figure 2-2  Schematic diagram of the perfusion circuit. 
(A) Illustration of the non-recirculating circuit where the perfusate is drawn up from (1) the reservoir by 
(2) a peristaltic pump, after which the perfusate is warmed at (3) the heat exchanger and bubbles in 
the perfusate are removed at (4) the bubble trap.  Through the pulmonary artery cannula, (5) the lung 
is perfused and the effluate is collected via the venous drainage cannula.  Effluate is drained via (6) 
the reservoir and to (7) the waste beaker.  (B) In the recirculating circuit the effluate in the reservoir is 
collected by a peristaltic pump and reused. 
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The lung can be perfused using either a non-recirculating or a recirculating 
system, and it is possible to switch between these two circuit types during the 
experiments.  In the simpler, non-recirculating circuit, residual blood is washed out in 
the initial equilibration period and the lung is continuously supplied with fresh 
perfusate.  Due to technical ease, the non-recirculating perfusion system has been 
used in most previous studies.  However, as we wanted to have the option to retain 
the cell population (e.g. lung-marginated leukocytes) in the circuit, we also 
developed a recirculating circuit.  The dead space of the perfusion circuit is 
approximately 2.5ml (including 0.5ml of reservoir volume), which is very similar to the 
actual mouse blood volume. 
 
Animal preparation 
Mice were anaesthetised with an intraperitoneal (i.p.) injection of 130 mg/kg 
ketamine and 13 mg/kg xylazine.  These doses were deliberately higher than we 
used in vivo (201) for the subsequent surgical procedure including laparotomy. 
Under the general anaesthesia, the mice were tracheostomised, intubated, 
and ventilated with air.  Thereafter, a midline laparotomy was performed and heparin 
(100 IU/body) was injected intravenously (i.v.) via the inferior vena cava (IVC) to 
prevent blood coagulation.  After exsanguination by cutting the IVC, the inhalational 
gas was changed from air to 5% CO2, 21% O2, 74% N2.  The 5%CO2 was 
supplemented because lung per se does not produce much CO2, and thus the 
perfusate would develop hypocapnic alkalemia if we continue ventilating with air 
alone.  Then the lower half of the body (below the liver) was severed to enable 
cannulation and prevent contamination from possibly damaged regions of the 
digestive tract.  After a midline thoracotomy, the main pulmonary artery (PA; 
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perfusion cannula) and left atrium (LA; drainage cannula) were cannulated with 
stainless steel cannulae via the right ventricle and left ventricle, respectively. 
The lungs were ventilated using a custom-made mouse ventilator-pulmonary 
function testing system, which is used for in vivo experiments in our laboratory (201, 
469), with a respiratory rate (RR) of 80 breaths/min, tidal volume of 7ml/kg, and 5 
cmH2O positive end-expiratory pressure (PEEP), unless otherwise stated.  SI 
(25cmH2O for 5 seconds, once in every 15 minutes) was applied to prevent the 
progression of atelectasis.  The lung perfusion was initiated with 0.1ml/min and 
increased to 0.6-0.75ml/min (corresponds to 25ml/kg/min) over 5 minutes using a 
peristaltic pump (Ismatec REGLO Digital Tubing pump; Laboratoriumstechnik 
GmbH, Wertheim-Mondfeld, Germany).  Complete and thorough perfusion was 
confirmed by the appearance of the lungs (as illustrated in Fig 2.3).  If the level of 
‘whiteness’ was unequal across the lungs following perfusion, the samples were 
abandoned. 
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Figure 2-3  Photograph of the perfused lung. 
(A) Pulmonary atrial cannula (1) and left atrial cannula (2) were inserted via the heart.  (B) Both sides 
of the lung (3) have homogeneous white appearance after starting perfusion. 
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Non-recirculating perfusion was performed for the first 10 minutes to wash out 
the residual blood from the lung (referred to as ‘equilibration period’), after which the 
lung was perfused either in a non-recirculating or re-circulating manner, depending 
on the purpose of the experiment.  In the experiments using the recirculating circuit, 
perfusate was exchanged every hour to limit the accumulation of metabolites within 
the circuit (as described in Chapter 3).  The perfusate exchange was achieved by 
switching to a non-recirculating perfusion for 5 minutes. 
Left atrial pressure (LAP) was set at 2.5 mmHg by lifting the reservoir up and 
down during perfusion.  The perfusate used was non-blood physiological buffer 
consisting of RPMI 1640 without phenol red (Invitrogen, Paisley, UK), supplemented 
with 4% low endotoxin bovine serum albumin (Sigma-Aldrich, Gillingham, UK) and 
sodium chloride – to increase osmolarity, as previously described (194).  Sodium 
bicarbonate was added before starting the experiments to adjust the perfusate pH to 
7.3-7.45.  The temperature of the water circulating in the plexiglass chamber was 
controlled at 37 oC by the thermostat.  The IL-1 IPL system has a lid for the chamber, 
which is also filled with the warmed water.  Therefore the temperature of this ‘water-
jacketed’ chamber is maintained and in fact we confirmed that the perfusate flowing 
within the chamber was well controlled at 37 oC. 
The tracheal pressure was continuously monitored via a pressure transducer.  
Perfusion pressure was also measured continuously via side ports at the PA and LA 
cannulae.  The respiratory system mechanics, including lung elastance (Ers) and 
resistance (Rrs) were periodically measured using the end-inspiratory pause 
technique (469).  Briefly, end-inflation occlusion was performed by shutting off both 
inspiratory and expiratory solenoid valves for 225 milliseconds and the plateau 
pressure was determined (Fig 2.4).  Ers and Rrs were calculated as below; 
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Ers = ((Pplat) – (PEEP)) / (VT) 
Rrs = ((PIP) – (Pplat)) / (Qaw) 
 
Where; 
Pplat: plateau pressure 
PEEP: positive end-expiratory pressure 
VT: tidal volume (determined by flow trace; Fig 2.4) 
PIP: peak inspiratory pressure 
Qaw: steady-state flow immediately prior to occlusion 
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Figure 2-4  Measurement of respiratory mechanics using end-inflation occlusion technique. 
Pressure and flow traces are acquired by pressure transducer and pneumotachograph, respectively.  
Using end-inflation occlusion technique, plateau pressure, PEEP, and peak pressure are determined 
to calculate respiratory system mechanics.  VT is calculated in the flow trace after correcting the zero 
drift. 
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2.2. Experimental protocols 
Model of ventilator-induced lung injury 
In order to compare the pathophysiology in different aetiologies of ventilator-induced 
lung injury (VILI), we developed in situ high-stretch induced and atelectasis-related 
VILI models in the IPL.  After the equilibration period, lungs were allocated to one of 
three groups: control, atelectasis, or high-stretch.  All the lungs were ventilated with a 
respiratory rate of 80/min, and perfused at 0.6-0.75ml/min (corresponds to 
25ml/kg/min) in a recirculating manner with hourly perfusate exchange, or in some 
cases non-recirculating manner for 3 hours.  The perfusate was collected regularly 
for cytokine analysis.  In the control group, the lungs were ventilated with low tidal 
volume (7ml/kg) with PEEP (5cmH2O), and regular SI was applied.  The atelectasis 
group received the same low tidal volume, but neither PEEP nor SI to allow 
significant atelectasis to develop.  In the high-stretch group, lungs were ventilated 
with high tidal volume (26-32ml/kg) and both PEEP (3cmH2O) and SI.  Lower PEEP 
of 3cmH2O was chosen for the high-stretch group because the lung hit the 
diaphragm and the inner surface of the retracted rib cage when the lung was 
ventilated with high tidal volume and 5cmH2O of PEEP.  At the end of protocol, lung 
lavage sample was taken by syringing both lungs via the endotracheal tube with 
750µl of saline (201) for analysis by the protein and cytokine assays. 
 
Ischaemia-reperfusion lung injury 
In an attempt to generalise my findings regarding lung-marginated leukocytes in VILI, 
we investigated another highly translational model, in situ transplantation-related 
ischaemia-reperfusion lung injury. 
	   88	  
In order to simulate the lung transplantation setting, we used a different buffer, 
lacking nutrients, to flush the residual blood from the lung.  We initially flushed out 
the residual blood with a 10-minute non-recirculating perfusion using ‘flushing’ buffer 
consisting of Hanks Balanced Salt Solution (HBSS; Invitrogen, Paisley, UK) 
supplemented with 5% low endotoxin BSA (1.2-1.5ml/min, corresponding to 
50ml/kg/min) for reasons that will be explained later in Chapter 6.  Since removal 
and reapplication of endothelial shear stress is considered to be involved in the 
pathogenesis of ischaemia-reperfusion injury (323), we increased the perfusion rate 
to 1.2-1.5ml/min to increase the shear stress. 
After the 10-minute flushing, ischaemia was induced for 2 hours by stopping 
the perfusion, while the lungs were kept at 37°C and inflated with 5 cmH2O of 
continuous positive airway pressure to prevent atelectasis.  The intravascular 
pressure was kept at 2.5 mmHg.  Importantly, we did not induce hypoxia in this 
model, because oxygen is provided from alveoli and this alveolar oxygen should 
maintain aerobic metabolism in the lung (319, 470) during graft storage in the lung 
transplantation setting. 
At the start of reperfusion with the usual RPMI-based buffer, SI was 
performed twice to recruit any regions that collapsed during the ischaemia.  
Perfusion was started at 0.1ml/min to avoid a sudden increase in perfusion pressure 
and the flow was gradually increased to 1.2-1.5ml/min (50ml/kg/min) over 5 minutes.  
Upon reperfusion, the non-recirculating circuit was used for an initial 10 minutes to 
replace the perfusate within the circuit, and thereafter switched to the recirculating 
circuit and continued for another 50 minutes (making up a total of 1-hour 
reperfusion).  Perfusate samples were taken from the circuit at each stage of the 
experiments (i.e. pre-ischaemia, post-ischaemia, post-reperfusion) for further 
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analysis.  At the end of the protocol, lung lavage samples were taken as described 
above, and the lung tissue was obtained for flow cytometry analysis. 
 
In vivo monocyte depletion/repletion 
As our group has previously proposed that lung-marginated monocytes play an 
important role in the development of ALI (219, 446), in some experiments, we 
decreased or increased the number of these cells within the isolated lungs to clarify 
their role within the aforementioned models.  In order to deplete the monocytes, we 
used systemic administration of clodronate-loaded liposomes, which was shown to 
selectively deplete monocytes/macrophages in the intravascular space (471).  The 
advantages and disadvantages of this and other monocyte depletion techniques will 
be discussed later in Chapter 5.  200µl of clodronate-liposomes were injected into 
mice 24 hours before setting up IPL.  In order to increase the number of lung-
marginated monocytes in the lung, a subclinical endotoxaemia 2-hit model was 
employed (219, 446).  20ng of ultra-pure grade LPS (O111;E4, Source Bioscience, 
Nottingham, UK) was injected into mice 2 hours before setting up IPL.  The dose of 
20ng was chosen because we previously found that administration of this small LPS 
dose did not cause any clinical symptoms or lung injury, yet recruits substantial 
number of leukocytes to the lung (446).  Thereafter, these pre-treated lungs were 
allocated to subsequent experimental protocols such as VILI and I/R. 
 
 
2.3. Sample assays 
Flow cytometry 
	   90	  
In order to quantify the numbers of each cell and its expression of cell surface 
antigens as cellular activation markers, we used a flow cytometry technique. 
 
Overview of FACS 
Flow cytometry, also called fluorescence-activated cell sorting (FACS), is a sensitive 
immunological method that uses fluorescent antibody-stained cell surface markers to 
determine the type of each cell (termed ‘immunophenotype’) and measure 
expression of cell-associated target antigens on a per cell basis.  This technique is 
often used for the analysis of cultured cells or blood cells, but we recently developed 
a FACS technique, which enables us to analyse the single cell suspensions 
produced from lung (208).  Recent multichannel FACS made it possible to 
simultaneously stain the cells with several antibodies, enabling more detailed 
immunophenotyping.  This is notable because such detailed analysis cannot be 
achieved by other methodologies including Western blot.  In the analysis of lung 
tissue sample, a single cell suspension has to be initially created by homogenising 
and filtering the tissue homogenate.  Cells are then labeled with a fluorophore 
conjugated antibody cocktail.  In the flow cytometer (CyAn; Beckman Coulter, High 
Wycombe, UK), each cell is exposed to 2 laser beams and the cell radiates various 
wave lengths of light depending on the amount of antigens, size, and the intracellular 
granularity.  This information is collected and analysed by software (FlowJo; Tree 
Star, OR, USA). 
 
Sample processing 
To make a lung single cell suspension sample for FACS analysis, lung was 
mechanically dissociated with a scalpel and the cell suspension was resuspended in 
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saline.  Some samples were thereafter incubated in 0.5mg/ml collagenase type IV 
(Sigma) at 37°C for 30 minutes to facilitate the cell collection, however collagenase 
can destroy the surface antigens and thus its use was limited to specific antigen 
measurements.  The resultant lung homogenate sample was pushed through a 
40µm nylon mesh sieve with a syringe plunger and flushed through using cold FACS 
wash buffer (2% foetal calf serum, 1% sodium azide, and 5mM EDTA) to produce 
the single cell suspension. 
The samples were then kept at 4°C and stained with a saturating 
concentration of a fluorescence-binding antibody cocktail for 30 minutes in the dark.  
The antibodies used were; anti-F4/80-FITC (AbD Serotec), anti-L-selectin-PE, anti-
E-selectin-PE, anti-Gr-1-PerCP, anti-CD31-PerCP, anti-CD11b-APC (Beckton 
Dickinson), anti-CD45-PECy7, and anti-CD11c-AlexaFluor 780 (eBioscience). 
In some experiments, the surface expression of L-selectin on perfusate 
leukocytes (which had been washed out from lung by perfusion) was analysed to 
characterise the time-course of leukocyte activation during the protocol.  To do this, 
perfusate samples were taken from the IPL circuit and centrifuged.  The pellet was 
resuspended with FACS wash buffer and the sample was stained with the antibody 
cocktail for 30 minutes in the dark at 4°C. 
After the 30-minute incubation of the samples with the antibody cocktail, 
residual antibodies were washed out and labelled samples were acquired by CyAn 
ADP Analyzer flow cytometer using Summit software (Beckman Coulter, 
Buckinghamshire, UK). 
 
Immunophenotyping and quantification of cell number 
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To differentiate between the subpopulation of leukocytes and subsets of monocytes, 
samples were incubated with F4/80-FITC, Gr-1-PerCP, and CD11b-APC antibodies.  
Forward scatter (FSC, representing the cell size) and side scatter (SSC, 
representing the cell granularity) of each cell were also used to characterise different 
cell types in the samples as previously described (446).  After excluding the cell 
debris by gating out the low FSC population, CD11b and SSC were used to identify 
the neutrophils and monocytes, while the monocyte subset populations and 
neutrophils were differentiated by F4/80 and Gr-1 (an example of lung homogenate 
sample is shown in Fig 2.5, identification of leukocytes were achieved in the same 
way).  Neutrophils were identified as a CD11b(+)F4/80(-) population and monocytes 
were identified as a CD11b(+)F4/80(+) population.  Monocyte subsets were 
differentiated by their expression of Gr-1 molecules.  Alveolar macrophages were 
also identified by their characteristic low positive CD11b expression and high 
autofluorescence (on PE channel) and F4/80 expression.  This was confirmed with 
positive staining for CD11c.  The absolute cell counts in each sample were 
measured using microsphere counting beads (Caltag Medsystems, 
Buckinghamshire, UK) and the total leukocytes recovered per lung was calculated.  
Data were analysed with FlowJo software (Treestar Inc, Oregon, USA). 
 Pulmonary endothelial cells were also identified as a CD45(-)CD31(+) 
population, confirmed with positive CD105 (endoglin) expression (Fig 2.6).  CD45 is 
expressed on leukocytes and not on endothelium, and CD31 is expressed on 
endothelium.  The characteristics of cell surface molecules on each cell type are 
summarised in Table 2.1. 
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Figure 2-5  Identification of leukocytes. 
Lung homogenate samples were stained with fluorescent-conjugated antibodies for flowcytometry.  
After gating out cell debris and counting beads by their low Forward Scatter (FSC) characteristics, 
alveolar macrophages were identified by their high expression of F4/80 and autofluorescence onto 
phycoerythrin channel within the CD11b negative population, confirmed with CD11c positive staining.  
Monocytes and neutrophils were identified by positive staining for CD11b and differential staining of 
F4/80 and Gr-1.  Monocytes were identified as CD11b+, F4/80+ events, and their subsets were 
defined as either Gr-1 high or low, differentiated from neutrophils as CD11b(+), F4/80(-),Gr-1 very 
high events. 
SSC: Side Scatter 
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Figure 2-6  Identification of endothelium. 
Lung homogenate samples were stained with fluorescent-conjugated antibodies for flowcytometry.  
After gating out the leukocytes by their positive CD45 stainings, pulmonary endothelium was identified 
as CD31(+) positive events, confirmed with positive staining for CD105 (endoglin). 
SSC: Side Scatter 	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 Endothelium Alveolar 
macrophages 
Neutrophils Gr-1 high 
monocytes 
Gr-1 low 
monocytes 
CD31 + - - - - 
CD45 - + + + + 
CD11b - - + + + 
F4/80  + - + + 
Gr-1   + + - 
CD11c  +    
CD105 +     
 
Table 2-1  Characteristics of cell surface molecules on lung cells  
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Quantification of cell adhesion molecules 
In order to quantify the surface expression of cell adhesion molecules, appropriate 
isotype controls (Beckton Dickinson) were used as the background signal and 
subtracted to determine the real signal from each cell.  Based on the pattern of 
changes, we used different calculation methods.  When all the cells show a shift in 
response to stimulus (e.g. L-selectin is shed upon activation, and this response is 
similar within all the cells), we used mean fluorescence intensity, which is calculated 
as below; 
 
<MFI> = <M1> - <M2> 
Where; 
MFI: mean fluorescence intensity 
M1: the mean signal in the target wavelength from cells stained with monoclonal 
antibody to the targeted antigen 
M2: the mean signal in the target wavelength from cells stained with non-specific 
antibody (isotype control) 
 
However, when only a small fraction of the cells respond and 
upregulate/downregulate the expression levels (e.g. E-selectin), using MFI may 
underestimate the signal because of the background.  In that case, setting a certain 
threshold and calculating percentage of ‘positive cells’ is used as an alternative 
outcome (Fig 2.7).  Both methods are accepted techniques within the literature (472, 
473). 
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Figure 2-7  Upregulation of E-selectin expression on pulmonary endothelium. 
Lung homogenate samples were stained with fluorescent-conjugated antibodies containing either 
isotype control (A) or E-selectin antibody (B).  Threshold was set and the ‘percentage positive’ 
(percentage of the cells within the ‘positive gate’) was calculated to evaluate the upregulation of the 
cell adhesion molecule.  Pulmonary endothelium was identified as CD45(-)CD31(+) events. 
SSC: Side Scatter 	  
	   98	  
Manual counting of leukocytes in effluate 
In order to characterise the marginated pool of leukocytes in lung, the number of 
leukocytes in perfusate was counted by a haemocytometer, with differential cytology 
performed by cytospin and Diff-Quik staining. 
 
Protein assay 
To assess alveolar-capillary barrier dysfunction, which is one of the important 
manifestions of acute lung injury, total protein content in lavage samples was 
measured.  At the end of the protocol, lung lavage samples were taken as described 
above and the protein content was determined by Bradford protein assay (Bio-rad 
Laboratories, Hemel Hempstead, UK).  In this assay, a Coomassie Brilliant Blue dye 
is used to bind to proteins and thus a change in the intensity of colour is proportional 
to the quantity of protein within the sample (474).  Known concentration of BSA 
standards were used to make a standard curve, and the protein concentrations were 
determined in triplicate using a colourimetric platereader (MRX II absorbance reader, 
Dynex Technologies, Magellan Biosciences).  The dilution effect by the alveolar 
oedematous fluid and pre-existent alveolar surface lining fluid on protein (and 
cytokine) measurements should be minimal, because of the large volume of the 
lavage fluid (750ul).  Pilot exeriments using ethylenediaminetetraacetic acid (EDTA) 
to induce barrier dysfunction showed a good correlation between the lavage protein 
concentration and the alveolar-capillary barrier permeability index using a fluorescent 
dye injected into the pulmonary circulation (209), regardless of the extent of lung 
injury (data not shown). 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
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In order to assess the inflammatory responses following the experimental protocols, 
we measured pro-inflammatory cytokine contents in perfusate and lavage samples 
by ELISA.  We used an in-house colourimetric sandwich ELISA to quantify soluble 
KC, MIP-2, and TNF released into perfusate and BALF.  Briefly, 96 Immuno 
MicroWell plates (NUNC, Denmark) were coated with 100µl monoclonal primary 
‘capture’ antibody.  Following overnight incubation, wells were washed with wash 
buffer (0.05% Tween 20 in PBS) and loaded with 300µl blocking buffer (consisting of 
1% BSA, 5% sucrose, and 0.05% azide in PBS) per well for 1 hour.  After washing 
the plate again, 100µl of standard samples with known concentration of target 
antigen or test samples were applied to the well in duplicate.  Samples were 
appropriately diluted so that the predicted mediator concentration fits within the limits 
of the standard curve.  Wells were then washed after 2 hour incubation, and 100µl of 
biotinylated secondary ‘detection’ antibody was applied and incubated for a further 2 
hours.  After washing the plates, 100µl of streptavidin-HRP solution diluted in PBS 
with 1% BSA (1:200 dilution) was added to each well for 20 minutes.  After a final 
series of wash, 100µl of substrate solution containing H2O2 and tetramethylbenzidine 
was added and the plates were kept in the dark for 30 minutes.  After the reaction 
was stopped with 2N sulphuric acid (Sigma), the Optical Density (OD) was 
determined within 10 minutes using the MRX II colourimetric platereader at 450nm 
absorbance.  Standard curve was calculated based on 4 parameter logistic curve fit 
technique using Revelation software to determine the antigen concentration in the 
tested samples. 
 
Statistical analysis 
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Data are expressed as mean ± standard deviation (SD).  Statistical analysis of data 
obtained was carried out using t-test, Pearson’s product-moment correlation, or one-
way or two-way ANOVA using Prism 4 software package (Graphpad).  A p-value of 
less than 0.05 was considered statistically significant. 
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3. Characterisation and optimisation 
of the mouse isolated perfused lung 
model 
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Summary 
Mouse IPL is an in situ experimental model, which allows various interventions and 
yet maintains physiological significance.  Using the IPL, I developed unique 
experimental models to address some of the previously unanswered questions 
relating to ALI.  After various optimisations of the IPL system settings, we found the 
lungs were physiologically stable for up to 3 hours. 
One of our main interests in the project was to clarify the role of lung-
marginated leukocytes, for which IPL is useful in excluding the effect of other organs 
and circulating cells.  By washing out the leukocytes in the pulmonary circulation, we 
found that the marginated pool in the lung contains more than 10 million leukocytes, 
similar to the circulating pool and much greater than we previously estimated.  
Recirculating perfusion allowed us to retain these leukocytes within the lung, but 
increased the cytokines in perfusate due to their accumulation.  To take advantage 
of the beneficial characteristics of both non-recirculating and recirculating perfusion, I 
developed a ‘modified recirculation’ protocol, in which we regularly exchanged the 
perfusate during recirculating perfusion.  This effectively retained 80% of leukocytes 
within the lung and yet reduced the cytokine accumulation that would otherwise arise 
with the recirculating perfusion. 
Despite the large cell numbers, the role of the leukocytes in the lung 
marginated pool has been ignored in the past IPL literature.  This modified perfusion 
protocol has proven to be useful in investigating the role and mechanisms of the 
lung-marginated leukocytes in the IPL system, which will be described in later 
chapters. 
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3.1. Background 
Inflammation is histologically characterised by leukocyte infiltration into tissue, and 
the sequential events of leukocyte kinetics (rolling, adhesion, crawling, and 
transmigration) are crucial in the development of inflammation (408).  The main 
research focuses of the leukocyte involvement in inflammatory pathologies have 
been the mechanism of the recruitment sequence and the role of ‘transmigrated 
leukocytes’.  However, even during normal homeostasis, a substantial number of 
leukocytes are present not within the circulating pool or bone marrow, but within 
tissue vascular beds, known as the peripheral or marginated pool.  Evidence 
indicates they are not simply at a transitional state, but actively play a role in the 
development of inflammation (407).  Regulatory factors of the marginated pool have 
been partly revealed; they may re-enter the circulating pool following stimuli including 
exercise and epinephrine, leading to acute leukocytosis (386, 400, 475).  On the 
other hand, during systemic inflammation, margination of leukocytes from the bone 
marrow pool to the microcirculation rapidly expands the marginated pool of 
leukocytes (386, 476). 
The marginated pool of leukocytes in the lung has been claimed to be the 
biggest marginated pool in the body and contain similar or larger numbers than the 
circulating pool, under physiological conditions (386, 391, 477).  These findings were 
mainly based on radioisotope studies in large animals such as dogs and rabbits, 
however there is a species difference in the size of the lung marginated pool (396, 
397), and the size of the lung marginated pool in small animals has been poorly 
defined.  Since neutrophils abundantly contain myeloperoxidase (MPO) (478), MPO 
assay of tissue homogenate as well as histological examination are standard 
methods to evaluate the leukocyte margination into organs, but these methods do 
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not directly represent the number of leukocytes.  We have previously developed a 
novel FACS methodology to quantify such lung-marginated leukocytes and 
estimated the total number of lung-marginated leukocytes as 1-2 millions (208, 219, 
446).  These previous data suggested that the size of marginated pool in mouse lung 
might be much less than the reported value of the number of these cells in the 
circulating pool (5-20 millions), despite the large variability of the number of 
circulating leukocytes from the literature ((446, 479, 480) and The Jackson 
Laboratory Mouse Phenome Database at www.jax.org/phenome). 
The pathological role of the marginated (not yet transmigrated) leukocytes has 
not been well clarified.  Our research group previously explored the importance of 
monocytes in the lung marginated pool, termed ‘lung-marginated monocytes’, and 
their interaction with pulmonary endothelium in the development of ALI using in vivo 
and in vitro models (219, 445, 446, 456).  However, in order to further investigate the 
role and mechanisms of the lung-marginated leukocytes, previous models used in 
our laboratory as well as in the literature have intrinsic limitations.  The in vivo 
system implicated a pathophysiological role of lung-marginated monocytes in ALI, 
but was unable to separate out the role of lung-marginated monocytes from that of 
other cells, in particular circulating monocytes and monocytes/macrophages within 
extrapulmonary organs.  For instance, intravenous injection of clodronate-loaded 
liposomes is often used to deplete monocytes in in vivo experiments (219, 446), but 
this treatment depletes both circulating and lung-marginated monocytes, making 
mechanistic analyses difficult.  On the other hand, while the in vitro co-culture 
system is a strong tool to elucidate mechanisms behind the monocyte-endothelial 
interaction, for example demonstration of the involvement of MAP kinases in the 
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cellular interaction (456), the physiological relevance of the in vitro co-culture system 
is not clear, because the cellular network in the lung is much more complex. 
To overcome these inherent model-related limitations, we planned to develop 
an in situ mouse IPL model, which would provide a versatile tool with which to 
investigate the events in the pulmonary circulation, without the influence of other 
extrapulmonary factors.  At the initial stage of the PhD project, we attempted to 
optimise the IPL system setting to increase the physiological stability, and 
characterise the kinetics of lung-marginated leukocytes during perfusion. 
 
 
3.2. Aims 
In this chapter, we specifically aimed to: 
1) Develop a stable mouse IPL model. 
2) Characterise the kinetics of leukocytes in the lung marginated pool during 
perfusion. 
3) Optimise the IPL setting for further experiments. 
 
 
3.3. Protocols 
Preparation of IPL 
Most of the surgical protocols have been described in the previous chapter.  Briefly, 
the lungs were taken from C57BL6 male mice and ventilated with 5%CO2 in air, 
(RR:80/min, Vt 7ml/kg, PEEP 5cmH2O) and the main pulmonary artery (inlet) and left 
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atrium (drainage) were cannulated for the subsequent lung perfusion.  The overall 
surgical procedure took 30 minutes, including the 15 minutes taken for cannulation. 
At the initiation of perfusion, the flow rate started at 0.1ml/min and was 
incrementally increased over 5 minutes to 0.6-0.75ml/min (corresponds to 
25ml/kg/min) to avoid a sudden increase in PAP.  SI (25cmH2O for 5 seconds) was 
regularly applied to prevent the progression of atelectasis.  Left atrium pressure was 
kept at 2.5mmHg throughout the perfusion.  The lungs were initially perfused in a 
non-recirculating manner with RPMI supplemented with 4% low endotoxin BSA for 
10 minutes to wash out the residual blood in the lung, and thereafter allocated to 
either non-recirculating or recirculating perfusion with the same perfusion medium, 
and perfused for a further 3 hours. 
Outputs from all transducers were recorded and analysed by a computer-
based data acquisition system.  As our ventilator produces a time-cycled, volume-
controlled ventilation, airway pressure should increase with lung injury. 
 
Sampling 
Effluate was collected from the end of the non-recirculating circuit (or the reservoir, 
when collecting the sample from the recirculating circuit) for leukocyte count, gas/pH 
profiling, and cytokine analysis.  Lung lavage was performed with 750µl of saline at 
the end of the protocol for protein quantification and cytokine analysis.  In some 
experiments, lung tissue samples were harvested to quantify the leukocyte number 
in the lung. 
 
In vivo untreated control samples 
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In order to assess the effect of surgical preparation and in situ perfusion, we 
compared some samples from in situ experiments with in vivo untreated 
(unperfused) controls.  These mice were sacrificed by anaesthetic overdose with 
isoflurane, and then tracheostomised and intubated for whole lung lavage.  Lung 
lavage was performed as described in Chapter 2. 
 
Assaying samples 
The number of leukocytes in perfusate samples was quantified using a 
haemocytometer and the ratio of leukocyte subsets was determined using Diff-Quik-
stained samples prepared by Cytospin.  The samples were stained with fluorescent 
antibody cocktails and analysed using a CyAn flow cytometer and FlowJo software.  
Total protein content in lavage was measured by Bradford assay and the cytokine 
concentration was determined by ELISA. 
 
 
3.4. Results 
Optimisation of the IPL preparation 
The mouse IPL system is a technically very challenging model, and it took several 
months for us to optimise the various settings to produce a system that could be 
used for my subsequent investigations. 
 
Ventilation 
While other investigators have used negative pressure ventilation within IPL systems 
(194, 481, 482), we chose to use positive pressure ventilation for our models.  
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Although negative pressure ventilation is more physiological in terms of spontaneous 
respiration, the majority of mechanical ventilators utilise positive pressure.  Because 
VILI is our primary focus in this project, we considered positive pressure to be the 
more appropriate mode. 
The normal mouse respiratory rate (RR) is reported as 150-200/min (483).  
Most literature, including ourselves, use a similar or lower RR around 100-180/min 
for in vivo mouse mechanical ventilation (201, 205, 208, 224, 484-486), because 
higher frequency may be injurious to the lung, if using the same tidal volume (487, 
488).  In terms of the RR in mouse IPL models, much of the previous literature used 
even lower RR ranging from 40-120/min (194, 260, 489-492), since gas exchange is 
not critical in this system due to the low O2 consumption/CO2 production of the lung 
tissue, compared to that of the whole body.  Because the IPL is already a somewhat 
non-physiological system, we chose a RR of 80/min to maintain the healthy lungs, 
rather than making an effort to replicate the physiological/spontaneous RR. 
The tidal volume used for these experiments was standardised at 7ml/kg, 
which is similar to the tidal volume of a spontaneously breathing mouse (6-9ml/kg) 
(483), and considered to be ‘low tidal volume’ in the clinical setting (36).  The IPL 
model is prone to atelectasis because the pleural pressure is equal to atmospheric 
pressure (an aspect which I specifically took advantage of in subsequent 
experiments to be discussed later).  Therefore we paid special attention to the 
recruitment procedure.  In the closed-chest setting, negative pleural pressure keeps 
the positive transpulmonary pressure and prevents the collapse of alveoli, so that the 
lung keeps some volume at the end-expiratory phase, known as the functional 
residual capacity (FRC).  In addition, application of PEEP is very important in 
ventilating mice even under the closed-chest condition, because FRC in conscious 
	   109	  
mice is normally maintained by the active inspiratory muscle tone, which can be lost 
following anaesthesia (493, 494).  While it is generally considered that the 
physiological negative pleural pressure in larger animals is -3 to -5 cm H2O at end-
expiration under closed chest conditions (495), there is little information about 
physiological values of pleural pressure in mice.  Direct measurement of pleural 
pressure in small animals is technically challenging due to the very thin pleural 
space, and the pleural pressure is not homogeneous across the pleural space (496).  
Attempts have been made to estimate the pleural pressure in the anaesthetised 
mouse by measuring oesophageal pressure (497, 498), and indicated that the end-
expiratory intrathoracic pressure might be around zero as the mouse rib cage is too 
fragile to produce elastic recoil.  However, the results should be carefully interpreted 
since anaesthetics might decrease muscle tone, thereby attenuating elastic recoil of 
the chest wall and decreasing the negative pleural pressure.  Previous literature 
using mouse IPL have generally applied 2-3 cmH2O of PEEP (194, 260), while IPL 
experiments from other animals used 4-5cm H2O of PEEP (499, 500).  Therefore, we 
compared the development of atelectasis with different levels of PEEP.  Fig 3.1 
shows the representative traces of the airway pressure in control experiments.  With 
3cmH2O of PEEP, there was a rapid increase of PIP by 20% (7.1 to 8.7 cmH2O) over 
the initial 5 minutes of ventilation, which was recruitable by SI and hence likely due 
to atelectasis.  However, with 5cmH2O, this increase was substantially attenuated 
(5% and 10% over 5 and 15 minutes, respectively).  Based on this pilot data and 
background, we chose 5 cm H2O of PEEP for subsequent experiments. 
The pressure used for lung recruitment (sustained inflation; SI) was also an 
important consideration, as the mouse lung is so compliant that it can be temporary 
inflated more than 60cmH2O without reaching a traditionally defined total lung 
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capacity (501).  That means there is no specific pressure point where all the lungs 
are ‘fully inflated’. Previous mouse IPL literature has used approximately 20cmH2O 
of SI (194, 237) (or not described recruitment manoeuvres (RMs) (260, 325, 489)), 
while in vivo mouse models often use higher pressure, around 30-35cmH2O (201, 
502).  Lai and colleagues estimated that the murine pleural pressure (by 
oesophageal probe) is approximately 5cm H2O when they applied 35cmH2O of 
airway pressure (498).  Based on the literature, we initially tried 30cmH2O for SI, but 
this resulted in rupture (confirmed by lack of pressure plateau during the end-
inspiratory pause) in 10-20% of the lungs, hence we chose 25cm H2O for SI, given 
every 15 minutes.  Using these settings, we were able to achieve stable respiratory 
mechanics for 3 hours. 
  
	   111	  
 
 
 
Figure 3-1  Changes in airway pressure with different PEEP levels. 
Representative airway pressure traces of different PEEP levels are shown.  The lungs were ventilated 
either with 5cmH2O (Top) or 3cmH2O (Bottom) of PEEP, and the tidal volume and RR were the same 
(Vt 7ml/kg, RR 80/min).  The frequency of the sustained inflations was different due to the rapid 
progression of atelectasis with the lower PEEP protocol.  Lungs were perfused with RPMI 1640 
supplemented with 4% low endotoxin bovine serum albumin (0.6-0.75ml/min). 
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Perfusate 
One of the major advantages of the IPL system compared to in vivo experiments is 
that the perfusate can be constituted with (489) or without blood (194).  We chose 
non-blood buffer in our experiments, because one of our main intentions was to 
clarify the role of lung-marginated leukocytes, and thus minimising the effect of 
circulating leukocytes in the baseline IPL system was essential.  We used RPMI 
1640 without phenol red and added BSA to increase the colloidal pressure as 
reported previously (194, 464).  We also added sodium chloride to further increase 
the osmolarity, as normal mouse serum osmolarity and sodium level are higher than 
for humans (503, 504).  The principal reported advantage of RPMI 1640 is that 
amino acids in the buffer make the lung sustainable for longer periods of time (464). 
The gas profile of the perfusate was not easy to standardise.  The main 
difficulty was that the CO2 and pH were variable, as they are very different according 
to the batch of RPMI, and the length of time the RPMI bottle is open (due to CO2 
evaporation).  Because the bicarbonate buffering system is an important determinant 
for the pH of RPMI, the standardisation of CO2 is crucial to maintain the pH.  
Bubbling the perfusate with 5% CO2 can control the pCO2 in the perfusate (344, 
505), but we found the approach difficult because the colloidal component (i.e. BSA) 
made the perfusate foam even if we bubbled slowly.  I therefore focused on 
controlling pH at around 7.3-7.5 by adding sodium bicarbonate (460).  The 
standardisation of oxygen was easier; due to the low oxygen consumption by the 
lung, oxygen levels were relatively constant in the IPL. 
 
Flow rate 
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In preliminary experiments, we tested various flow rates, and found the lung endures 
1.5ml/min (50ml/kg/min) for 3 hours, but developed oedema with 3h of 3ml/min 
(100ml/kg/min) perfusion.  The reasons why the lung could not endure what is a 
slower flow rate than in vivo may reflect those non-physiological components of the 
IPL preparation including the open-chest, acellular non-blood perfusate, and initial 
surgical insults.  Including an additional safety margin, we chose 0.6-0.75ml/min 
(corresponds to 25ml/kg/min) for our experiments, because we intended to focus on 
immunological aspects of the lung, rather than circulation dynamics.  The perfusion 
rate (0.6-0.75ml/min) was similar to most of the literature, and certainly not the 
lowest reported (506).  Importantly, even the fastest flow rate (2ml/min) reported 
among the previous literature (464, 507) was only 15% of the actual mouse cardiac 
output estimated by ultrasonographic cardioechography (14.8ml/min for 24g mice) 
(508). 
 
Dead volume of the perfusion circuit 
Most mouse IPL experiments have been carried out with a non-recirculating 
perfusion system.  Where recirculating perfusion systems have been used, the dead 
volume of the circuit was often much higher (237, 507, 509) than the actual 
estimated mouse blood volume (80-100ml/kg) (510).  Using tubing with smaller 
diameter, I was able to make a recirculating perfusion circuit with 2.5ml of volume, 
including the reservoir and the bubble trap, both of which have 0.5ml capacities.  
This volume is almost the same as the blood volume of a 25-30g mouse. 
 
Mouse IPL model is physiologically stable for up to 3 hours 
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With the optimised setting, I tested the stability of my mouse IPL model using the 
non-recirculating circuit.  Airway and perfusion pressure were stable throughout 3 
hours (Fig 3.2), and these values were compatible with the previous literature (194).  
Gas and pH profiles in the perfusate were also stable throughout the 3 hours (Table 
3.1).  Lavage protein, at the end of 3-hour perfusion, was significantly higher than the 
untreated, unperfused in vivo data (p<0.01 by t-test, Fig 3.3), but the level of 
increase is only marginal (and unlikely to have biological significance) compared to 
our in vivo ALI model (201, 511, 512).  Because the concentration of protein in the 
perfusate (4% BSA) is almost the same as plasma (503), this result suggests that 
such perfusion did not substantially increase the alveolar-capillary barrier 
permeability. 
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Figure 3-2  Physiological parameters during 3-hour non-recirculating perfusion. 
Peak airway pressure (A) and pulmonary artery pressure (B) during 3-hour non-recirculating 
perfusion.  Lungs were perfused with RPMI 1640 supplemented with 4% low endotoxin bovine serum 
albumin (0.6-0.75ml/min). 
Lungs were ventilated with 7ml/kg and 5cm H2O of PEEP, respiratory rate 80/min, n=5. 
 
 pH pCO2 (mmHg) pO2 (mmHg) HCO3- (mmHg) BE 
Start 7.44 ± 0.03 29.4 ± 3.6 140.8 ± 7.4 21.7 ± 0.6 -3.4 ± 0.8 
End 7.46 ± 0.03 27.1 ± 3.1 123.2 ± 3.2 21.7 ± 1.2 -3.4 ± 1.5 
 
Table 3-1  Perfusate profile at the start and end of 3-hour non-recirculating perfusion. 
Lungs were perfused with RPMI 1640 supplemented with 4% low endotoxin BSA (0.6-0.75ml/min).  
Lungs were ventilated with 7ml/kg and 5cm H2O of PEEP, respiratory rate 80/min, n=4 each. 
BE: Base Excess 
 Lavage protein (mg/ml) 
In vivo (untreated) 0.12 ± 0.01 
IPL (after 3h perfusion) 0.19 ± 0.04 ** 
 
Table 3-2  Lavage protein concentration after 3-hour non-recirculating perfusion. 
Total protein content at the end of 3-hour non-recirculating perfusion.  Lungs were perfused with 
RPMI 1640 supplemented with 4% low endotoxin bovine serum albumin (0.6-0.75ml/min).  Lungs 
were ventilated with 7ml/kg and 5cm H2O of PEEP, respiratory rate 80/min, **p<0.01 vs. in vivo 
(untreated), n=4-5 each. 
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Mouse lung contains ∼10 million leukocytes 
In order to characterise the leukocytes marginated within the pulmonary circulation 
under normal conditions, we counted the number of leukocytes in the effluate during 
the 3 hours non-recirculating perfusion period. 
 Surprisingly, we found that approximately 10 million leukocytes were washed 
out during the 3-hour perfusion (Table 3.2), and more than half of these cells were 
morphologically monocytes, different from the circulating pool where neutrophils and 
lymphocytes are the majority (513).  Apparently, the fraction of the leukocyte subsets 
was similar throughout; monocytes were the biggest fraction and lymphocytes were 
the smallest population.  Half of these leukocytes were washed out within the first 30 
minutes, but they continued to come out from the pulmonary circulation throughout 
the 3 hours – about a million leukocytes were found in the perfusate between 2 h 
and 3 h (Fig 3.3).  This result suggests that a large number of leukocytes are present 
in the pulmonary circulation and short-term perfusion does not wash out all of these 
lung-marginated leukocytes. 
  
	   117	  
Total leukocytes Neutrophils (%) Monocytes (%) Lymphocytes (%) 
1.06 ± 0.07 × 107 cells 30.0 ± 9.6 60.5 ± 3.6 9.5 ± 6.9 
 
Table 3-3  Profile of washed out leukocytes. 
Number of total leukocytes that were counted by haemocytometer.  Leukocyte subset was visually 
differentiated by cytospin.  n=3. 
 
	    
Figure 3-3  Number of ‘washed out’ leukocytes during 3-hour non-recirculating perfusion. 
The total number of cells in the lung was counted by haemocytometer and the fraction was 
determined by cytospin.  Each time point represents the number of total leukocytes washed out from 
the pulmonary circulation over the previous 30-minute period; i.e. the value at 60 minute means the 
number of cells washed out between 30-60 minutes.  n=3 each. 
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Exchange recirculation protocol maintains lung-marginated 
leukocytes and prevents cytokine accumulation 
As mentioned previously, one of our main aims during my PhD project was to 
evaluate the roles of lung-marginated leukocytes during ALI.  Clearly, the wash-out 
of ~10 million leukocytes during the standard non-recirculating perfusion of the IPL is 
inconsistent with such an aim.  Therefore we attempted to develop a recirculating 
version of the protocol, in which the leukocytes would at least be retained within the 
system.  In the initial series of pilot experiments, we used a general-grade BSA to 
make the perfusate rather than the low-endotoxin grade albumin we normally used 
(due to supply problems at the time).  Under these conditions we found that barrier 
integrity (BAL protein) was relatively well maintained over 3 hours (0.31±0.09 mg/ml, 
n=3), but the recirculating system induced a massive amount (20-600 fold increase) 
of soluble inflammatory mediator accumulation within the system compared to a non-
recirculating protocol (Fig 3.4).  Therefore, we developed a novel ‘modified 
exchange’ protocol, designed to hopefully retain the lung-marginated leukocytes 
within the lung, while minimising the accumulation of metabolites within the system.  
To do this, we exchanged the perfusate every hour by temporarily (5 minutes) 
switching from the recirculating to the non-recirculating circuit. 
The ‘modified recirculating perfusion’ did not affect the physiological 
parameters under non-injurious ventilation settings (Table 3.4).  Although the 
modified recirculating perfusion (now using low endotoxin BSA as originally planned) 
still produced some increase in the cytokine levels in the perfusate (~5x higher levels 
at 3 hours) compared to non-recirculating levels (Fig 3.5), we considered this to be a 
great improvement on the standard recirculating system.  Additionally, the cytokine 
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levels in the lung lavage fluid from the modified recirculating perfusion protocol were 
the same as those found in the non-recirculating perfusion protocol (Fig 3.6).  Most 
importantly, the modified recirculating perfusion decreased the number of washed 
out leukocytes by 80% (2.28 ± 0.57×106 cells in total, n=3), compared to the non-
recirculating system (> 1 ×107 recovered cells, as shown in table 3.3).  To address 
the possibility that many leukocytes may simply have become attached to the circuit 
tubing during the modified perfusion protocol, we washed the circuit with EDTA-
containing perfusate (to facilitate leukocyte release (514)) for 30 minutes, after 
removing the lung and any residual perfusate.  However, only a further 0.8 million 
leukocytes were washed out during this procedure, indicating that the vast majority 
were retained within the lung vasculature. 
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Figure 3-4  Perfusate cytokines at the end of 3-hour perfusion with general-grade bovine 
serum albumin. 
Lungs were perfused with 0.6-0.75ml/min with general-grade bovine serum albumin in either non-
recirculating or recirculating perfusion protocol.  The cytokine concentration was determined by 
ELISA. 
All the lungs were ventilated with 7ml/kg and 5cm H2O of PEEP, respiratory rate 80/min, n=2-3 each. 
 
 PIP (cmH2O) PAP (mmHg) Lavage protein (mg/ml) pH pO2 (mmHg) 
Non-recirculating 9.62 ± 0.38 6.8 ± 1.8 0.19 ± 0.04 7.44 ± 0.03 140.8 ± 7.4 
Modified recirculating 9.82 ± 0.35 7.1 ± 1.1 0.21 ± 0.04 7.40 ± 0.02 168.9 ± 0.8 
 
Table 3-4  Physiological parameters at the end of 3-hour perfusion protocols. 
Lungs were perfused with 0.6-0.75ml/min for 3 hours in either non-recirculating or modified 
‘exchange’ perfusion protocol. 
All the lungs were ventilated with 7ml/kg and 5cm H2O of PEEP, respiratory rate 80/min. 
n=2-4 each. 
PIP: Peak Inspiratory Pressure 
PAP: Pulmonary Arterial Pressure 
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Figure 3-5  Perfusate cytokines in the non-recirculating and modified recirculating perfusion 
protocol. 
Lungs were perfused with 0.6-0.75ml/min in either non-recirculating or modified ‘exchange’ perfusion 
protocol.  The cytokine concentration was determined by ELISA. 
All the lungs were ventilated with 7ml/kg and 5cm H2O of PEEP, respiratory rate 80/min. *p<0.05, 
**p<0.01, ***p<0.001 vs. non-recirculating perfusion by 2-way repeated measures ANOVA, n=5 each. 
 
 
Figure 3-6  Lavage cytokines in the non-recirculating and modified recirculating perfusion 
protocol. 
Lungs were perfused with 0.6-0.75ml/min in either non-recirculating or modified ‘exchange’ perfusion 
protocol.  The cytokine concentration was determined by ELISA. 
All the lungs were ventilated with 7ml/kg and 5cm H2O of PEEP, reapiratory rate 80/min, n=5 each. 
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3.5. Discussion 
In this chapter, we optimised and characterised the IPL setting for the subsequent 
investigation about the role of lung-marginated leukocytes in lung injury.  During this 
process, we demonstrated that the lung contains a substantial number of leukocytes 
in the peripheral pool, and the method of perfusion influences how many lung-
marginated leukocytes are removed from the system. 
 
Lung-marginated leukocytes in IPL 
With the system optimised, we first investigated the size and nature of the 
marginated leukocyte pool within the lungs, by characterising the cells recovered 
during the perfusion process.  The previous literature using the IPL system has 
largely ignored the role of such leukocytes in the marginated pool.   This is probably 
because most people assumed that these lung-marginated leukocytes were washed 
out during the initial flushing for 10-20 minutes to remove the residual blood in the 
lung (indeed, the lung becomes white in colour after this initial perfusion).  We had a 
similar assumption such that initial brief perfusion would wash out the majority of the 
already marginated leukocyte population, and simple reconstitution (by adding donor 
leukocytes to the IPL) would provide a straightforward experimental system for 
investigations of the roles/mechanisms of leukocyte-endothelial interaction. 
However, we found that the 3-hour non-recirculating perfusion washed out 
∼10 million leukocytes, with more than 5 million leukocytes still in the lung after the 
initial 30-minute perfusion.  Because it was possible that the residual ‘circulating’ 
leukocytes in the lung contributed to the 10 million leukocytes, we estimated the 
residual blood leukocytes in the lung.  To do that, we assumed most of the residual 
blood was washed out by the initial 10 minutes, when the lung became completely 
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white in appearance and the volume of effluate was approximately 5-6ml.  Because 
the haematocrit of this 5-6ml effluate was less than 1% whereas the normal 
haematocrit is reported as approximately 40% (480), we estimated the residual blood 
was less than 0.15ml.  Using the normal WBC count of 8×106/ml (480), this means 
up to 1.2 million leukocytes were in the residual blood.  Therefore, at least 9 million 
leukocytes were from the lung marginated pool.  The size of leukocytes is often 
bigger than the lung capillaries and thus leukocytes need to deform for passage 
through the lung microcirculation (394, 515).  Infection increases the stiffness of 
leukocytes and this mechanism may contribute to the leukocyte sequestration in the 
lung (516).  Nevertheless, even after washing out more than 10 million leukocytes 
from the pulmonary circulation by non-recirculating perfusion, the PAP barely 
changed.  This might be because the number of capillary segments is far greater 
than the number of lung marginated cells (515, 517). 
Historically, the size of the marginated pool was investigated mainly using 
radioisotopes (477), but leukocyte separation and radiolabelling procedures may 
activate leukocytes and alter their kinetics (386, 518, 519).  The size may be different 
among species, and the size of mouse lung marginated pool has not been well 
investigated (386, 397).  Our group has previously developed a flow cytometric 
technique for the quantification of the leukocytes in lung (as described in Chapter 2).  
Based on this technique, we estimated the total number of lung-marginated 
leukocytes as 1-2 million in healthy lung, and the number was expanded by 
infectious stimuli (445, 446).  The number of lung neutrophils determined by this 
FACS technique was shown to correlate well with the conventional MPO assay of 
the lung homogenate (208), which is considered to represent the number of 
neutrophils.  However, a recent publication reported Gr-1 high inflammatory 
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monocytes also highly express MPO (520), suggesting the non-specificity of MPO 
assay.  Therefore, the type of immunological approach used here may be a more 
reliable one to differentiate the leukocyte subsets. 
Nonetheless, my data revealed a substantial underestimation of the absolute 
number of lung-marginated leukocytes by our current FACS technique.  Sample loss 
during the processing (e.g. when making single cell suspension) may have 
decreased the number of lung-marginated leukocytes, and as a result, we apparently 
underestimated the absolute number of lung-marginated cells (446).  In a recent 
paper, Barletta et al. investigated the number of leukocytes within specific 
compartments (marginated, interstitial, and alveolar compartments) in mouse lungs 
using FACS and in vivo antibody-labelling techniques (389).  Their findings were 
consistent with my own, with ~11 million marginating leukocytes of which 60% were 
monocytes.  The reasons behind the discrepancy between their FACS technique and 
ours could be due to the processing techniques including their use of enzymes 
including collagenase and DNase.  However, we have tested collagenase digestion 
techniques previously, and found that they did not greatly improve the cell collection 
efficacy, but resulted in destroying some surface markers. 
From a methodological perspective, this simple wash-out method using IPL 
may be a good tool to quantify the lung-marginated leukocytes.  In this chapter, we 
identified the leukocyte subsets of the washed-out cells by light microscopic 
examination, but the use of FACS for these cells should be able to precisely clarify 
the leukocyte subsets in future.  Since it is difficult to perfuse all the lungs for several 
hours to quantify the lung-marginated leukocytes, our current FACS technique may 
still be a reasonable approach in most cases to rapidly and easily estimate the 
relative increase/decrease of leukocytes within the lung tissue after stimuli.  Further 
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technical improvements should be required for such FACS-based quantification, and 
this IPL wash-out technique might be useful as a ‘gold standard’ for the technical 
development.  The bottom line for this project is that lung-marginated leukocytes 
were still being washed out from the lung after several hours of non-recirculating 
perfusion.  Thus our original plan to flush out and reconstitute lung-marginated cells 
would be impractical, although this did mean that endogenous marginated 
leukocytes could in theory be studied if a protocol could be developed that retained 
them within the system. 
 
Cytokine production in IPL 
In preliminary experiments to investigate the use of a recirculating perfusion, we 
found substantial accumulation of cytokines in perfusate.  This accumulation could 
have been due to the use of less than optimal BSA and/or the recirculating perfusion 
itself.  Using low endotoxin BSA was effective to reduce the background cytokine 
production in previous literature (194, 521).  Although the supplier tests the 
endotoxin contamination in the standard quality BSA, it only assures the LPS 
contamination as less than 40ng/ml in the perfusate, whereas the low endotoxin BSA 
assures the LPS contamination as less than 4ng/ml.  Because the purification 
processes are different between these two specifications of BSA, it is possible that 
another contaminant may also have contributed to this high cytokine production.  
Accumulation of the cytokines in the recirculating protocol was probably enhanced 
by the small dead volume of my recirculating circuit and secondary effects; i.e. auto-
stimulation of the lung by the secreted cytokines.  Interestingly, despite the very high 
concentration of various cytokines in the 3-hour recirculating system with standard 
BSA, the integrity of alveolar-capillary barrier was maintained.  In particular, TNF has 
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been considered as injurious to lung (522, 523), but our data might suggest that 
another co-factor is needed to disrupt the barrier integrity. 
The kinetics of cytokine production in the non-recirculating perfusion with low 
endotoxin BSA was comparable with the previous literature (195, 524).  The 
production of cytokines was very low for the first hour, but rapidly increased after 
this.  The question why the IPL system releases such a high concentration of 
cytokines (compared to in vivo levels in plasma) into perfusate even in non-injurious 
conditions (194) was previously raised by Dreyfuss, who suspected this may reflect 
significant contamination of such preparations (199).  However, the effect of 
contamination should be limited in our studies with the use of low-endotoxin BSA, 
since we standardised the washing protocol between experiments using LPS-
absorbing agents polymyxin B, and obtained relatively constant results throughout 
the project.  It is still possible that even a very small amount of endotoxin or other 
contaminants resulted in the high level of cytokine production in non-injurious 
conditions, hence more rigorously quality-controlled solution including clinical-grade 
human albumin might be an option to further decrease the baseline cytokine 
production.  Several other factors in this preparation can cause such cytokine 
increases.  For instance, these kinetic profiles may represent non-physiological 
features of the IPL setting such as the initial ischaemia-reperfusion effect by the 
surgical preparation, lack of bronchial circulation, and lower shear stress to the 
pulmonary endothelium.  Lack of blood component in the perfusate can also affect 
the cytokine concentrations.  Recent evidence showed that chemokines (e.g. KC and 
MIP-2) may be absorbed by red blood cells in vivo via Duffy Antigen Receptor for 
Chemokines (DARC) (525), and therefore the lack of ‘sink’ (i.e. blood) in the IPL 
system likely exaggerates the level of the chemokines we measured.  The 
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assumption is in line with papers by Bagby and colleagues, which demonstrated that 
intratracheally instilled recombinant MIP-2 is rarely detected in plasma (526) and this 
was due to the rapid clearance of MIP-2 by erythrocytes (527).  In fact, recent 
publications reported the gene polymorphism of DARC was associated with the 
worse clinical outcomes among African Americans with ALI, together with the 
enhanced levels of IL-8 (528). 
 
Optimal perfusion protocol 
Through the preliminary experiments, we found that lung-marginated leukocytes 
were lost during non-recirculating perfusion whereas cytokines were accumulated by 
recirculating perfusion.  In order to minimise both of these issues, we perfused the 
lung in a recirculating manner, but exchanged the perfusate by 5-minute wash-out 
every hour.  The modified recirculating perfusion effectively decreased the loss of 
leukocytes and yet lessened the cytokine accumulation effect.  This new perfusion 
protocol did not affect the physiological data, compared to the non-recirculating 
perfusion. 
 
Evaluation of alveolar-capillary permeability 
Increased alveolar-capillary permeability is a primary physiological finding in ALI 
(529).  In order to assess the lung permeability, we only evaluated lavage protein, 
which represents the whole alveolar-capillary barrier dysfunction consisting of the 
epithelial barrier and endothelial barrier, whereas some literature has focused on the 
endothelial barrier using techniques including filtration coefficient in IPL (530, 531).  
However, as measurement of filtration coefficient needs specialised equipment (506, 
532), which does not fit my IPL system, we were unable to use this method. 
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Lavage protein and PIP are established methods to evaluate the barrier 
dysfunction and lung oedema (201).  There are other methods to evaluate the lung 
injury, but we did not use them for several reasons.  Wet-dry ratio is one of the most 
simple and standard techniques to measure the extravascular lung water content.  
We did not use this technique, because we prioritised taking lung lavage samples to 
quantify the various cytokines.  However, wet-dry ratio has been shown to correlate 
closely with the respiratory mechanics both in vivo (201, 209, 533) and ex vivo (325, 
326, 534).  Histology is also a standard method to assess the lung injury, however 
this is not a very sensitive or quantitative method and in addition, leukocyte 
infiltration into the tissue, a major finding in histological examination, is absent in the 
non-blood perfusion system. 
In this chapter, the minimal change in lavage protein level together with stable 
respiratory mechanics in IPL suggests there were minimal changes in alveolar-
capillary permeability during the 3-hour perfusion.  Qualitatively, we also found that 
the amount of perfusate volume in the reservoir changed very little over 3 hours in 
the control IPL model with the modified recirculating perfusion mode, suggesting 
there was only relatively minor extravascular leak of the perfusate.  In contrast, as 
described later, in the IPL model with the lungs injured by VILI and I/R, progressive 
decreases in the reservoir volume were observed throughout the experiment.  
Overall, these data and observations indicated that alveolar-capillary barrier 
dysfunction was not substantial during the 3-hour perfusion. 
 
In summary, we optimised the mouse IPL model, which is physiologically stable up 
to 3-hour perfusion.  However, relatively high cytokine level at 3 hours might suggest 
a limitation of the current non-blood perfusion system, thus caution is needed to use 
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this preparation for more than 3 hours.  Using the mouse IPL model, we found that 
the marginated pool of leukocytes in mouse lung is as large as the circulating pool, 
suggesting an important role of the mouse lung marginated pool in intravascular 
immunity.  Recirculating perfusion with regular perfusate exchange effectively 
contained these lung-marginated leukocytes while minimising the background 
cytokine levels within the circuit.  The lung-marginated leukocytes have been 
somewhat overlooked in the previous literature, but this modified recirculating 
perfusion protocol allows us to better investigate the lung-marginated leukocyte-
related inflammatory response. 
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4. Comparison of high-stretch and 
atelectasis in pathophysiology of 
ventilator-induced lung injury 
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Summary 
Mechanical ventilation promotes pulmonary inflammation and alveolar-capillary 
barrier dysfunction, a process known as ventilator-induced lung injury (VILI).  Various 
injurious mechanisms of VILI have been proposed, including overdistension of 
alveoli and the repetitive collapse and reopening of lung units associated with 
atelectasis.  It is likely that differences in the pathological mechanisms induced by 
high-stretch and atelectasis exist, but these have not been well elucidated, partly 
because of difficulty of modelling atelectrauma in healthy lungs.  In this chapter, we 
took advantage of the zero pleural pressure of IPL to develop both ‘atelectrauma’ 
and ‘volutrauma’ VILI models to compare the pathophysiology of two distinct entities. 
Both high-stretch and atelectasis-related induced VILI models in the IPL 
produced severe permeability increase, but the pattern of cytokine production was 
different.  High-stretch substantially induced cytokine release, both in the intra-
alveolar and intravascular space, compared to controls.  In stark contrast, atelectasis 
induced much smaller increases in intra-alveolar cytokines than high-stretch, with 
similar low levels of cytokines in the intravascular space to controls. 
Spill-over of lung-borne cytokines is considered to be the key to produce 
MODS in ALI patients.  From this perspective, we have attained unique evidence 
that high-stretch has much bigger impact on systemic propagation of lung 
inflammation than atelectrauma, whereas both high-stretch and atelectrauma 
contribute to permeability increase.  These two models should be useful for further 
clarification of the specific molecular mechanisms behind VILI. 
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4.1. Background 
The fact that positive pressure ventilation can injure the lung was described 
centuries ago (104), and the understanding of the pathological mechanism has 
dramatically progressed over the last 30-40 years.  Since the concept of ventilator 
‘induced’ lung injury was first proposed by Webb and Tierney (108), several 
pathophysiological concepts in VILI have been proposed, including barotrauma, 
volutrauma, atelectrauma, and biotrauma (104).  From these pathophysiological 
concepts, it was proposed that low tidal volume to avoid overstretch and high PEEP 
to limit atelectasis should be protective within ventilated patients.  The clinical 
application of such a protective ventilation strategy achieved a decrease both in pro-
inflammatory cytokines in lavage fluid and plasma, and mortality in clinical trials (109, 
164, 196).  However, considering each factor, compared to the use of low tidal 
volume to decrease volutrauma, our understanding about the open lung strategy to 
limit atelectrauma are not concrete. 
Clinically, in contrast with the influence of reduced tidal volume (36, 535), 
testing of increased PEEP levels did not significantly improve mortality in large-scale 
clinical trials (162, 172-174).  Recent meta-analyses and systematic reviews have 
attempted to address the clinical effect of altered PEEP, but different inclusion 
criteria resulted in opposite conclusions (174, 186).  Experimentally, the main focus 
of the research in VILI has been volutrauma, and the specific molecular mechanisms 
behind atelectrauma have not been well elucidated. 
One of the difficulties of the investigation of atelectrauma arises due to the 
difficulty of modelling this in animals.  For instance, atelectasis can increase the 
resistance of pulmonary circulation and therefore cause right ventricular dysfunction 
in vivo (130).  It is also difficult to create significant atelectasis and resultant 
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atelectrauma in healthy lungs due to negative pleural pressure, therefore most 
previous atelectrauma models incorporated additional insults including pre-injury 
(139, 144, 148), relatively high tidal volume (193, 466), or both (467) to facilitate the 
atelectasis and amplify the lung injury, making mechanistic analyses difficult. 
Inducing lung injury without using these confounding factors was attempted in 
some experimental paradigms, but these also had model-specific problems.  Slutsky 
and colleagues used an ex vivo isolated non-perfused lung model to show a proof of 
concept that atelectasis can cause lung injury via epithelial shear stress induced by 
repetitive collapse and reopening of half-atelectatic lung units (139) and enhance the 
cytokine production in response to high-stretch (193, 216).  However, this model 
included problems such as the effect of ischaemia due to the lack of nutrition 
supplementation and the accumulation of mediators inside the lung tissue due to the 
lack of blood flow.  Duggan et al. attempted to develop in vivo atelectasis models by 
ventilating rats with zero PEEP and low tidal volume.  Although that protocol resulted 
in high mortality, it was mainly due to the right cardiac failure (confirmed by 
echocardiography) due to atelectasis-induced hypoxia and resultant resistance 
increase in pulmonary circulation, rather than permeability-related ALI (153, 154).  
D’Angelo et al. attempted to create significant atelectasis and resultant atelectrauma 
by using open-chest rabbits or rats with zero PEEP, but the lung injury was only 
marginal with normal gas profile and mild bronchial injury by histology, unless 
additional surfactant depletion was induced (150, 536).  Bilek et al. developed a 
creative in vitro model of collapse/reopening by using a flow chamber lined with rat 
pulmonary epithelial cell lines, and demonstrated the importance of surfactant in 
preventing atelectrauma (152).  However, this lacks the complex lung cellular 
network making it difficult to extrapolate its findings to in vivo situations. 
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It has now become clear that inflammation is also crucial in the development 
of VILI, a concept often termed ‘biotrauma’.  Evidence from animal studies has 
shown quite convincingly that the blockade of inflammation by depleting leukocytes 
(191, 219) and humoral mediators (537) can attenuate high-stretch induced VILI.  
Using the mouse IPL, Uhlig and colleagues reported that the over-stretched lung 
secreted various mediators including mouse IL-8 homologues, KC and MIP-2, and 
TNF into the pulmonary circulation via activation of the NF-kappaB pathway in the 
lung (194, 195), suggesting that the lung per se can produce several pro-
inflammatory cytokines in response to high-stretch.  The effects of lung-borne 
mediators onto extrapulmonary organs may have major deleterious impacts on 
clinical outcome.  Patients with ALI usually die from multiple organ dysfunction 
syndrome (MODS), and irreversible respiratory failure accounts for only 10-20% of 
the mortality in ALI patients (37, 38).  Clinical evidence indicates that pro-
inflammatory cytokines including IL-6, IL-8, and TNF correlate with lung injury (196, 
538) as well as extrapulmonary organ injury (240).  Collectively, these results 
suggest that lung can produce inflammatory mediators in response to high-stretch 
and these mediators induce pulmonary and extrapulmonary organ injury.  
Nevertheless, due to the difficulty of modelling atelectrauma as described above, the 
effect of atelectrauma on the lung-borne cytokine production has not been clarified. 
In this chapter, using an open-chest mouse IPL setting, we attempted to 
develop a ‘pure’ atelectrauma model and compare its pathological mechanism to a 
high-stretch volutrauma model, with a particular focus on production of pro-
inflammatory cytokines.  We proposed that ‘zero’ pleural pressure (i.e. equal to the 
atmospheric pressure) of the isolated perfused lung setting would create substantial 
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atelectasis and thus cause atelectrauma while maintaining other physiological 
parameters. 
 
 
4.2. Aims 
The specific aims of this chapter were to: 
1) Develop an atelectasis-related VILI model using the IPL. 
2) Compare the pathophysiology of high-stretch induced VILI and atelectasis-
related VILI, with particular focus on pro-inflammatory cytokine secretion into 
the intra-alveolar and intravascular compartments. 
 
 
4.3. Protocols 
Isolated perfused lung 
The surgical preparation of the IPL has already been described in Chapter 2 and 3.  
Lungs were allocated to one of three groups: control, atelectasis, or high-stretch.  All 
the lungs were ventilated with respiratory rate of 80/min, and perfused at 0.6-
0.75ml/min (25ml/kg/min) with non-blood buffer in a recirculating manner, or in some 
cases non-recirculating manner for 3 hours.  As described previously, the 
recirculating protocol included hourly perfusate exchange, and samples were 
collected for cytokine analysis.  In the control group, the lungs were ventilated with 
low tidal volume (7ml/kg) with PEEP (5cmH2O), and regular SI (25cmH2O, every 15 
minutes) was applied.  The atelectasis group received the same low tidal volume, but 
neither PEEP nor SI.  To develop the high-stretch induced VILI, we modified 
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previously developed high-stretch protocols in IPL (194, 539) by adding PEEP and 
regular RMs to minimise the influence of atelectrauma.  In the high-stretch group, the 
lungs were ventilated with high tidal volume (30-32ml/kg) and both PEEP (3cmH2O) 
and SI.  Lower PEEP of 3cmH2O was chosen for the high-stretch group because the 
lung hit the diaphragm and the inner surface of the retracted rib cage when the lung 
was ventilated with high tidal volume and 5cmH2O of PEEP.  This resulted in 
generation of significant surface pressure on the lungs, making it difficult to 
standardise the transpulmonary pressure.  Lung lavage samples were taken at the 
end of experiments for analysis of total protein and specific cytokines.  Total protein 
level was quantified by protein assay and the cytokines were measured by ELISA. 
 
Measurement of lung mechanics 
The tracheal pressure and perfusion pressure were continuously monitored.  
Respiratory mechanics, both elastance and resistance, were measured every 15 min 
(just before the SI, if SI was applied) by end-inflation pause technique as described 
in Chapter 2.  At the end of the protocol, 2 SI were applied to assess whether the 
collapsed regions were easily recruitable or not.  The respiratory mechanics were 
measured 3 times (before/after the first SI and after the second SI) to examine the 
effectiveness of the RM. 
 
Statistics 
Data are expressed as mean ± SD.  Statistical analysis of data obtained was carried 
out using t-test, Pearson’s product-moment correlation, or one-way or two-way 
ANOVA using Prism 4 software package (Graphpad).  A p-value of less than 0.05 
was considered statistically significant. 
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4.4. Results 
Atelectasis protocol induces lung injury in IPL 
Utilising the open-chest IPL setting, we initially attempted to develop and 
characterise the unique atelectasis-related VILI model.  In order to do that, the 
atelectasis group was ventilated with the same low tidal volume as the control group, 
but the PEEP was removed and SI was not applied.  During the 3-hour period, the 
PIP was stable in the control group.  In contrast, the PIP dramatically increased 
within the first hour in the atelectasis group.  Thereafter, the PIP was relatively stable 
until the last 60 minutes when it started to increase again (Fig 4.1).  At the end of the 
protocol, lavage protein level showed a large increase in the atelectasis group (more 
than 20 times higher than the control group), suggesting alveolar-capillary barrier 
permeability was increased following the 3-hour atelectasis protocol (Fig 4.2). 
  
	   138	  
 
Figure 4-1  Time course of peak inspiratory pressure. 
All the lungs were ventilated with 7ml/kg.  Control lungs received 5cmH2O of PEEP and regular 
sustained inflation, but the atelectasis group received neither PEEP nor sustained inflation.  Lungs 
were perfused at 0.6-0.75ml/min with a modified recirculating perfusion.  n=5 each 
 
 
 
Figure 4-2  Lavage protein at the end of the protocol. 
***p<0.001 vs. control, n=5 each. 
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At the end of the 3-hour protocol, SI was applied twice to recruit collapsed 
lung regions, to determine the degree of mechanics change that was due to either 
oedema or derecruitment.  The lung mechanics were measured before and after 
performing the RMs.  The RMs caused minimal changes in the elastance and 
resistance of the respiratory system in the control group.  In the atelectasis group, 
the first SI changed the elastance and resistance increase of the respiratory system 
by 50% and 20%, respectively, and the second SI changed these respiratory 
mechanics less than 10% (Fig 4.3 A). 
Since these parameters can represent the derecruitment as well as 
pulmonary oedema, particularly in the atelectasis group, we investigated the 
correlation between mechanics parameters and a standard barrier dysfunction 
marker, lavage total protein before and after a single RM.  In the atelectasis model, 
the level of lavage protein was strongly and significantly correlated with lung 
elastance only after recruitment (Fig 4.3 B), and resistance was well correlated with 
permeability increase whether recruitment procedure was performed or not (Fig 4.3 
C).  These results suggest that the lung developed both recruitable and unrecruitable 
components following the 3-hour protocol; the former represents the derecruitment 
and the latter represents collapsed and injured regions.  Based on the results, 
subsequent data reporting ‘mechanics changes’ utilise the value after one deep 
inflation at the end of the atelectasis protocol to reflect the extent of lung injury. 
Lung mechanics change (after recruitment) strongly suggest lung oedema 
developed following the 3-hour atelectasis protocol to a much greater extent than in 
the control ventilation group (Fig 4.4).  The development of pulmonary oedema was 
also supported by the presence of foamy fluid within the endotracheal tube at the 
end of the atelectasis protocol.  
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Figure 4-3  Measurement of respiratory mechanics at the end of the protocol. 
To differentiate the effect of derecruitment and pulmonary oedema, I investigated how recruitment 
manoeuvres changes the elastance and resistance of the respiratory system at the end of the control 
and atelectasis protocol, compared to the start of each protocol.  The effect of recruitment was 
evident in the atelectasis model at the first recruitment procedure, but not at the second recruitment, 
suggesting the single recruitment manoeuvre is sufficient to re-open the recruitable lung regions (A).  
With the single recruitment, the correlation between lavage protein level and lung elastance (Ers) or 
resistance (Rrs) became clearer in the atelectasis model (B and C), tested by Pearson’s product-
moment correlation, suggesting that the lung developed both recruitable and unrecruitable 
components following the 3-hour atelectasis protocol; the former represents the derecruitment and the 
latter represents collapsed and injured regions.  
	   141	  
 
 
 
Figure 4-4  Changes in lung mechanics at the end of the protocol. 
Changes (from the start of each protocol) in elastance and resistance of the respiratory system after a 
recruitment manoeuvre at the end of the control and atelectasis protocol.  ***p<0.001 vs. control, n=5 
each. 
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Atelectasis-related lung injury induces pulmonary inflammation 
We next characterised the inflammatory response in the atelectasis-related lung 
injury model.  We measured mouse IL-8 homologues, KC and MIP-2, and TNF in 
two compartments; the intra-alveolar space, represented by lavage cytokines, and 
the intravascular space represented by perfusate cytokines. Intra-alveolar cytokines 
were significantly increased in the atelectasis model compared to control ventilation 
(Fig 4.5), but intravascular cytokines were not different between strategies.  This 
increase in lavage cytokine could have arisen from two sources.  Firstly, because of 
the increased barrier permeability in the atelectasis model, cytokines may have 
translocated from the intravascular space, where they accumulate despite the 
exchange of perfusate every hour, to the intra-alveolar space.  Alternatively, 
atelectasis-related lung injury may have promoted local pulmonary inflammation. 
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Figure 4-5  Perfusate (A) and lavage (B) cytokines at the end of the atelectasis protocol. 
All the lungs were ventilated with 7ml/kg.  Control lungs received 5cmH2O of PEEP and regular 
sustained inflation, but atelectasis group received neither PEEP nor sustained inflation.  Lungs were 
perfused at 0.6-0.75ml/min with a modified recirculating perfusion.  **p<0.01, *p<0.05 vs. control, n=5 
each. 
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In order to further investigate the source of intra-alveolar cytokines in the 
atelectrauma model, we carried out the same ventilation protocol with a non-
recirculating circuit to minimise the cytokine accumulation in the circuit and any 
subsequent translocation from the intravascular to intra-alveolar space.  As 
expected, this non-recirculating perfusion decreased perfusate cytokines in the 
atelectasis model, but lavage chemokine (MIP-2 and KC) levels were almost the 
same as those found in the modified recirculating perfusion, suggesting chemokines 
were produced locally in the intra-alveolar space rather than being translocated from 
the intravascular space.  In contrast, TNF levels were decreased both in the 
perfusate and lavage from the non-recirculating group (Fig 4.6A).  Interestingly, the 
lung protein permeability and the lung mechanics changes following atelectasis were 
also decreased by the non-recirculating perfusion, further supporting that 
translocation was unlikely to explain the intra-alveolar cytokine increases (Fig 4.6B). 
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Figure 4-6  Comparison of recirculating and non-recirculating circuit in the atelectasis 
protocol. 
 (A) Cytokine levels in perfusate and lavage fluid, following atelectasis protocol in recirculating circuit 
and non-recirculating circuit.  (B) Lung injury following atelectasis was attenuated by non-recirculating 
perfusion.  Dashed lines represent the level of control ventilation in a non-recirculating.  The lung 
mechanics were measured after a recruitment manoeuvre at the end of protocol.  Dashed lines 
represent the level of control ventilation in a non-recirculating circuit.  **p<0.01. *p<0.05 vs. 
recirculating by t-test, n=5 each. 
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High-stretch also induces lung injury in IPL 
To investigate the difference in pathophysiology between atelectrauma and 
volutrauma, we developed an in situ high-stretch induced VILI model that produces 
comparable lung injury to the atelectrauma model.  Ventilation with high tidal volume, 
PEEP, and regular SI caused a rapid increase in PIP after a 2-hour stable period 
(Fig 4.7A).  Lavage protein level and lung resistance both increased to the same 
level as observed in the atelectrauma model, confirming a similar extent of alveolar-
capillary barrier disruption.  Lung elastance also increased significantly compared to 
control, although the magnitude was less than that seen in the atelectrauma model 
(Fig 4.7B). 
These results suggest that we developed high-stretch induced VILI that 
produce a similar extent of increased permeability pulmonary oedema as the already 
developed atelectasis-related VILI model. 
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Figure 4-7  Peak inspiratory pressure during the 3-hour protocol (A) and protein levels and 
lung mechanics at the end of the protocol (B). 
The lungs were ventilated either control, high-stretch, or atelectasis protocol.  All the lungs were 
perfused at 0.6-0.75ml/min with a modified recirculating perfusion.  The data of control and atelectasis 
groups are the same as the previous figures.  **p<0.01, *p<0.05, n=5-6 each. 
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Comparison of atelectrauma and volutrauma demonstrated a 
distinct inflammatory pattern 
We next compared the cytokine productions in these two VILI models.  Perfusate 
cytokines increased substantially throughout the 3-hour protocol in the high-stretch 
model.  This is in clear contrast with the atelectasis model in which systemic 
cytokines were not elevated, compared to the control group (Fig 4.8).  Intra-alveolar 
KC and MIP-2 also increased significantly in both the atelectasis and high-stretch 
groups, but the impact was much larger in the latter group.  Although a similar 
tendency was also seen in lavage TNF, it did not reach statistical significance 
because of relatively low values and variability of the measurements (Fig 4.9). 
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Figure 4-8  Perfusate cytokines during the 3-hour protocol. 
The lungs were ventilated using either control, high-stretch, or atelectasis protocol.  All the lungs were 
perfused at 0.6-0.75ml/min with a modified recirculating perfusion.  The data of control and atelectasis 
groups are the same as the previous figures.  There were significant interactions between the time 
and ventilation protocols by 2-way repeated measures ANOVA.  ***p<0.001, **p<0.01 vs. control and 
atelectasis groups at 3-hour time point, tested by 1-way ANOVA.  n=5-6 each. 
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Figure 4-9  Lavage cytokines at the end of the 3-hour protocol. 
The lungs were ventilated using either control, high-stretch, or atelectasis protocol.  All the lungs were 
perfused at 0.6-0.75ml/min with a modified recirculating perfusion.  The data of control and atelectasis 
groups are the same as the previous figures.  ***p<0.001, **p<0.01, *p<0.05 by 1-way ANOVA with 
Bonferroni.  n=5 each. 
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4.5. Discussion 
In this chapter, taking advantage of the open-chest IPL setting, I first developed a 
unique atelectasis-related VILI model and compared its characteristics with the 
modified high-stretch induced VILI model.  The comparison of these two VILI models 
demonstrated the similar impact on the development of pulmonary oedema, but 
different impact on the production and secretion of the pro-inflammatory cytokines. 
 
Atelectrauma model 
The clinical effects and underlying mechanisms of atelectrauma have not been well 
clarified.  This is partly because of the difficulty of modelling ‘pure’ atelectrauma 
within the healthy lung due to the negative pleural pressure.  Traditionally, several 
experimental models of atelectrauma have been utilised, although the majority of 
models incorporated additional insults such as pre-injury and relatively high tidal 
volume.  The use of such a pre-injured lung may resemble a clinical scenario, but 
this 2-hit model inevitably introduces some complexities when it comes to 
interpreting the results.  We took advantage of the open-chest ‘zero’ pleural pressure 
of the IPL model to create a pure atelectrauma model. 
The absence of PEEP and SI in the atelectasis model induced substantial 
increase in PIP within an hour.  Although we did not objectively assess the functional 
residual capacity over this period, this rapid increase is likely to be due to atelectasis 
as the lung visually got smaller, a phenomenon that did not occur within the control 
lungs.  The rate of PIP increase reduced after 1 hour, probably because the 
delivered tidal volume was at this point sufficient to keep the remaining aeratable 
lung units open.  The increase of PIP during the final hour resulted in all likelihood 
from the developing pulmonary oedema caused by atelectrauma, supported by the 
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lavage protein and non-recruitable resistance and elastance changes measured at 
the end of the protocol.  Qualitatively, foaming fluid flooding into the endotracheal 
tube was also seen at the end of the protocol, further supporting the development of 
pulmonary oedema in the atelectasis protocol.  Collectively, these data suggest 
atelectasis per se caused severe lung injury in the IPL even with the low tidal 
ventilation. 
Since the dramatic increase of PIP can reflect various changes in the 
respiratory system, we analysed the PIP in more detail by measuring elastance and 
resistance of the respiratory system, using the end-inflation occlusion technique 
(469).  Interestingly, both PIP and elastance data showed very small variability 
before the RMs regardless of the extent of lung injury (represented by lavage 
protein), but showed greater variability which was well correlated with lavage protein 
after the single RM, suggesting the RM was useful to differentiate the derecruitment 
and ‘real’ lung injury.  These classical physiological parameters (i.e. elastance and 
reistance) are based on the lamped model, where we model the entire lung as a tube 
connected to a bellows.  In this lamped model, the resistance generally reflects both 
narrowing of the conducting airways and changes in parenchymal mechanical 
properties (e.g. viscosity), whereas the elastance primarily represents the events in 
lung parenchyma including parenchymal elasticity and surface tension.  Therefore, 
the change would be dominantly occurred to resistance, if only the proximal side of 
the lung (i.e. conducting airways) were affected, whereas both resistance and 
elastance would be changed if the distal side of the lung (i.e. lung parenchyma) were 
involved (494, 540).  In this chapter, my results indicated that this atelectasis 
protocol induced both recruitable (i.e. derecruitment) and non-recruitable (i.e. 
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pulmonary oedema or non-recruitable collapse of the alveolar units, with conducting 
airway injury) mechanical changes to the lung. 
There has been a debate about the superiority of an emerging computational 
technique over the conventional lamped model assumption (541, 542).  Recent 
advances in computational technologies have made it possible to model and 
calculate the lung mechanics using a more elaborate technique, a low-frequency 
forced oscillation technique (LFOT) based on a constant-phase model (543-545).  
However, direct relevance between the parameters in this model (tissue damping (G) 
and tissue elastance (H)) and the physiological/pathological pulmonary conditions 
have not yet been established (494).  Compared to LFOT, end-inflation occlusion 
technique has advantages including an intuitive link between these parameters and 
tissue structural changes, but also contains disadvantages; e.g. these parameters 
can be heavily influenced by the respiratory frequency and ventilator circuit (541, 
542).  In the IPL model, because we are ventilating the lungs with a constant 
respiratory rate, LFOT may not necessarily be superior. 
Whether inflammation is involved in the development of atelectrauma has 
been a controversial issue in the previous literature (538).  Experimentally, when 
combined with low tidal volume, atelectasis per se has not conclusively been shown 
to induce cytokine production in intra-alveolar and vascular compartments (203, 247, 
491), but with relatively higher tidal volume, zero PEEP showed synergistic effects in 
pro-inflammatory cytokine production in the intra-alveolar space (193, 216, 247, 
486).  Using an in vivo surfactant-depleted rat model, Tsuchida et al. demonstrated 
that the alveolar injury mainly happened in the non-atelectatic lesion after the 
injurious ventilation, whereas distal airway injury due to shear stress occurred both in 
the non-atelectatic and atelectatic lesion.  Based on the finding, they suggested that 
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the alveolar injury in the atelectatic lung may be due to the ‘baby lung’ phenomenon; 
i.e. relatively high tidal volume applied to the aeratable lung regions (148).  As such, 
atelectasis might amplify the impact of high-stretch induced intra-alveolar cytokine 
production. 
Previous studies in IPL often focused on either intra-alveolar (139, 193, 482) 
or intravascular (194, 195, 491) cytokine secretion in VILI.  The simultaneous 
analysis of the cytokine levels in both compartments sheds light on the mechanisms 
of cytokine production in our model.  In this chapter, we showed that intra-alveolar 
cytokines were increased by the atelectrauma model, in agreement with the previous 
literature (139, 482, 491).  It is generally accepted that following high-stretch 
ventilation, alveolar macrophages are the primary source of pro-inflammatory 
cytokines within the alveolar space (213, 214).  However, the potential source of 
alveolar cytokines following ‘pure’ atelectasis has not been investigated.  This 
increase in lavage cytokines could (theoretically at least) be due to the cytokine 
translocation from the intravascular to intra-alveolar space.  Spill-over of cytokines 
from the intra-alveolar to intravascular space due to the loss of barrier integrity 
(termed decompartmentalisation) has been proposed following high lung stretch 
(245).  Our recent data showed cytokine translocation in the opposite direction 
following stretch; soluble TNF receptor 1 (sTNFR1) was increased in lavage fluid by 
high-stretch, due to the loss of alveolar-capillary barrier function by VILI and resultant 
translocation of plasma sTNFR1 into the intra-alveolar space (539).  In order to 
clarify the source of intra-alveolar cytokines, we utilised the non-recirculating system 
and confirmed that the intra-alveolar chemokines (MIP-2 and KC) were likely to be 
produced locally in response to the atelectasis protocol.  With regard to the 
chemokines KC and MIP-2, the current proposed pathological mechanism of 
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atelectrauma may fit for such a local intra-alveolar inflammation.  Nieman and 
colleagues investigated the alveolar instability during the ventilation of the injured 
lung, using intravital microscopy.  They claimed that the resultant shear stress on 
epithelia due to the unstable alveoli may cause such an inflammatory/injurious 
response to the lung (143-145, 546).  Because in vitro evidence has shown that 
pulmonary epithelium produces IL-8 (of which KC and MIP-2 are functional 
homologue in mice), in response to stretch stimuli (215, 547), the epithelial shear 
stress may also directly contribute to the intra-alveolar chemokine production.  In 
terms of TNF, the fact that lavage TNF was significantly lower in the non-
recirculating perfusion may suggest that the intra-alveolar TNF increase might come 
from or be affected by, at least in part, an intravascular source. 
It is also notable that the non-recirculating perfusion attenuated the 
atelectrauma.  From the aspect of a propagation mechanism, this further decreased 
the possibility of chemokine translocation from the intravascular space to intra-
alveolar space, hence supported the intra-alveolar cytokine production by atelectasis 
and the following mechanical ventilation.  Attenuation of atelectrauma by non-
recirculating perfusion also suggested the contribution of soluble mediators in VILI; 
this aspect will be further discussed later in the final discussion. 
My result regarding intravascular cytokines in the atelectrauma model is 
generally in line with a paper by Meier and Uhlig, who reported that the removal of 
PEEP per se did not affect the level of perfusate cytokines in mouse IPL, although 
zero PEEP increased the perfusate cytokine levels and pulmonary oedema when 
combined with high tidal volume (491).  Despite similar findings regarding cytokine 
production, our model has an advantage over Meier’s paper, because that model 
may not be a model of lung injury.  Specifically, the model did not produce overt lung 
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oedema probably due to the mode of their ventilator (pressure-controlled ventilation).  
This pressure control ventilation system minimises the effect of repetitive collapse 
and reopening because the tidal volume decreases as lung dysfunction progresses; 
thus the tidal volume delivered may be very small after developing atelectasis.  By 
contrast, our volume controlled ventilation system produced substantial permeability 
increase to the atelectatic lung. 
 
High-stretch model 
To compare the pathological mechanisms of atelectrauma with high-stretch, we 
mimicked our previous in vivo VILI protocol (201) to develop a volutrauma model in 
the IPL.  We have paid special attention about the PEEP and SI (by applying higher 
pressure than the previous literature) to minimise the influence of atelectrauma in the 
high-stretch model.  We applied approximately 30ml/kg of high tidal volume with 
PEEP and SI.  During the pilot experiments, we noticed that the PEEP and SI were 
both needed to mimic the time course of our in vivo VILI model (201, 208, 209, 219, 
539, 548), which are characterised by an initial 1-2 hour stable period followed by a 
rapid increase in respiratory system elastance and resistance.  In the IPL model, 
unless we applied PEEP and SI, the airway pressure started to increase immediately 
after commencing the high-stretch protocol, much like we observed in the atelectasis 
protocol, suggesting collapse of the lung units affects the progression of lung injury 
even with such high tidal volumes.  This is particularly important because most 
literature do not appreciate the importance of recruitment manoeuvres in IPL.  In that 
literature, which purports to create a high-stretch induced VILI model, it does not 
describe the time-course of changes in either respiratory mechanics or the 
recruitment manoeuvre procedures.  Importantly, high-stretch ventilation without 
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proper SI and PEEP resulted in a ‘bi-phasic pattern’ – rapid deterioration of 
respiratory mechanics in the early phase and exponential, further deterioration in the 
later phase (491).  My results would suggest that these patterns were caused by 
mixing the components; an early-stage atelectasis due to insufficient recruitment 
procedure and volutrauma in the later stage.  The application of 30ml/kg is 
compatible with the previous mouse in vivo VILI model (201), however, this tidal 
volume is much higher than what is considered clinically to represent ‘injurious’ 
ventilation, which is approximately 10-12ml/kg (36).  In order to cause high-stretch 
induced VILI in healthy and very compliant mouse lungs (501), we had to apply such 
a high tidal volume.  It is also worth pointing that the volumes that cause high-stretch 
should not be expected to be the same in each species. 
 
Comparison of atelectrauma and volutrauma 
The comparison of 2 VILI models showed a distinct pattern in physiology and 
cytokine production, suggesting a differential pathogenesis.  In terms of physiology 
data, in the high-stretch model, the PIP started to increase after a 2-hour stable 
period, suggesting that the permeability change starts to occur around this time 
point.  In contrast, the initial increase in PIP within an hour in the atelectrauma 
model, underlines the importance of the recruitment procedure in maintaining 
respiratory physiology in the IPL system.  Regarding the lung mechanics data, 
elastance increases were much greater in the atelectasis model, compared to the 
high-stretch model.  This may suggest that the end-inflation occlusion method, 
and/or equipment used is more sensitive to detect changes due to atelectasis rather 
than influx of fluid, or indeed that atelectasis has a greater impact on elastance per 
se.  Some pure mathematical components may also contribute to this, since the 
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starting elastance in the high-stretch is higher than atelectasis because of the tidal 
volume difference, such that the divisor for calculating percentage change is 
somewhat smaller in the atelectasis model. 
Compared to the control group, lavage protein increase in the 2 VILI models 
was similarly very high - higher than our previous in vivo high-stretch VILI model 
(201, 539).  The barrier dysfunction could be due to some hydrostatic factor rather 
than permeability increase, however, the PAP in both VILI models was similar or 
lower, compared to the control (7.8±0.4, 6.0±0.8, 7.6±0.6mmHg; in control, high-
stretch, and atelectasis group, respectively; n=5 each), suggesting both VILI models 
induced alveolar-capillary barrier dysfunction.  The lower PAP in the high-stretch 
model may be due to the recruitment of pulmonary vasculature by the expansion of 
lung volume.  Because of the open-chest in this setting, high-stretch does not cause 
an increase of pleural pressure and resultant compression to the pulmonary 
microvasculature. 
In terms of inflammatory profile, the current high-stretch model clearly 
increased the cytokine production both in the intra-alveolar and intravascular space, 
whereas atelectrauma increased these cytokines only in the intra-alveolar space 
(albeit to a smaller extent than the high-stretch model), despite the similar degree of 
alveolar-capillary permeability increase.  It has been suggested that regional over-
stretch due to baby lung phenomenon, rather than the atelectasis-related unique 
pathophysiology (i.e. epithelial shear stress), may be responsible for atelectasis-
related alveolar injury (148); however such a clear distinctive pattern in the cytokine 
concentration suggests that a different pathological mechanism exists in these 2 VILI 
models.  My results are in line with clinical evidence, which has indicated that the 
systemic cytokine release by atelectasis may be minimal, whereas systemic 
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inflammation by high-stretch is a well-accepted concept (36, 194).  Studies using 
ventilated patients without acute lung injury mostly showed no differences in plasma 
cytokines (203, 528, 549) when ventilated with zero PEEP.  Atelectasis is a common 
finding in the postoperative setting with an incidence of up to 90% (550), and there 
has been an argument about the role of atelectasis in early postoperative fever 
(EPF).  There was a belief that atelectasis is the main cause of EPF (551), but that is 
strongly criticised as “common textbook dogma” (552) or misconception (553) by 
several investigators.  In fact, recent systematic review by Mavros et al. showed 
there was no association between atelectasis and EPF (554), supporting the 
absence of systemic cytokine release by atelectasis. 
There are some model-related limitations to interpret the data.  Firstly, as I 
discussed in the previous chapter, the perfusate cytokine data might have been 
affected by the ‘noise’ from our IPL system (i.e. high levels of perfusate cytokines in 
the control group), but the clear difference between atelectasis and high-stretch 
should be independent from this.  Secondly, although we measured the three 
representative lung-borne pro-inflammatory mediators, which we speculate playing a 
role in the development of MODS and therefore contribute the mortality in ventilated 
patients, we have not experimentally shown if the mediators in the perfusate from 
high-stretch can actually cause MODS.  This aspect will be further discussed in the 
final chapter. 
I believe my results also provide insights regarding mechanisms of 
inflammatory propagation from the injured lung to the extrapulmonary organs.  It has 
become a generally accepted concept that inflammation during VILI mainly occurs 
within the intra-alveolar space initially and the produced inflammatory mediators can 
then spill-over into the intravascular space as impairment of the alveolar-capillary 
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barrier progresses, known as decompartmentalisation.  This theory has been 
proposed mainly by showing that a certain amount of intratracheally administered 
recombinant proteins leak into the systemic circulation, when endothelial injury is 
present (245, 526).  However, there are potential flaws in the previous studies.  
Firstly, recombinant proteins may not be the same as the natural proteins.  
Recombinant proteins can be produced by various systems such as bacteria, 
mammalian cells, transgenic animals and plants; however the post-translational 
modifications of proteins (e.g. glycosylation, phosphorylation, or proteolytic cleavage) 
are different by species.  For instance, bacteria do not perform glycosylation 
reactions, thus the use of these biological system results in producing different type 
or pattern of glycosylation, which may cause dramatic effects on the activity and 
characteristics of the protein (555).  Secondly, barrier dysfunction often does not 
mean the free movement of all substances.  There are several pathways by which 
substances can pass through the cellular barrier – e.g. transcellular, paracellular, 
diffusion, carrier protein, channels.  It is probably too naïve to think a barrier 
dysfunction for a particular substance means universal breakdown of the filtering 
function of the plasma membrane.  For instance, chemokines pass through the 
cellular barrier by using a specific DARC-mediated transcytosis mechanism (525).  
Thirdly, since the previous studies did not label the administered recombinant 
proteins (e.g. with radioisotope or fluorescence dye), they could not differentiate the 
applied recombinant protein and endogenous protein in their assay.  Therefore, it 
was possible that the applied high-dose recombinant pro-inflammatory cytokines 
induced rapid endogenous production of the same cytokines from the lung or other 
extrapulmonary organs. 
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In fact, the data we presented in this chapter are not entirely consistent with 
the idea that cytokines simply leak out of the lung when it becomes injured.  In 
particular, the atelectrauma model induced a substantial increase in lung 
permeability, and a 3-4 fold increase in chemokines (MIP-2 and KC) and TNF within 
the alveoli compared to control ventilation, but no increase in systemic cytokines.  
The fact that the high-stretch group produced higher perfusate cytokines from one 
hour, before lung barrier dysfunction was evident, also supports that there is a 
different mechanism responsible for the high-stretch induced systemic cytokine 
release, other than decompartmentalisation, which I will go on to explore in 
subsequent chapters. 
 
In summary, we successfully developed an in situ atelectrauma model showing 
severe pulmonary oedema and pulmonary inflammation.  Comparison of this model 
with a volutrauma model revealed a distinct inflammatory pattern of systemic 
cytokine release in these VILI models.  Furthermore, these studies shed light on the 
inflammatory propagation mechanism, as the data were not consistent with the 
current decompartmentalisation paradigm.  Patients with ALI often die from MODS 
rather than acute respiratory failure, and these VILI models are useful to clarify the 
mechanism behind the inflammatory propagation. 
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5. The role and mechanisms of lung-
marginated monocytes in ventilator-
induced lung injury 
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Summary 
Leukocytes play an important role in the development of VILI.  The main focus of 
leukocyte involvement in VILI has historically surrounded the role of alveolar 
macrophages and neutrophils.  Using an in vivo VILI model, we previously found that 
lung-marginated monocytes seem to be important in developing high-stretch induced 
lung oedema, although technical issues limited our ability to draw definitive 
conclusions.  To further elucidate the role and mechanisms of lung-marginated 
monocytes in VILI, we utilised the two previously developed VILI models in IPL, 
which allowed us to investigate the specific role and mechanisms of lung-marginated 
monocytes in the absence of extrapulmonary factors. 
We depleted lung-marginated monocytes by in vivo pretreatment with 
intravenous clodronate-loaded liposome injection.  This attenuated both lung 
oedema and cytokine production in the high-stretch model.  In contrast, monocyte 
depletion had no effect on lung oedema or cytokine production in the atelectrauma 
model.  We also attempted ‘monocyte addition’ experiments, using in vivo subclinical 
endotoxaemia to enhance the number of lung-marginated monocytes within the IPL 
preparation.  However, despite apparent exacerbation of pulmonary oedema by the 
LPS pre-treatment, model-related variability in this high-stretch VILI model made it 
difficult to draw definitive conclusions under these circumstances. 
Overall, these results strongly suggest that lung-marginated monocytes are 
involved in cytokine production and lung oedema, but only in response to high-
stretch, not atelectasis.  Monocyte-targeted therapies may be useful in attenuating 
the ‘inflammatory’ high-stretch induced VILI. 
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5.1. Background 
The intra-alveolar space is considered to be the primary site of inflammatory 
cascades during the early stage of VILI (556), and injurious mechanical ventilation 
may facilitate the spill-over of those intra-alveolar cytokines 
(decompartmentalisation).  In line with this, I demonstrated in the previous chapter 
that high-stretch ventilation induced upregulation of pro-inflammatory cytokines, both 
within the alveolar space and systemically.  However, atelectasis-related VILI did not 
cause systemic cytokine release, despite the severe permeability increase and intra-
alveolar cytokine production, inconsistent with the current decompartmentalisation 
paradigm.  We therefore considered an alternative mechanism for the production of 
systemic cytokines in the high-stretch VILI model involving other cells, which may be 
in the intravascular space, including pulmonary endothelium and lung-marginated 
leukocytes. 
It has been acknowledged for many years that high-stretch ventilation causes 
injury not only to the epithelium, but also pulmonary endothelium (107), suggesting 
VILI is a ‘whole-lung’ event where both intra-alveolar and intra-vascular components 
are stretched.  More recent experimental evidence also showed that high-stretch of 
intact lung produces NO in pulmonary endothelium (557), and upregulates 
endothelial cell adhesion molecules (255, 256) and intracellular phosphokinase 
signalling pathways (557). 
 The main focus of leukocyte involvement in developing VILI has historically 
been neutrophils (205, 208, 558).  This was mainly due to observations that; 1) 
neutrophils are sequestrated and seen in the injured lung tissue (156); and 2) 
neutrophil depletion or blocking sequestration attenuated VILI (191, 205, 559).  
Compared to neutrophils, the role and mechanisms of monocytes have been 
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underestimated and unclear, although MCP-1, a chemokine for monocytes, has 
been shown to be increased within the intra-alveolar space following high-stretch 
ventilation (560, 561).  However, our understanding of the roles of monocytes in 
inflammatory disease has been dramatically improved due to recent technical 
advances.  Firstly, improvement in multi-colour flow cytometric techniques has made 
it possible to differentiate monocyte subsets (423).  Secondly, techniques for 
depleting monocytes have been developed, the most widely used of which is 
clodronate-induced apoptosis of phagocytic cells (562).  Using these techniques, our 
research group recently reported that monocytes are involved in the development of 
VILI (219).  In that paper, we showed that a particular subset of less mature 
‘inflammatory’ monocytes (Gr-1 high monocytes in mouse) was recruited to the lung 
in response to high-stretch in vivo, and depletion of these inflammatory Gr-1 high 
monocytes attenuated VILI.  To further clarify the role, we also used a small dose of 
LPS to increase the number of lung-marginated monocytes and that exacerbated 
VILI as expected.  Importantly, using an in vivo leukocyte labelling technique and IPL 
wash-out technique, we also found that the majority of the lung-marginated 
monocytes recruited by the endotoxaemia were placed within the lung 
microvasculature (446), suggesting that monocyte-endothelial interaction may play a 
role in the exacerbation of VILI.  However, there was a limitation in our ability to 
separate the specific effects of lung-marginated monocytes and their interaction with 
pulmonary endothelium, from those of circulating monocytes (or indeed tissue 
macrophages such as Kupffer cells in the liver), which are also depleted in vivo by 
clodronate-loaded liposome treatment.  In this regard, the IPL is a useful tool to 
overcome these difficulties. 
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In this PhD project, we found in Chapter 3 that murine lung contains a large 
number of marginated monocytes (and neutrophils) even under physiological 
conditions.  We further found in Chapter 4 that high-stretch produced greater 
systemic cytokine release, potentially via the activation of intravascular components 
including pulmonary endothelium and lung-marginated leukocytes.  These results 
together with our previous in vivo findings drove us to further investigate the lung-
marginated leukocyte-related inflammatory mechanisms in VILI.  Since the lung-
marginated leukocytes are in direct contact with pulmonary endothelium, and there 
has been ample evidence indicating the synergistic role of the interaction between 
monocytes and endothelium, we hypothesised that interactions between ‘activated’ 
pulmonary endothelial cells and the enormous (but generally unappreciated) number 
of lung-marginated leukocytes within the lung capillary bed may play a significant 
role in systemic (extra-alveolar) cytokine production in response to high-stretch 
ventilation. 
 
 
5.2. Aims 
In this chapter, we aimed to: 
1) Investigate the involvement of lung-marginated monocytes in the high-stretch 
model, using IPL.  
2) Investigate the role involvement of lung-marginated monocytes in the 
atelectrauma model, using IPL. 
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5.3. Protocols 
Monocyte depletion in VILI 
Surgical preparation and basic system settings have been described previously.  
Briefly, the lungs were perfused with RPMI 1640 supplemented with 4% low-
endotoxin BSA (0.6-0.75ml/min) in a recirculating manner for 15 minutes or 3 hours, 
with hourly exchanges of perfusate. 
In the high-stretch protocol, the lungs were ventilated with high tidal volume 
(28-32ml/kg), PEEP (3cmH2O), and regular SI (25cmH2O for 5 seconds every 15 
minutes).  In the atelectasis protocol, the lungs were ventilated with low tidal volume 
(7ml/kg), but no PEEP or SI.  In order to deplete lung-marginated monocytes, some 
mice were pretreated in vivo with intravenous clodronate-loaded liposomes (200µl) 
24 hours before setting up IPL as previously described (219).  Perfusate and lavage 
samples were taken at the end of the experiments to measure cytokines and total 
protein content.  Lung injury was assessed by respiratory mechanics and lavage 
total protein concentration measured by protein assay.  The cytokine concentration 
in perfusate and lavage samples was determined by ELISA (lower detection limit: 
7.8pg/ml for all the ELISAs). 
 
2-hit high-stretch protocol 
Based on our previous in vivo VILI experiments (219), some mice were pretreated 
with 20ng of intraperitoneal LPS, 2 hours before setting up the IPL, as this LPS dose 
and time point showed maximal margination of inflammatory monocytes to the lung 
(446).  The end point was variable, because in some experiments oedema fluid rose 
up into the endotracheal tube before completing the 3-hour ventilation protocol.  
Accordingly, we had to compare the level of cytokines in perfusate taken from the 
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circuit at 2 hours, while the lung and lavage samples were collected and processed 
at the end of the protocol.  This was because the perfusate cytokine levels represent 
the accumulated cytokines in the circuit, thus the levels were affected by the end 
time point; i.e. the length of time of cytokine accumulation after the last wash out of 
the circuit. 
 
Flow cytometric quantification of lung-marginated leukocytes 
In some experiments, the lungs were harvested at the end of the protocol to quantify 
leukocytes in the lung.  The counting protocol by flow cytometry has been described 
in Chapter 2.  Briefly, lung cell suspensions were stained with specific fluorescent-
antibodies and samples were acquired by CyAn flow cytometer, and absolute cell 
counts in samples were determined using microsphere beads. 
 
Statistics 
Data are expressed as mean ± SD.  Statistical analysis of data obtained was carried 
out using t-test or one-way or two-way ANOVA using Prism 4 software package 
(Graphpad).  A p-value of less than 0.05 was considered statistically significant. 
 
 
5.4. Results 
Monocyte depletion attenuates pulmonary oedema and cytokine 
production in the in situ high-stretch VILI model 
We first investigated the effect of monocyte depletion by clodronate-liposomes in the 
high-stretch model.  As expected, clodronate-liposome pretreatment was effective to 
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selectively deplete both Gr-1 high and Gr-1 low monocytes (Fig 5.1) (although this 
did not attain statistical significance).  The clodronate-liposome treatment did not 
influence the baseline, but significantly attenuated the change in airway pressure 
over time during high-stretch ventilation (p<0.001 by 2-way repeated measures 
ANOVA; Fig 5.2A).  Similarly, clodronate-liposome treatment tended to decrease the 
lavage protein at the end of the high-stretch protocol, although it did not reach 
statistical significance (p=0.18, n=3-5 each; Fig 5.2B).  This suggests that the 
pulmonary oedema was attenuated by monocyte depletion. 
In terms of the cytokine production, monocyte depletion markedly attenuated 
cytokine release into the perfusate (Fig 5.3), in particular TNF (p<0.001).  In lung 
lavage samples at the end of the perfusion, somewhat unexpectedly, monocyte 
depletion also significantly decreased the level of intra-alveolar KC (p<0.05) 
following high-stretch ventilation, with MIP-2 showing a similar trend (p=0.07).  
Monocyte depletion appeared to decrease the lavage fluid TNF as well, but the 
difference was not statistically significant due to the high variability in the TNF 
measurements (Fig 5.4). 
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Figure 5-1  The number of lung leukocytes following in vivo clodronate-liposome pretreatment 
and in situ high-stretch protocol. 
The number of leukocytes in lung was counted by flow cytometry at the end of the 3-hour protocol.  
Some animals received 200µl of intravenous clodronate-liposomes 24 hours before setting up 
isolated perfused lung.  n=3-6 each; p value was calculated by t-test. 
 
 
Figure 5-2  Development of lung injury in in situ high-stretch protocol following in vivo 
clodronate-liposome pretreatment. 
 (A) Peak inspiratory pressure during the 3-hour high-stretch protocol and (B) total protein in lavage 
samples at the end of the protocol.  Lung monocytes were depleted by in vivo pretreatment with 
clodronate-liposomes (200µl, 24h).  ***p<0.001 vs. high-stretch by 2-way repeated measures ANOVA, 
n=3-5 each. 
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Figure 5-3  Perfusate cytokines at the end of in situ high-stretch protocol following in vivo 
clodronate-liposome pretreatment. 
Lung monocytes were depleted by in vivo pretreatment with clodronate-liposomes (200µl, 24h).  
Lungs were ventilated with high-stretch protocol.  ***p<0.001, *p<0.05 by t-test, n=3-6 each. 
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Figure 5-4  Lavage cytokines at the end of in situ high-stretch protocol following in vivo 
clodronate-liposome pretreatment. 
Lung monocytes were depleted by in vivo pretreatment with clodronate-liposomes (200µl, 24h).  
Lungs were ventilated with high-stretch protocol and cytokine levels in the lavage fluid were measured 
at the end of perfusion.  *p<0.05 by t-test, n=3-6 each. 
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Lung-marginated monocytes may regulate intra-alveolar cytokine 
production in response to high-stretch 
The observation that intra-alveolar cytokine levels in the high-stretch model were 
apparently decreased by depletion of marginated monocytes, could imply some form 
of communication between marginated monocytes and cells within the alveolar 
space.  We (and others (213, 214)) have previously shown that alveolar 
macrophages are responsible for a large proportion of inflammatory mediator 
production (including TNF, MIP-2 and KC) within the alveolar space during high-
stretch, and moreover that they are very rapidly (within 5 minutes) activated by high-
stretch ventilation in vivo (563).  We therefore investigated whether lung-marginated 
monocytes may influence this early macrophage activation.  Initially, experiments 
were carried out using flow cytometry to evaluate macrophage activation in terms of 
activity of intracellular mitogen-activated protein kinase pathways.  Unfortunately 
these experiments failed to show consistent upregulation of pathway activity 
following high-stretch ventilation for between 5-30 minutes (not shown).  However, 
we did find that by 15 minutes of high-stretch ventilation, cytokine concentrations 
were increased by a small but significant amount in the alveolar space (Fig 5.5).  
Intriguingly, alveolar cytokine concentrations were significantly decreased following 
depletion of lung-marginated monocytes.  At this early time point there was no 
detectable upregulation of cytokines within the perfusate, and only a minimal 
increase in capillary-alveolar barrier permeability in the clodronate-pretreated group  
(Fig 5.6), suggesting it is unlikely that an unidentified soluble mediator may have 
traversed from the vascular space to influence macrophage function.  These data 
may therefore suggest that lung-marginated monocytes do indeed influence alveolar 
macrophage activity, although the mechanism behind this remains unexplored.  
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Figure 5-5  Lavage cytokines at the end of 15-minute protocol 
Lung monocytes were depleted by in vivo pretreatment with clodronate-liposomes (200µl, 24h).  
*p<0.05 by 1-way ANOVA with Bonferroni, n=3-6 each. 
 
 
Figure 5-6  Total protein concentration in lavage fluid at the end of 15-minute protocol. 
Lungs were ventilated using the control or high-stretch protocol with or without clodronate 
pretreatment (200µl, 24h).  *p<0.05 by 1-way ANOVA with Bonferroni, n=3-6 each. 
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Monocyte depletion did not attenuate pulmonary oedema or 
cytokine production in the in situ atelectrauma model 
My results in Chapter 4 indicated that atelectrauma induced a similar degree of lung 
‘injury’ compared to high-stretch ventilation, but a substantially lesser degree of 
soluble inflammatory mediator production.  Given that monocyte depletion clearly 
attenuated both inflammation and oedema formation following high-stretch, we 
investigated if monocyte depletion would influence atelectrauma-induced oedema 
and inflammation.  Monocyte depletion did not change the PIP or lavage protein (Fig 
5.7), and the level of cytokine production was also not significantly changed by 
monocyte depletion (Fig 5.8 and 5.9). 
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Figure 5-7  Development of lung injury in in situ atelectasis protocol following In vivo 
clodronate-liposome pretreatment. 
(A) Peak inspiratory pressure during the 3-hour atelectasis protocol and (B) total protein in lavage 
samples at the end of the protocol.  Lung monocytes were depleted by in vivo pretreatment with 
clodronate-liposomes (200µl, 24h).  n=3-5 each. 
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Figure 5-8  Perfusate cytokines at the end of in situ atelectasis protocol following in vivo 
clodronate-liposome pretreatment. 
Cytokine levels in the perfusate at the end of 3-hour protocol.  Lung monocytes were depleted by in 
vivo pretreatment with clodronate-liposomes (200µl, 24h).  Lungs were ventilated with atelectasis 
protocol.  p value was calculated by t-test, n=3-5 each. 
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Figure 5-9  Lavage cytokines at the end of in situ atelectasis protocol following in vivo 
clodronate-liposome pretreatment. 
Lung monocytes were depleted by in vivo pretreatment with clodronate-liposomes (200µl, 24h).  
Lungs were ventilated with atelectasis protocol and cytokine levels in the lavage fluid were measured 
at the end of perfusion.  p-value was calculated by t-test, n=3-5 each. 
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Subclinical endotoxaemia exacerbated high-stretch induced injury 
Having found that monocyte depletion appeared to attenuate cytokine production 
and oedema following high-stretch, we attempted to explore the mechanisms of 
monocyte involvement under what may be considered more physiologically relevant 
conditions, i.e. following monocyte activation and recruitment induced by 
endotoxaemia.  We first investigated the effect of in vivo subclinical endotoxaemia on 
the number of lung-marginated leukocytes in the in situ system.  In line with previous 
in vivo findings (219), the pretreated mice did not show any clinical symptoms after 
this small dose of LPS injection, and the number of neutrophils and Gr-1 high 
monocytes (the ‘inflammatory’ subset) were significantly higher (p<0.05) in the LPS 
pretreated lung.  The number of Gr-1 low monocytes did not change, which is also 
consistent with our previous in vivo findings (Fig 5.10).  Since this leukocyte number 
in the lung is after the 3-hour perfusion, these numbers represent truly ‘marginated’ 
leukocytes, rather than any simply sitting within the vasculature. 
This subclinical endotoxaemia resulted in a significant change in airway 
pressure over time during perfusion/ventilation (p<0.05).  However, we had to 
terminate all the experiments with LPS-pretreated lungs and some experiments in 
the unpretreated group before the end of 3-hour perfusion, because oedematous 
fluid was visibly rising into the endotracheal tubes (End time: 167±17 and 149±17min 
in unpretreated and LPS-pretreated group, respectively).  Since the 2-way ANOVA 
does not allow such missing data, we analysed the airway pressure data up to 135 
minutes, when all the lungs were still viable (Fig 5.11A).  There was also a tendency 
towards an increase in lavage protein, although the difference was not statistically 
significant due to the high variability (p=0.28, Fig 5.11B). Consistent with the 
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physiological findings, the cytokine data were also variable.  Because early 
termination also affects the level of accumulated perfusate cytokines at the end of 
the experiments, the perfusate data were compared at 2 hours, which represents the 
accumulated cytokines from 1 - 2 hours of perfusion.  The cytokine levels in 
perfusate and lavage fluid were not different between the un-pretreated and 
pretreated lung, except a significant but small decrease in perfusate MIP-2 (p<0.05; 
Fig 5.12). 
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Figure 5-10  The number of lung leukocytes following in vivo LPS pretreatment and in situ 
high-stretch protocol. 
Quantified by flow cytometry at the end of the 3-hour high-stretch protocol.  20ng of LPS was injected 
intraperitoneally 2 hours before setting up isolated perfused lung.  *p<0.05 by t-test, n=4-5 each. 
  
	   182	  
 
Figure 5-11  Development of lung injury in in situ high-stretch protocol following in vivo LPS 
pretreatment. 
(A) Peak inspiratory pressure during the high-stretch protocol and (B) total protein in lavage samples 
at the end of the protocol.  Experiments were terminated early when oedematous fluid was visible in 
the endotracheal tubes, indicating substantial lung oedema.  Subclinical endotoxaemia was induced 
by in vivo pretreatment with intraperitoneal LPS injection (20ng), 2 hours prior to the isolated perfused 
lung setup.  *p<0.05 by 2-way repeated measures ANOVA up to 135 min, n=4 each. 
 
 
Figure 5-12  Perfusate and lavage cytokines in in situ high-stretch protocol following in vivo 
LPS pretreatment. 
Cytokine levels in (A) the perfusate at the 2-hour time point and (B) the lavage fluid at the end of the 
protocol.  Subclinical endotoxaemia was induced by in vivo pretreatment with intraperitoneal LPS 
injection (20ng, 2h).  *p<0.05 by t-test, n=4 each. 
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5.5. Discussion 
In this chapter, we investigated whether increasing/decreasing the number of lung-
marginated monocytes made a difference within the two VILI models.  My results 
showed that monocyte depletion attenuated the pulmonary oedema and cytokine 
production (in both intravascular and intra-alveolar compartments) in the high-stretch 
model, but not in the atelectrauma model.  In line with the monocyte depletion 
experiments, the pretreatment with subclinical endotoxaemia caused increases in 
lung-marginated neutrophils and inflammatory subset monocytes, and accelerated 
the development of pulmonary oedema in the high-stretch model. 
Historically, the role of monocytes in VILI has been poorly appreciated, 
compared to neutrophils, for a number of reasons.  Firstly, since the monocytes do 
not easily transmigrate to intra-alveolar space, it is difficult to access these 
monocytes within the lung parenchyma by lung or bronchoalveolar lavage.  
Furthermore, even when the monocytes are migrated into the intra-alveolar space, it 
is difficult to visually differentiate monocytes from alveolar macrophages under the 
conventional light microscopic examination of lavage fluid.  Secondly, the importance 
of categorisation within monocytes has only been properly elucidated within the last 
5-10 years (423).  In this regard, recent advances in FACS techniques have allowed 
us to immunophenotype these monocytes within the lung tissue (219, 446).  Thirdly, 
it has recently become apparent that previous techniques used for the depletion of 
neutrophils, such as administration of Gr-1 antibodies, also deplete ‘inflammatory’ 
subset monocytes (564, 565), almost certainly causing an overestimation of the role 
of neutrophils within inflammatory conditions.  Our previous findings indicated that 
lung-marginated monocytes, and their interaction with the pulmonary endothelium, 
may be important during acute lung injury of various aetiologies (219, 445, 446), but 
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the mechanisms of monocyte-related pathogenesis in VILI remain largely unknown, 
and there are technical difficulties in further investigating this in vivo.  One challenge 
was to separate out the ‘pure’ role and mechanisms of lung-marginated monocytes 
from that of circulating monocytes, which we have addressed using the IPL system. 
 
Methodology for depleting monocytes 
The use of clodronate-loaded liposomes is a standard method to deplete monocytes 
and macrophages (219, 327, 446, 539, 562, 566).  A recently developed alternative 
involves CD11b-diphtheria toxin receptor transgenic mice, whereby administration of 
diphtheria toxin selectively kills monocytes and macrophages (567), but this method 
inevitably limits its application due to the necessity of systemic application of toxin 
and genetic manipulation.  Currently, the clodronate-liposome method is still popular 
to deplete monocytes/macrophages due to its technical simplicity and relatively well-
characterised effect.  Off-target effects of clodronate have been reported; for 
instance, neutrophil depletion (568) has been reported previously, but we did not see 
a significant change in neutrophil number in our previous experiments (219, 446) and 
my results in this chapter.  Indeed, previous studies that showed neutrophil depletion 
may simply mean that monocytes were involved in the regulation of neutrophil 
migration as suggested by others (569).  Inhibition of matrix metalloproteinases by 
clodronate was also reported (570), but others opposed this idea (571, 572).  
Liposomes are artificially prepared spheres consisting of concentric phospholipid 
bilayers separated by an aqueous layer.  Clodronate (dichloromethylene 
bisphosphonate) is a member of the family of bisphosphonates originally developed 
for the treatment of osteolytic bone diseases, in which clodronate suppresses the 
activity of osteoclasts.  The clodronate is encapsulated in the liposome and released 
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when phagocytic cells engulf the clodronate-loaded liposomes and digest the 
phospholipid layers by intracellular lysosomes; subsequently, accumulated 
clodronate induces apoptosis to the phagocytic cells (471, 562).  Since the liposome 
does not cross the endothelial/epithelial barriers, the depletion effect is 
compartmentalised (562, 573).  Systemic injection of clodronate-liposome has been 
shown to deplete lung-marginated monocytes (219, 446), circulating monocytes, and 
macrophages in other organs (573, 574), whereas intratracheal instillation of 
clodronate-liposomes depletes alveolar macrophages (539, 575).  Thus in the IPL, in 
vivo pretreatment with systemic clodronate-liposome injection should primarily 
influence lung-marginated monocytes. 
 
The effect of monocyte depletion in VILI 
In my experiments, the number of monocytes was seemingly decreased by 
clodronate-liposome treatment although the difference did not reach statistical 
significance.  The substantial variability observed was probably due in part to ‘noise’ 
inherent in the IPL preparation induced by factors such as washing-out of leukocytes 
by perfusion.  Similarly, because our current FACS technique seriously 
underestimates the number of lung-marginated leukocytes as discussed in Chapter 
3, this methodology-related variability may have also contributed to a lack of 
statistical power. 
Although leukocyte involvement in VILI has been previously suggested (and 
demonstrated), this concept was based mainly on the high-stretch model (205, 208, 
548, 558, 576).  It has remained largely unknown whether leukocytes are similarly 
involved in the development of atelectrauma.  Only a few studies suggested 
neutrophils may be recruited into lung and activated during the development of 
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atelectasis (577) or after ventilating the atelectatic lung (578).  The absence of any 
impact of monocyte depletion during atelectasis-related lung injury in my 
experiments was in general compatible with the current proposed mechanism of 
atelectrauma; i.e. repetitive collapse and opening of the lung units, a primarily intra-
alveolar event (104, 139).  However, there is also an evidence that endothelial bleb 
formation was seen in an in vivo atelectrauma model, suggesting that shear stress 
might affect the endothelium (153). 
In this chapter, we demonstrated that monocyte depletion significantly 
attenuated the pulmonary oedema in the in situ high-stretch induced VILI model.  My 
results together with our previous in vivo work (219) confirm the importance of lung-
marginated monocytes in VILI, specifically induced by high-stretch (the speculative 
mechanisms behind the monocytes-related pathophysiology in VILI will be discussed 
later in the final chapter).  Interestingly, the results also indicated clear decrease of 
cytokines both in the vascular and intra-alveolar space following monocyte depletion.  
Systemic release of lung-borne cytokines is likely to be related to MODS, a major 
cause of mortality in ALI patients (196, 538).  Our results provide a possible insight 
into the cellular source of these lung-borne cytokines.  TNF is produced mostly by 
monocytes and alveolar macrophages, whereas parenchymal cells contribute less 
(579).  KC and MIP-2 are considered to be mainly produced by alveolar 
macrophages and epithelial cells (215, 580-582), but other evidence suggests the 
production of IL-8 by pulmonary endothelium (218, 583).  In light of this previous 
evidence, our results may indicate that high-stretch induced intravascular cytokine 
production by pulmonary endothelium and lung-marginated monocytes. 
Interestingly, we also found that intra-alveolar cytokine increases were 
attenuated by monocyte depletion, both at the end of 3-hour protocol, and at a very 
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early time point (15 minutes).  We have previously shown that alveolar macrophages 
are activated very early (within 5 minutes) during high-stretch ventilation (563), and 
these data may suggest that lung-marginated monocytes might communicate with 
the intra-alveolar compartment and, at least in part, regulate the inflammatory 
response.  It is also notable that such attenuation in intra-alveolar cytokine 
production was not seen in the atelectrauma model.  This may suggest that high-
stretch or the consequent pulmonary endothelial activation triggers the inter-
compartmental communication. 
At the moment, it is unclear what mechanisms may be involved in the 
communication between the two compartments.  While it is possible that at 3 hours, 
high levels of circulating mediators could have influenced alveolar cytokines (either 
simple ‘decompartmentalisation’ of TNF, MIP-2 or KC into the alveolar space, or 
translocation of some other unidentified soluble mediator activating macrophages), 
this is highly unlikely to explain the findings at 15 minutes - perfusate mediators were 
undetectable and the alveolar-capillary barrier was intact at this time point.  Using an 
intravital microscopic technique, Bhattacharya and colleagues previously showed 
that there is a rapid (within a minute) Ca-mediated alveolo-capillary crosstalk in 
response to intra-alveolar TNF administration (584) and mechanical stretch (585), 
resulting in calcium influx into the pulmonary endothelium or P-selectin upregulation.  
I speculate such a mechanism may be involved in this intra-alveolar cytokine 
regulation, working in the other direction (i.e. lung-marginated leukocyte/endothelium 
to intra-alveolar cells).  In fact, Kaestle et al. has shown that endothelial NO can 
regulate alveolar fluid clearance (586).  We attempted to further clarify the cellular 
mechanisms/activations behind this phenomenon, and measured various cellular 
‘early’ activation markers/signalling molecules by FACS at various time points (5, 15, 
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30 minutes).  The molecules we measured were; L-selectin on lung-marginated 
leukocytes (neutrophils and Gr-1 high monocytes), and phosphorylated MAP kinases 
(p38/MK2/ERK), E-selectin and P-selectin on pulmonary endothelium.  We chose 
these parameters because these molecules can be upregulated within this time 
frame measured (up to 30 minutes).  Unfortunately, these data did not show any 
significant differences between high-stretch and control samples (thus were not 
shown in the results section), so further investigation is needed to elucidate our 
findings. 
Several arguments can arise about the findings in the 15-minute experiment.  
Firstly, despite literature indicating that the liposomes do not cross endothelial-
epithelial barriers (219, 562), it was possible that systemic clodronate affected 
alveolar macrophages.  However, the clodronate-pretreated lungs seemingly 
contained a similar number of alveolar macrophages, as the lungs without 
clodronate-pretreatment.  This was evaluated in lung single cell suspensions by flow 
cytometry as high autofluorescent and CD11b(-)F4/80(+) populations, as described 
in Chapter 2 (5.90±1.76×105 vs. 6.25±1.10×105 cells/lung, unpretreated vs. 
monocyte-depleted lungs, respectively; n=3-6 each).  It does remain possible that 
off-target effects of clodronate-liposomes, such as functional modulation of 
macrophages, could have affected our results in a way FACS quantification of 
macrophages cannot detect.  This remains to be evaluated.  Secondly, it can be 
argued that 15 minutes was too early to see such a cytokine induction, suggesting 
that the cytokine production was not purely due to the high-stretch, but modified by 
the IPL preparation; i.e. priming effects by surgical insults.  While this may be true, it 
does not disprove our idea of the monocyte-related regulation of intra-alveolar 
inflammation, since the barrier integrity was maintained. 
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There are a number of other potential issues surrounding the ‘depletion’ 
experiments that ought to be mentioned.  Firstly, clodronate-liposome treatment 
induces cellular apoptosis in monocytes, and it is unclear how and when apoptotic 
monocytes are removed from the lung, and if these dead or dying cells affect the 
result.  It seems unlikely though that this could lead to decreased permeability and 
inflammation, as found in these experiments.  Secondly, we used unpretreated 
controls to compare with clodronate-liposome pretreatment, rather than other 
controls such as administration of PBS-loaded liposomes.  However, it is arguable 
whether PBS-loaded liposomes are an appropriate control, because the liposome 
per se has been shown to affect macrophage function (562).  Thirdly, we did not 
identify which subset of monocytes was responsible for the cytokine production.  
Based on our previous in vivo experiments (219), I assume that inflammatory 
monocytes are likely to be the key players in this cytokine production in the high-
stretch model.  Finally, as discussed in the previous chapter, lack of blood may have 
exaggerated the systemic chemokine (KC and MIP-2) concentration, but the 
conclusions regarding the impact of marginated monocytes in VILI should be 
independent from this. 
 
2-hit model of in situ high-stretch induced VILI 
In the monocyte depletion experiments, we attained promising results suggesting the 
role of lung-marginated monocytes during high-stretch induced inflammation and 
injury, confirming some of our previous in vivo data.  To attempt to translate this 
finding towards more clinical settings, we employed a ‘2-hit’ VILI model, which was 
used previously (219, 446) and should amplify the effect of lung-marginated 
monocytes, if they are clinically important.  From the experimental viewpoint, 
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investigation of 1-hit models usually gives an easy-to-understand result, whereas 2-
hit models are sometimes highly clinically relevant.  Indeed, VILI usually happens 
following an initial insult, which drives the requirement for ventilation in the first place.  
Ample evidence has indicated that such pre-injury or pre-stimulation sensitises the 
lungs to subsequent stimuli, leading to VILI (219, 560, 587-590).  Neutrophils (560, 
589, 590), soluble mediators (560, 587, 588), and monocytes (219) have been 
implicated in the ‘priming’ mechanism behind the sensitisation.  Experimentally, 
endotoxaemia is often used as a first hit (219, 560, 587, 588), as the use of LPS per 
se is a technically simple and hence reproducible insult, yet clinically relevant. 
Our research group has demonstrated unique ‘stop-and-go’ kinetics of the 
inflammatory monocytes in a subclinical endotoxaemia model.  The inflammatory Gr-
1 high monocytes were very rapidly recruited from bone marrow to the lung in 
response to subclinical endotoxaemia, but after 2 hours had disappeared from the 
lung tissue.  In contrast, neutrophils started to recruit at a later time point and stay in 
the lung longer.  Furthermore, at the point when the number of lung-marginated 
monocytes was maximally increased, the lungs were sensitised to subsequent 
insults such as a yeast (zymosan) injection (446).  This result suggested that the 
temporary stay of the inflammatory monocytes in the pulmonary microcirculation may 
play a role in pulmonary inflammation, supporting the likelihood that interaction of 
monocytes with endothelial cells in the lung are important.  Such ‘stop-and-go’ 
kinetics of monocytes might be one of the reasons why the role of monocytes in ALI 
has traditionally been underestimated.  This in vivo finding drove us to investigate 
the mechanisms of monocyte-endothelial interaction in the lung and we have indeed 
recently showed a synergistic activation of monocytes and pulmonary endothelium 
via the p38/MK2 pathway using an in vitro co-culture model (456).  Therefore, it was 
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our prediction that the 2-hit model of LPS followed by VILI, in which monocyte 
recruitment to the lungs is enhanced, and both monocytes and endothelial cells 
potentially activated before ventilation starts, would highlight a major role for 
monocytes in the progression of injury and inflammation.  However, in reality, the 2-
hit VILI model did not produce such clear results.  With the LPS-pretreatment, the 
numbers of lung-marginated neutrophils and inflammatory monocytes were 
significantly increased in the lung as anticipated, and pulmonary oedema (PIP 
increase) was exacerbated, similar to previous in vivo results (219).  In contrast to 
these expected results, lavage protein levels and cytokine levels showed high 
variability, making the interpretation difficult. 
There are a number of possible reasons why this experiment did not show a 
clear difference.  Firstly the very nature of the IPL model potentially introduces a lot 
more ‘noise’ into the results than in vivo experiments, including variability in 
perfusate, surgery, and lung geometry.  Among them, a fundamental difficulty to 
control the transpulmonary pressure in the IPL model particularly made it difficult to 
establish stable results.  In our surgical preparation, we cut and open the rib cage, 
but otherwise leave it as intact as possible to try to maintain the original geometry of 
the lung, allowing the lung to slide along with the rib cage upon ventilation.  
Therefore, the transpulmonary pressure is changed by the mechanical feature of rib 
cage, which should be similar, if we use the closed chest condition.  However, once 
cutting and opening the rib cage, such surface pressure of the rib cage is very 
difficult to control and standardise, as it is determined by how I cut the rib cage and 
how I place the lung preparation on the bed.  It was therefore intrinsically difficult to 
control the variability within the high-stretch ventilation, in which transpulmonary 
pressure is the critical determinant of the severity of injury (207).  The variability in 
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our high-stretch model might be a little higher than previous studies (194, 195, 237, 
491).  However, some of these models did not intend to produce substantial lung 
injury like ours, and thus lower tidal volume was applied (195, 237).  Furthermore, 
we recruited the lung with higher PEEP and higher SI pressure than the previous 
studies (194, 237), to decrease the atelectrauma component and enhance the high-
stretch component, therefore we might have also enhanced the inherent variability of 
high-stretch model.  Nevertheless, I do not think this variability disqualifies the 
findings in the previous chapters, because we mainly compared the effects of high-
stretch vs. atelectasis.  Because these two models are categorically different in their 
pathophysiology, the signals were expected to be big, and hence the variability 
within the high-stretch model did not cause many serious issues.  However, in this 
chapter, we attempted to compare two high-stretch groups with various 
interventions.  Unless we achieve a big enough signal (which seems to have been 
the case in the monocyte depletion experiments), the noise of the baseline (high-
stretch model) may be too large to detect any signal. 
Secondly, as lungs from LPS-pretreated mice tended to develop a more rapid 
pulmonary oedema, it was difficult to directly compare the results, in particular 
perfusate cytokines collected at the end, which represents the accumulated 
cytokines between 2-hours and the end of the experiments (and thus the time of 
termination is a major factor).  To attempt to bypass this we compared the 
accumulated cytokines between hours 1-2 instead; however the data in the previous 
chapters showed that the cytokine levels increased most dramatically after 2 hours.  
Because we had to compare at a shorter time point, the signal-noise ratio of the 
perfusate cytokines may be insufficient to detect differences between treatments. 
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Finally, the cytokine production, in reality might not be different following LPS 
treatment.  Data from Chapter 4 indicate that high-stretch ventilation activates both 
intra-alveolar and intravascular components, and the current data using monocyte 
depletion indicate that leukocytes (potentially via interaction with endothelial cells) 
play a role in producing cytokines.  As discussed previously (Chapter 3), even 
untreated mouse lungs contain as many as 10 million leukocytes.  Although the LPS 
pretreatment clearly induced an increase in lung-marginated leukocytes it is not clear 
from the flow cytometric technique used how much of an increase in the total 
leukocyte number this actually represents.  Therefore it is possible that the 
leukocyte-endothelial responses to the high-stretch insult may be at or close to 
maximal even under baseline conditions; hence the depletion of lung-marginated 
leukocytes may produce a clearer signal than addition of leukocytes. 
Interestingly, the LPS pretreatment did cause a significant physiological 
change (airway pressure increase) over time in the high-stretch model.  This result 
might suggest that there may be another factor which we have not measured, and 
which modulates pulmonary oedema.  This point will be further discussed in the final 
chapter. 
 
In summary, we have demonstrated that lung-marginated monocytes are activated 
following high-stretch ventilation, leading to pulmonary oedema and pro-
inflammatory cytokine production, potentially challenging the current 
decompartmentalisation paradigm.  However, these monocytes are not involved in 
the development of pulmonary oedema and cytokine production in the atelectrauma 
model.  Monocyte-targeted therapy may be useful in attenuating lung oedema and 
both pulmonary and systemic inflammation in high-stretch induced VILI.  
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6. The role of lung-marginated 
monocytes in ischaemia-
reperfusion lung injury 
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Summary 
Ischaemia-reperfusion (I/R) lung injury is a major complication in the lung 
transplantation setting and clinically defined as primary graft dysfunction (PGD).  It is 
known that the pre-existing status of the organ donor strongly influences the later 
development of PGD, and infection is one such ‘priming’ factor.  From an 
experimental viewpoint, the IPL is a strong tool to investigate ischemia-reperfusion 
injury. 
As with VILI, the main focus of leukocyte involvement in PGD has been 
neutrophils and alveolar macrophages.  Based on our previous results, we 
hypothesised that monocytes marginated and activated within the lung due to 
infectious stimuli also play a role in PGD.  To investigate this, we used a donor lung 
injury model of I/R, in which in vivo subclinical endotoxaemia was followed by 
preparation of the IPL model and subsequently stopping and re-starting perfusion to 
induce I/R. 
In vivo subclinical endotoxaemia dramatically enhanced the alveolar-capillary 
barrier dysfunction in the I/R model, together with increases in TNF production.  Flow 
cytometry data indicated an underlying cellular mechanism involving recruitment and 
activation of a substantial number of activated leukocytes together with pulmonary 
endothelial activation. 
Taken together, these results potentially indicate the importance of lung-
marginated leukocytes in this I/R model.  Any molecular mechanism behind this 
monocyte-related microvascular inflammation remains to be elucidated, and this in 
situ model will provide versatile tools for further investigation and developing novel 
therapies to prevent PGD. 
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6.1. Background 
Since the first lung transplantation was successfully performed in 1983 (591), the 
understanding and protocol of lung transplantation have substantially improved, 
including the optimal preservation fluid and cooling system (592), yet the 3-month 
mortality is still around 10% and the median survival length is worse than other organ 
transplantations (290).  Lung ischaemia-reperfusion (I/R) injury is a major transplant-
related complication, and clinically defined as primary graft dysfunction (PGD) (291).  
PGD typically develops within the first 72 hours after the transplantation and is 
characterised by hypoxaemia, permeability lung oedema, and pulmonary 
hypertension (329, 593).  PGD affects not only the short-term mortality outcome, but 
also the long-term pulmonary function (295) and increases risks for bronchiolitis 
obliterans syndrome (296).  Organ donors often have complications such as 
neurogenic pulmonary oedema.  Such pre-existing disease in donors, whether it is 
symptomatic or asymptomatic before harvesting, could contribute to subsequent 
PGD and poor clinical outcome following lung transplantation.  In fact, only 20-30% 
of donor lungs are evaluated as suitable for transplantation due to underlying 
dysfunction.  Understanding the pathological mechanisms behind donor lung injury is 
crucial to decrease PGD and hence improve the overall clinical outcome in this area. 
The main research focus of leukocyte involvement in I/R has been recipient 
neutrophils (336-341) and donor alveolar macrophages (325, 327, 339, 342).  In line 
with this, Fiser et al. demonstrated the attenuation of lung I/R by filtering out the 
leukocytes in the perfusate or depleting alveolar macrophages by intravenous 
gadolinium chloride injection (339); both of the treatments can deplete monocytes in 
the circulating pool and marginated pool (431).  Although the monocyte chemokine 
MCP-1 (343, 594), and one of the primary monocyte-related cytokines TNF (342, 
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531, 595), have been implicated in PGD, the role and mechanisms of monocytes 
and lung-marginated leukocytes in PGD have not yet been investigated. 
In the previous chapter, we presented data that lung-marginated monocytes 
are involved in the development of pulmonary oedema and cytokine production in 
VILI.  From an experimental viewpoint, modelling lung I/R injury in mouse in vivo is 
technically very challenging and only a few models have been developed by either 
single lung transplantation (596, 597) or hilar ligation of one lung (444, 534).  In 
contrast, inducing bilateral lung I/R injury is technically easier and more 
straightforward in the mouse IPL model, simply by stopping and restarting the 
perfusion pump (325, 326, 598, 599).  As shown in the previous chapter, the IPL 
model has advantages to clarify the role and mechanisms of lung-marginated 
monocytes.  In addition, the recent technical development of EVLP means we have 
an opportunity to access/manipulate these donor lung-marginated leukocytes in the 
clinical setting, further encouraging development of this very translational model. 
Based on this background and results from the previous chapters, I aimed to 
investigate the role and mechanisms of lung-marginated monocytes in a transplant-
related lung injury model using the IPL.  Since organ donors can develop subclinical 
infection because of immunological dysfunction and bacterial translocation from 
intestine at their end-stage, the 2-hit LPS + I/R model is a theoretically very 
translatable scenario. 
 
 
6.2. Aims 
In this chapter, we aimed to: 
1) Develop an in situ I/R model. 
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2) Investigate the impact of subclinical endotoxaemia on lung injury and 
inflammation following subsequent I/R injury. 
 
 
6.3. Protocols 
I/R lung injury 
Surgical preparation was the same as that used in the high-stretch protocol.  A 
number of mice were pre-treated with 20ng of intravenous LPS, 2 hours before 
sacrifice and preparation for IPL, as a subclinical inflammatory insult.  Lungs were 
ventilated with 5%CO2 in air throughout the protocol.  In lung transplantation 
settings, lungs are initially flushed with flushing buffer to remove the residual blood 
from the lung.  In order to simulate this, we initially flushed out the residual blood with 
a 10-minute non-recirculating perfusion using ‘flushing’ buffer consisting of Hanks-
balanced salt solution buffer (HBSS), supplemented with 5% low-endotoxin BSA.  
We did not use the usual RPMI-based buffer because this contains nutrients 
including amino acids, which are not present in clinically used flushing solutions.  We 
also used a higher flow rate (1.2-1.5ml/min, corresponding to 50ml/kg/min) in this 
model than used in previous chapters in an attempt to increase the degree of shear 
stress, because loss and reapplication of endothelial shear stress have been 
suggested to play a pathological role in I/R (320).  After the 10-minute flushing, 
ischaemia was induced by stopping the perfusion for 2 hours, while the lungs were 
kept at 37°C and inflated with 5cmH2O of CPAP to prevent atelectasis. Intravascular 
pressure was kept at 2.5mmHg during the ischaemic period.  After 2 hours of 
ischaemia, reperfusion was initiated using RPMI with 4% low endotoxin BSA (1.2-
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1.5ml/min, corresponding to 50ml/kg/min) with a stepwise increase of the flow to 
avoid a rapid rise in the perfusion pressure, in a non-recirculating manner for 10 
minutes to replace the perfusate in the circuit.  Thereafter, the circuit was switched to 
the recirculating system and perfusion was continued for another 50 minutes.  After a 
total of 1-hour reperfusion, lavage and lung samples were taken for further analysis 
as described in the previous chapter.  Perfusate samples were taken at each stage 
from the circuit (pre/post ischaemia and post-reperfusion), and used for flow 
cytometry and cytokine assays. 
 
Sample analysis 
The cytokine concentration in perfusate and lavage samples was determined by 
ELISA.  Protein concentration in lavage fluid was determined by the Bradford method 
using a protein assay kit.  Most of the protocols employed for analysing leukocytes in 
perfusate and lung homogenate by FACS have been already described in Chapter 2 
and 3. 
Briefly, to analyse the leukocytes in the perfusate, we span down the cells in 
the perfusate and resuspended the pellet in FACS wash buffer.  Lung samples were 
divided into two and single cell suspensions were prepared with slightly different 
protocols depending on the antigen of interest, to ensure the optimal working 
condition for each antigen staining.  To measure E-selectin on pulmonary 
endothelium, we digested the lung samples with collagenase for 30 minutes at 37°C 
as we have previously described (445).  To count leukocytes and measure their L-
selectin expression, a lung cell suspension was prepared by mechanical disruption 
using a scalpel, because L-selectin is collagenase-sensitive.  The cells were then 
stained with fluorophore-conjugated anti-mouse antibody mixtures in the dark at 4°C 
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for 30 minutes.  Identification of neutrophils and monocytes has been described in 
the previous chapter.  Pulmonary endothelium was identified as CD31(+) events, as 
described in chapter 2.  The percentage of E-selectin positive events within all 
endothelial events was measured to analyse the endothelial activation.  The stained 
samples were acquired using a CyAn flow cytometer and FlowJo software.  Absolute 
cell counts for each sample were determined using microsphere beads. 
 
Statistics 
Data are expressed as mean ± SD.  Statistical analysis of data obtained was carried 
out using t-test or one-way or two-way ANOVA using Prism 4 software package 
(Graphpad).  A p-value of less than 0.05 was considered statistically significant. 
 
 
6.4. Results 
In vivo subclinical endotoxaemia enhanced I/R induced alveolar-
capillary barrier dysfunction 
Initial experiments were carried out to optimise the protocol for inducing I/R-related 
injury.  These pilot experiments indicated that 1 hour of ischaemia followed by 2 
hours reperfusion induced very little injury (even with LPS-pretreated lungs).  In 
contrast, extending the ischaemia period to 2 hours, with 1 hour of reperfusion 
(keeping the preparation life to 3 hours, consistent with other models as presented in 
earlier chapters) produced a slight increase in lavage protein, which was dramatically 
enhanced by subclinical endotoxaemia (Fig 6.1A).  Despite the clear increase in 
lavage protein, the airway pressure did not change significantly in the donor lung 
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injury (LPS + I/R) group (Fig 6.1B).  However, qualitatively pulmonary oedema was 
obvious in the donor lung injury group, since oedematous foam came up the 
endotracheal tube when we disconnected the tube from the ventilator at the end of 
these experiments.  Importantly, there were no significant differences in any of the 
baseline characteristics of the lungs between the unpretreated lungs and LPS-
pretreated lungs, before starting the I/R protocol (Table 6.1). 
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Figure 6-1  Development of lung injury in I/R and donor lung injury model. 
(A) Total protein content in lavage and (B) peak inspiratory pressure during 1-hour reperfusion 
following 2-hour ischaemia.  Subclinical endotoxaemia was induced by in vivo pretreatment with 
intravenous LPS injection (20ng, 2h).  *p<0.05, n=4 each. 
  
	   203	  
 Un-pretreated LPS-pretreated 
Body weight (g) 29.45±0.97 29.13±1.75 
Vt (ml/kg) 7.15±0.44 7.01±0.24 
PIP (cmH2O) 9.48±0.95 9.77±0.61 
Plateau pressure (cmH2O) 8.60±0.90 8.86±0.58 
Rrs (cmH2O·sec/ml) 0.94±0.15 0.91±0.17 
Ers (cmH2O/ml) 18.57±2.69 19.34±2.93 
PAP (mmHg) 8.23±1.15 8.79±1.69 
 
Table 6-1  Baseline characteristics of the lungs. 
Physiological parameters before starting the ischaemia.  The lungs in the LPS-pretreated group were 
pretreated in vivo with intravenous LPS injection (20ng, 2h).  n=4 each. 
PIP: Peak Inspiratory Pressure 
Rrs: Resistance of respiratory system 
Ers: Elastance of respiratory system 
PAP: Pulmonary Arterial Pressure 
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In vivo subclinical endotoxaemia enhanced TNF production during 
reperfusion 
Perfusate cytokine analysis demonstrated that systemic TNF release in the 
reperfusion stage was dramatically enhanced by subclinical endotoxaemia 
pretreatment (p<0.05).  Chemokines KC and MIP-2 were also increased after the 
reperfusion, regardless of the pretreatment with LPS (Fig 6.2).  Lavage cytokine 
analysis showed a significant increase in TNF in the presence of subclinical 
endotoxaemia (p<0.05).  Chemokines in the lavage samples also seemed to be 
enhanced by subclinical endotoxaemia, but the differences were not statistically 
significant (Fig 6.3). 
These results indicated that lung-marginated monocytes (and possibly 
macrophages), which are the main producers of TNF, are activated in the I/R model, 
but only following the ‘priming’ by LPS. 
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Figure 6-2  Perfusate cytokines in I/R and donor lung injury model. 
Cytokines in the perfusate were measured at each stage of the ischaemia-reperfusion (I/R) protocol 
(2-hour ischaemia and 1-hour reperfusion).  Subclinical endotoxaemia was induced by in vivo 
pretreatment with intravenous LPS injection (20ng, 2h).  *p<0.05 at the post-reperfusion period, 2-way 
repeated measures ANOVA with Bonferroni, n=3-4 each. 
 
Figure 6-3  Lavage cytokines in ischaemia-reperfusion (I/R) and donor lung injury model. 
Cytokines in the lavage was measured at the end of the I/R protocol (2-hour ischaemia and 1-hour 
reperfusion).  Subclinical endotoxaemia was induced by in vivo pretreatment with intravenous LPS 
injection (20ng, 2h).  *p<0.05 by t-test, n=4 each. 
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I/R activated both newly-recruited and resident inflammatory 
leukocytes 
To further clarify the cellular mechanisms occurring in the I/R model, we analysed 
the number and activation level of lung-marginated leukocytes.  In line with the 
previous data in Chapter 5 (Fig 5.1), the subclinical endotoxaemia had a strong 
tendency to increase the number of inflammatory monocytes and neutrophils in the 
lung (Fig 6.4).  In order to determine the activation level of these leukocytes, we 
measured surface expression levels of L-selectin, which is shed from Gr-1 high 
monocytes and neutrophils when they are activated.  To analyse the serial 
activation, leukocytes in the effluate were collected and analysed at each stage 
(pre/post ischaemia and post reperfusion).  Before ischaemia, the level of L-selectin 
on Gr-1 high monocytes seemed to be decreased in LPS pretreated animals, 
whereas that on neutrophils was almost the same between the two groups.  
Ischaemia was found to significantly induce L-selectin shedding from neutrophils 
(p<0.05), and similar trends were also seen in Gr-1 high monocytes.  Reperfusion 
seemed to further induce L-selectin shedding from neutrophils and Gr-1 high 
monocytes, as seen in the difference between the post-ischaemia and post-
reperfusion samples, but the difference was not statistically significant and the 
impact was much smaller, compared to the difference between pre and post-
ischaemia (Fig 6.5).  To further support this finding, we also analysed the L-selectin 
expression on the remaining leukocytes in the lung at the end of the I/R protocol.  In 
agreement with the perfusate leukocytes results, the lung-marginated leukocytes 
were activated at the end of the protocol (Fig 6.6).  Importantly, the above activation 
patterns were consistently seen regardless of the presence of subclinical 
endotoxaemia, suggesting that I/R (or possibly the IPL preparation itself) activated 
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both the ‘already resident’ population and LPS-induced ‘newly recruited’ population 
of leukocytes. 
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Figure 6-4  The number of lung leukocytes following in vivo LPS pretreatment and in situ 
ischaemia-reperfusion (I/R) protocol. 
The number of leukocytes was counted by flow cytometry.  Subclinical endotoxaemia was induced by 
in vivo pretreatment with intravenous LPS injection (20ng, 2h).  n=2-3 each. 
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Figure 6-5  Expression of L-selectin on inflammatory leukocytes in perfusate. 
To investigate the time course of leukocyte activation, L-selectin on inflammatory leukocytes in the 
perfusate sample was quantified by flow cytometry at different stages of the ischaemia-reperfusion 
(I/R) protocol; i.e. pre-ischaemia, post-ischaemia, and post-reperfusion.  Decrease of L-selectin 
expression indicates shedding of the molecule due to leukocyte activation.  In some experiments, 
subclinical endotoxaemia was induced by in vivo pretreatment with intravenous LPS injection (20ng, 
2h), to recruit inflammatory leukocytes to the lung.  *p<0.05 by 1-way ANOVA with Bonferroni.  n=3-4 
each. 
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Figure 6-6  Expression of L-selectin on inflammatory leukocytes in lung at the end of the 
protocol. 
L-selectin on inflammatory leukocytes in the perfusate sample was quantified by flow cytometry at the 
end of the ischaemia-reperfusion (I/R) protocol.  Decrease of L-selectin expression means the 
shedding of the molecule due to the leukocyte activation.  In some experiments, subclinical 
endotoxaemia was induced by in vivo pretreatment with intravenous LPS injection (20ng, 2h).  
*p<0.05 by 1-way ANOVA with Bonferroni.  n=3-5 each. 
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In vivo subclinical endotoxaemia activated pulmonary endothelium 
We also measured the activation levels of pulmonary endothelium to elucidate the 
cellular mechanisms taking place in the donor lung injury (LPS+I/R) model.  
Compared to I/R alone, pretreatment with subclinical endotoxaemia significantly 
upregulated endothelial E-selectin by the end of the protocol (p<0.01; Fig 6-7). 
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Figure 6-7  Expression of cell adhesion molecules on pulmonary endothelial cells. 
Level of E-selectin on the pulmonary endothelium was measured by flow cytometry.  E-selectin 
%positive events within pulmonary endothelial cell populations was measured by flow cytometry to 
assess the endothelial activation.  (A) Representative plots from ischaemia-reperfusion group or 
donor-injury group.  Plots within the surrounded area are considered as ‘positive events’.  (B) 
Percentage positive events are shown.  Subclinical endotoxaemia was induced by in vivo 
pretreatment with intravenous LPS injection (20ng, 2h).  **p<0.01 by t-test, n=3 each. 
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6.5. Discussion 
In this chapter, to further investigate the role and mechanisms of lung-marginated 
monocytes in ALI, I developed a highly clinically relevant donor lung injury model of 
I/R in the IPL.  My donor lung injury model induced by subclinical endotoxaemia 
showed significant increases in the number of inflammatory leukocytes, alveolar-
capillary barrier dysfunction, and TNF production following the I/R protocol. 
One of our main intentions to develop the IPL model was to clarify the role 
and mechanism of lung-marginated leukocytes, in particular monocytes.  Although 
we did find evidence regarding the involvement of these lung-marginated monocytes 
in pulmonary oedema and cytokine production in high-stretch induced VILI, there 
were complications relating to the model, which made it difficult to draw many 
conclusions about the effects of clinically relevant pre-existing injury/inflammation.  
For example, the nature of the high-stretch model is such that once pulmonary 
oedema starts to develop, this worsens in a very rapid, maybe exponential manner, 
as the high volume of gas is delivered to a diminishing aeratable area.  This makes it 
very difficult to design a model in which one can induce injury/oedema, and then 
detect exacerbation of that injury within the pre-determined period following a 
‘priming’ insult, but still keep the preparations viable at the end.  In contrast, it is 
much easier to design an experiment where injury is attenuated.  In order to 
investigate the mechanisms by which underlying (subclinical) inflammation may 
exacerbate lung injury, it was therefore felt necessary to explore an alternative 
model. 
Compared to the largely conceptual VILI model, the ischaemia-reperfusion 
model is more clinically relevant and translational.  Such experiments using the 
mouse IPL system have the potential to provide many useful insights related to the 
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cutting-edge technology surrounding the human EVLP, which is used in the lung 
transplantation setting (315, 316).  There are a number of other reasons why the I/R 
model may be useful for my particular studies based around leukocyte-endothelial 
interactions in ALI.  Firstly, TNF has been implicated in the development of I/R (531), 
although it has been generally considered to be produced from alveolar 
macrophages (325, 344).  Based on the results in the previous chapter, we 
hypothesised that lung-marginated monocytes also play a role in I/R, since 
monocytes are also an important producer of TNF in the lung (445).  Secondly, we 
have previously demonstrated that the direct cellular contact between lung-
marginated monocytes and pulmonary endothelium induce a synergistic effect in a 
membrane TNF-dependent manner.  TNF is a pleiotropic cytokine that is initially 
expressed on the cell surface (membrane TNF).  Membrane TNF is cleaved by a 
metalloproteinase enzyme, tumour necrosis factor alpha converting enzyme (TACE), 
to release the soluble form of TNF.  Our previous in vivo (445) and in vitro (456) 
study demonstrated that the direct cellular interaction between monocytes and lung 
capillary endothelium is very effective to activate both cell types, leading to the 
strong expression of the membrane TNF (456).  Moreover, It is known that the lack 
of flow may enhance the leukocyte-endothelial interaction (600), which is shown to 
be important in the development of I/R injury of other organs (601). 
 
Optimisation of lung I/R injury model 
In the development and optimisation of the I/R model, there were a number of 
important practical decisions to make.  One issue about ischaemic time versus 
reperfusion time has already been discussed, but other considerations included the 
type of gas, temperature and perfusate to use. 
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Ventilation gas 
We initially debated whether to induce hypoxia or not during the ischaemia period. 
I/R injury models of other organs usually involve hypoxia because the lack of blood 
flow means lack of oxygen delivery to those organs (329, 593).  However, lung I/R is 
very different, as oxygen is present in the intra-alveolar space, and therefore a state 
of hypoxia is unlikely to occur solely from lack of oxygen in the perfusate (or blood) 
(323, 330).  Therefore, hypoxia may deviate this preparation from clinical relevant 
scenarios, where the donor lung is kept inflated with air supplemented with oxygen 
up to 50% during the preservation period (334).  Technically, introducing hypoxia 
requires anoxic gas such as 5%CO2 in 95% N2, but it may be difficult to precisely 
control alveolar oxygen levels with such an anoxic gas due to oxygen from the 
perfusate.  Perfusate can be oxygenated through the circuit, because oxygen can 
penetrate the circuit tubings and the reservoir is open to the atmosphere.  Therefore, 
we chose to use 5% CO2 in air and kept the lung inflated with 5cmH2O of PEEP. 
 
Temperature 
We kept the lung at 37 degrees during the ischaemic period, known as a warm 
ischaemia model, whereas the lung is cooled during most of the ischaemia period in 
the actual lung transplantation setting (cold ischaemia).  Warm ischaemia may better 
reflect a different clinical condition such as pulmonary embolism-related I/R, rather 
than lung transplant-related I/R per se.  However, to avoid too much technical 
complexity (e.g. filling the very small mouse chest cavity with ice and water, without 
interfering with the optimal alignment of pulmonary arterial and left atrial cannulas, 
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which are crucial for stable operation of the IPL), and thus reduce noise within the 
system, we used the warm ischaemic model. 
 
Perfusate 
Historically, Intracellular type solutions such as Euro-Collins solution and University 
of Wisconsin solution have been used for flushing the pulmonary circulation to 
remove the residual blood from the lung.  Since the beneficial effects of low-
potassium (extracellular type solutions) have been shown, it is now becoming 
standard practice to use low-potassium and dextran solution including Perfadex, and 
more recently Steen solution (334), which contains albumin and dextran to increase 
the colloidal osmolarity for absorbing extravascular lung water.  To reflect this, we 
used HBSS-based buffer instead of RPMI-based buffer for the initial 10-minute 
equilibration period.  We did not use RPMI, because addition of amino acids might 
be beneficial for organ preservation (602), and thus in a sense, could distort the 
clinical relevance of this model. 
 
Barrier dysfunction and cytokine production in the donor lung injury model 
The LPS pretreatment successfully exacerbated the I/R injury in terms of the lavage 
protein level.  Despite the clear increase in lavage protein, the airway pressure did 
not change much during reperfusion regardless of the LPS pretreatment.  
Qualitatively, we saw oedematous fluid coming up to the endotracheal tube, which 
may mean more than 30-40% increase of extravascular lung water (532), suggesting 
that the absence of airway pressure increase was likely a ‘false negative’.  This 
means the airway pressure increase is not an early or sensitive marker of ALI in this 
setting.  This is perhaps somewhat inconsistent with results in previous chapters, 
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where PIP change was often clearer than the lavage protein change.  This apparent 
inconsistency might be explained by the possibility that higher tidal volume 
ventilation may lead to a bigger signal, and therefore more sensitivity to detect 
relatively small changes in mechanics due to influx of fluid.  It was possible that 
plugging of increased number of leukocytes within the microcirculation might 
contribute to the development of I/R (603), but in our model, the PAP was not 
different between the two groups at the end (8.17±0.02 vs. 8.27±0.95 mmHg; I/R and 
LPS+I/R, respectively), suggesting such a microhaemodynamic alteration was not 
the main reason for the breakdown of the alveolar-capillary barrier. 
 It is notable that the baseline characteristics of the lungs (including mechanics 
and pre-ischaemia perfusate cytokines) were almost the same regardless of the 
presence or absence of LPS pretreatment.  Extrapolating to the clinical scenario, 
under the current donor lung selection criteria, it is likely that lungs exposed to such 
a subclinical infection would have been deemed acceptable to transplant.  Clearly 
however, the susceptibility to ischaemia and subsequent reperfusion were 
dramatically different. 
With regard to the cytokine production, the in vivo LPS pretreatment 
dramatically enhanced the TNF production, in particular within the perfusate.  
Indeed, the impact on perfusate TNF increase was surprisingly high, compared to 
the previous high-stretch VILI model.  At the end of the I/R models, the level of 
perfusate KC and MIP-2 was compatible to the previous high-stretch model; 3-4 
times higher than 3 hours of non-injurious ventilation and perfusion, indicating that 
I/R injury upregulates chemokine production (compared to ‘control’ IPL).  However, 
the level of perfusate TNF in the LPS+I/R model was >10 times higher than the high-
stretch model, and >50 times higher than non-injurious controls.  This suggests that 
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the LPS pretreatment predominantly enhances the TNF production.  Lavage 
cytokines also showed a similar pattern.  Despite the very high intra-alveolar TNF 
production, the levels of intra-alveolar chemokines (KC and MIP-2) were much lower 
than the high-stretch model, suggesting the preferential activation of TNF production 
pathway by the LPS pretreatment in the I/R model. 
 
Cellular activation in the donor lung injury model 
In this chapter, further to the physiological data, we investigated the cellular 
activation level to explore the immunological mechanisms underlying the 
development of injury. 
To assess the leukocyte activation, we measured the expression level of L-
selectin on leukocytes in perfusate as well as the leukocytes in the lung homogenate 
samples.  The analysis of leukocytes in effluate allowed us to characterise the serial 
activation changes in leukocytes.  It was possible that washed-out leukocytes and 
residual leukocytes in the lung could show a different level of activation, but we 
confirmed that significant L-selectin shedding from residual leukocytes in lung 
homogenate was seen at the end of the experiments.  L-selectin is constitutively 
expressed on inflammatory monocytes and neutrophils, and upon activation of these 
cells, L-selectin is rapidly shed from the cell surface by TACE, regulation of which is 
via a ROS-mediated pathway (604).  In order to assess the time course, we 
measured L-selectin on leukocytes in the perfusate.  At the baseline (before the 
ischaemia), the L-selectin level in the I/R group was almost the same as the LPS+I/R 
group in neutrophils, but appeared to be decreased by pretreatment in Gr-1 high 
monocytes, potentially suggesting the activation of ‘already resident’ lung-
marginated Gr-1 high monocytes by LPS pretreatment, or that newly-recruited Gr-1 
	   219	  
high monocytes were activated.  The L-selectin was decreased after the ischaemia 
period as the expression significantly decreased on both inflammatory leukocytes.  
Reperfusion seemed to further decrease the expression level, probably suggesting 
the further activation of these leukocytes by reperfusion via ROS production (322, 
330).  Alternatively, it was possible that the IPL surgical preparation per se induced 
such leukocyte activation.  Although I confirmed that the L-selectin expression did 
not decrease up to 30 minutes from the start of perfusion, we do not know if the IPL 
preparation itself activates lung-marginated leukocytes after 2-3 hours from the start 
of perfusion. 
The LPS pretreatment increased the number of lung-marginated leukocytes, 
seemingly with a higher impact than that of the 2-hit VILI model (Fig 5.10).  Although 
we did not statistically analyse the data due to the small number of samples, this 
result might suggest the strong leukocyte-endothelial interaction within the lung 
during ischaemia, and thus more leukocytes remained in the lung rather than being 
washed out.  Alternatively, it was possible that the route of systemic LPS injection 
(intraperitoneal injection in Chapter 5, and intravenous injection in Chapter 6 to 
further facilitate the leukocyte recruitment to the lung) made this difference.  
However, our previous in vivo experiments similarly showed LPS-induced priming 
effects by both administration routes (219, 446), with little obvious difference. 
As discussed above, we considered monocyte-endothelial interaction may be 
a key in the I/R model.  To investigate this aspect, we measured E-selectin as a cell 
activation marker for pulmonary endothelium.  The significant elevation of E-selectin 
suggests that both monocytes and endothelium were activated by the LPS 
pretreatment.  Although we only found the difference in the upregulation of E-selectin 
by comparing the % positive events on pulmonary endothelium due to the small 
	   220	  
signal-noise ratio, this form of analysis is an established method (472, 473).  Further 
technical improvements to increase the signal-noise ratio of the E-selectin 
measurement or measuring other soluble endothelial activation markers such as 
glycocalyx and von Willebrand factor (605, 606) should be useful to further support 
the evidence of endothelial activation.  In order to further clarify the mechanisms 
behind the monocyte-endothelial interaction in the lung, we originally planned to 
deplete monocytes in this donor lung injury model, and investigate the effect of 
monocyte depletion in terms of these cell activation markers.  However, we had an 
unexpected problem relating to the clodronate manufacture.  The new batch of 
clodronate-liposome injection caused massive pulmonary haemorrhage because of 
pulmonary embolism, probably due to the aggregation of liposome molecules.  
Although we attempted to solve this by sonication and washing, we were unable to 
remove the problem.  Therefore unfortunately, we have not been able to complete 
this set of experiments. 
Flow cytometric analysis of cell activation was also attempted in the previous 
chapter (i.e. VILI model), but we were unable to detect any significant changes from 
the analysis.  In contrast, we were able to detect the cellular activation in 
endothelium and leukocytes in this donor lung injury model.  It is likely that the static 
incubation of the monocyte-endothelial ‘co-culture’ and autocrine effects during the 
ischaemic period (i.e. cells are further activated by accumulated mediators that have 
been produced by the cells themselves) amplified the monocyte-endothelial 
interaction, leading to the dramatic enhancements in the permeability increase and 
the TNF production. 
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In summary, we have shown that subclinical endotoxaemia exacerbated in situ I/R 
injury, suggesting the impact of donor lung injury in developing PGD.  Since the 
monocytes are one of the main producers of the TNF, I hypothesise that monocyte-
endothelial interaction was enhanced by the pretreatment and produced higher TNF, 
resulting in the exacerbation of the I/R injury.  Our results also indicated that such a 
subclinical infection may not be reflected by physiological parameters, despite the 
dramatic outcome difference.  Since we have a good opportunity to access to the 
pulmonary circulation in the transplantation setting (i.e. EVLP), further investigation 
of the lung-marginated monocytes and their interaction with pulmonary endothelium 
in I/R injury may help develop novel preventive therapies for PGD. 
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7. Final discussion 
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7.1. Summary of the findings 
In this PhD project, we developed a mouse IPL model to address previously 
unanswered questions in ALI.  Our main intentions were two-fold: 1) Elucidate the 
pathophysiology of VILI by comparing an atelectrauma and high-stretch model; 2) 
Elucidate the role and mechanism of lung-marginated monocytes in ALI. 
 In Chapter 3, we characterised the lung physiology and the kinetics of lung-
marginated leukocytes during the perfusion.  We found that the mouse lung contains 
∼10 million leukocytes and the modified recirculating perfusion effectively retained 
the majority of leukocytes within the system. 
 Using the optimised system, we successfully developed two VILI models of 
different aetiology in Chapter 4; i.e. atelectasis and high-stretch.  Removal of PEEP 
and recruitment manoeuvres induced atelectasis-related lung injury without any 
other insults and the comparison of the two VILI models revealed that high-stretch 
produced much higher amounts of pro-inflammatory cytokines, compared to 
atelectasis.  The results also raised a question to the current decompartmentalisation 
paradigm and suggested that high-stretch may activate not only the intra-alveolar 
components, but also the intravascular components. 
 Based on the hypothesis, we investigated the role of lung-marginated 
monocytes in VILI in Chapter 5.  Indeed, monocyte depletion effectively attenuated 
pulmonary oedema and systemic cytokine release in the high-stretch model, but not 
in the atelectrauma model.  Furthermore, our results indicated that the lung-
marginated monocytes might be also involved in intra-alveolar cytokine production. 
 Since the high-stretch model had a model-related variability which limited 
ability to further investigate the detailed mechanism of lung-marginated monocytes, 
we developed a more translational model of PGD and donor lung injury in Chapter 6, 
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to clarify the role of lung-marginated monocytes.  LPS pretreatment, as a model of 
donor lung injury, primed the lung towards increased alveolar-capillary permeability 
and cytokine production both into the perfusate and lung lavage fluid.  At a cellular 
level, the donor lung injury model activated pulmonary endothelium and (potentially) 
lung-marginated leukocytes, suggesting the monocyte-endothelial interaction might 
enhance the TNF production and barrier dysfunction. 
 In this final discussion, I would like to integrate and discuss some of the key 
findings in this project. 
 
 
7.2. Reappraisal of the biotrauma theory 
What are the Injurious lung-borne mediators in VILI? 
Since the biotrauma theory was proposed, too many candidates have been 
proposed as injurious without careful interpretation/analyses.  This theory is very 
attractive, since it opens the way to a novel pharmacological therapy for VILI and 
resultant MODS, both of which are still major problems in ICU.  However, the 
biotrauma theory itself is still a hypothesis, because of the difficulty to distinguish 
‘therapeutic target mediators’ from biomarkers.  In fact, proving the causative agents 
may need various approaches like Koch’s postulates (236). 
For instance, TNF has been consistently implicated in VILI for more than 10 
years (201, 537, 607), but antibody blockade of TNF was not successful in the past 
clinical trials (608, 609).  This may be because of the complex TNF biology, where 
the two receptors, TNFR1 and TNFR2, have opposite roles in VILI.  Using knockout 
mice, we have previously shown that the TNFR1 knockout mice were protected, but 
TNFR2 knockout mice were more vulnerable to VILI (209).  In line with this, we 
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recently found the specific targeting of intra-alveolar TNFR1 was effective to 
attenuate VILI (561).  In order to obtain this result, we needed to wait for the 
technical advancement, which allowed us to use novel IgG fragment antibody 
(known as domain antibodies) to TNFR1.  When we further explore the clinical 
application of this treatment, we also have to consider how we can effectively 
administer the antibody.  For instance, inhomogeneous inflation status of injured lung 
makes it difficult to equally deliver the intratracheally administered reagents.  
Similarly, although hypoxic pulmonary vasoconstriction (HPV) is somewhat impaired 
in patients with ALI, HPV is still operative in most patients (610).  Because of this, 
systemically administered drugs may not be able to achieve the effective 
concentration at the injured lung regions.  As such, while knockout mice are useful to 
explore the novel therapeutic targets, it is only the first step of the future clinical 
application; we need to further test the efficacy of pharmacological blockades, 
pharmacokinetics, and then the three phases of human clinical trials. 
The results from this PhD project may add some insights to the biotrauma 
hypothesis.  I measured levels of the mouse analogues of IL-8 (KC and MIP-2), and 
TNF in several occasions.  IL-8 is a neutrophil chemoattractant (611) and considered 
to be a very important factor developing VILI (205), because neutrophils are 
implicated in VILI (208, 612).  IL-8 is also known to activate neutrophils (611), thus 
this chemokine should activate the lung-marginated neutrophils in the IPL system.  
Similarly, as described above, TNF is also implicated in VILI.  Nevertheless, in 
Chapter 3, the accumulation of lung-borne mediators including TNF, KC and MIP-2 
did not cause a significant alveolar-capillary barrier dysfunction - even when the 
cytokine concentration reached to 10-100ng/ml (when we used general-grade BSA, 
as opposed to low endotoxin BSA, and recirculating circuit without perfusate 
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exchange), the permeability rarely changed.  The above results indicate that barrier 
dysfunction does not necessarily correlate with cytokine levels, at least not MIP-2, 
KC and TNF.  This finding is in line with the previous literature that showed LPS-
induced perfusate cytokine increases did not cause pulmonary oedema in mouse 
IPL (195).  Another study using rat IPL also showed TNF application into the 
perfusate did not cause permeability changes (531, 613). 
In contrast, in Chapter 4, non-recirculating perfusion seemed to attenuate the 
alveolar-capillary permeability in the atelectrauma model, suggesting that 
accumulated mediators can enhance the development of VILI.  It may be because 2-
hit (mediators plus injurious ventilation) was needed to aggravate the pulmonary 
oedema.  For instance, alveolar-capillary permeability is determined by the 
permeability of two barriers (endothelial and epithelial barrier), and the ‘injurious’ 
mediators might only affect the endothelial barrier permeability, but making a 
significant pulmonary oedema may need epithelial barrier breakdown by injurious 
ventilation.  The bottom line we can draw from our results is that TNF or IL-8 does 
not cause pulmonary oedema per se, and ‘yet unidentified factors’ or combinations 
of insults may be produced in response to injurious ventilation. 
Regarding the ‘yet unidentified factors’, Jaecklin and Kavanagh recently 
conducted a thought-provoking study (237).  They took the perfusate from an 
isolated lung ventilated with either normal or high tidal volume, and transferred the 
perfusate to another IPL system, which was ventilated with normal tidal volume.  
This transfer caused lung injury to the ‘recipient’ IPL only when the perfusate was 
taken from the high-stretch lung, suggesting the over-stretched lung produced a 
humoral factor capable of causing lung injury.  They tried to characterise the factor 
responsible for the recipient injury, and suggested the pathogenic factors were lipid-
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soluble and protein-bound molecules.  Although these lipid-mediators such as TXB2, 
PGD2, and PGE2 were correlated with lung injury in their model, inhibition of these 
mediators by ibuprofen, a cyclooxygenase inhibitor, failed to attenuate the lung 
injury.  Importantly, the concentration of IL-6, TNF, and MIP-1a in the donor 
perfusate did not correlate with the development of lung injury in the recipient IPL. 
However, the interpretation of such IPL studies must be done carefully for 
various reasons, particularly when we attempt to identify such injurious mediators.  
Firstly, lung is not a primary target of the lung-borne mediators – extrapulmonary 
organs first receive and respond to the mediators, hence lung would receive both 
lung-borne mediators and the newly-produced (by extrapulmonary organs) 
‘secondary’ mediators.  In fact, since patients with ALI often die from MODS rather 
than acute respiratory failure, the effects of these lung-borne mediators to the 
extrapulmonary organs are very important aspects.  Markovic and colleagues (524) 
used a similar approach as the aforementioned Jaecklin paper, but the perfusate 
from lungs were used to stimulate liver endothelial cell lines or neutrophils.  They 
showed that the perfusate from the lung challenged with LPS inhalation contained 
much higher amounts of various cytokines and activated the liver endothelium and 
neutrophils. 
Secondly, as I discussed in Chapter 3, the artificial perfusate consisting of 
physiological buffer and colloid without blood components is not a genuine 
propagation mediator, hence may modify various effects.  For instance, lack of Duffy 
antigen receptor for chemokines (DARC) on erythrocytes may have exaggerated the 
concentration of KC and MIP-2, or lack of plasma protein may result in the absence 
of some mediator productions. 
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It has to be also considered that the IPL setting can be easily contaminated.  
Through the project, I noticed daily cleaning protocol as well as the sterile handling 
of the perfusate make significant impacts on the IPL, particularly pro-inflammatory 
cytokine production.  As shown in chapter 3, the standard quality of BSA clearly 
increased the cytokine response, although this BSA is universally used for various 
experiments.  That may suggest the high sensitivity to the contaminants of the IPL 
setting.  To overcome that potential problem, testing other agents such as clinical 
grade human albumin may be an option.  Alternatively, the cleaning protocol can be 
more standardised if we can develop a very sensitive assay system to detect all the 
contaminants, possibly by bioassay.  Although we paid special attention to decrease 
endotoxin, other contaminants might have still contributed to the high level of 
cytokine production in the non-injurious setting as shown in the project. 
There are some new approaches to identify the novel candidates for the 
injurious mediators.  The cutting-edge ‘systems biology’ approach including 
metabolomics should allow us to simultaneously analyse the changes in thousands 
of small molecules and identify the candidates by bioinformatics techniques (614).  
Historically, circulating mediators mean either chemical compounds such as 
cytokines and lipid mediators, or cells including erythrocytes and leukocytes.  Recent 
research revealed a third family of circulating mediators, known as microparticles.  
Microparticles are plasma membrane-derived vesicles shed from activated cells and 
play a role in the remote intercellular communication (615).  Investigation of such 
new mediators may be important and in fact has been implicated in some animal ALI 
models (616-618).  These new approaches may help a more detailed analysis to 
identify novel injurious mediators from the numerous candidates. 
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Reappraisal of the decompartmentalisation paradigm 
My project may provide some insights into the cellular sources and propagation 
mechanism of the lung-borne mediators in VILI.  It was often considered that high-
stretch mainly affects the intra-alveolar space rather than vascular space and hence 
these mediators should be produced by intra-alveolar components, including 
pulmonary epithelium and alveolar macrophages.  Based on this interpretation, 
decompartmentalisation theory became a well-accepted concept to explain the 
development of MODS in the patients with VILI (245, 248).  In this project, we 
demonstrated in Chapter 4 that the decompartmentalisation paradigm may not be 
always correct – despite the severe barrier dysfunction and intra-alveolar cytokine 
production, systemic cytokines were not increased in the atelectrauma model.  
Therefore, instead of decompartmentalisation, we hypothesised the ‘whole lung 
activation’ theory.  Previous papers (107, 218, 254-256) indicated that the 
intravascular component may also be directly activated by high-stretch.  Dreyfuss et 
al. reported that short periods (5 or 10 minute) of high-stretch resulted in endothelial 
bleb with permeability oedema, suggesting that endothelial injury is an important 
trigger in the pathogenesis in high stretch-induced lung injury (107).  Since high-
stretch causes activation of ‘whole lung’ (i.e. both intra-alveolar and intravascular 
components), we hypothesised that the intravascular activation may be responsible 
for the high cytokine concentration in the intravascular space (i.e. perfusate).  In line 
with this hypothesis, I have shown in Chapter 5 that lung-marginated monocytes 
were important in that cytokine production process.  Because lung carries a 
substantial number of leukocytes in the microcirculation as shown in Chapter 3, it is 
likely these lung-marginated leukocytes also contribute to producing the lung-borne 
cytokines in response to high-stretch.  These leukocytes may be activated via 
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endothelial stretch and subsequent leukocyte-endothelial interaction, or might be 
deformed and activated by inflating alveoli. 
To further clarify the mechanisms of inflammatory propagation, it is essential 
to identify the cellular sources of the cytokines.  For instance, we have recently 
developed in vivo flow cytometric detection technique of intracellular signalling 
molecules (563), and this technique can be used to detect intracellular cytokine 
production (619).  Perfusion of metalloproteinase inhibitors (e.g. BB94) may further 
help the intracellular cytokine detection, because that blocks the extracellular 
secretion of cytokines (445, 446, 456), and hence should improve the sensitivity of 
detecting intracellular cytokines (e.g. TNF) by FACS. 
Historically, intra-alveolar delivery of drugs has been considered to be more 
effective (despite the difficulty of intratracheal drug application) in the treatment of 
VILI (173, 243, 561), because the intra-alveolar space was considered to be the 
main place where inflammation occurs.  The above results give us an idea that 
intravascular approach of pharmacological intervention may be an effective therapy 
for VILI.  Because intravenous drug application is technically much more feasible in 
patients with VILI, targeting monocytes, pulmonary endothelium, or the interaction 
(e.g. monoclonal antibody for VLA-4) between them may open the way to develop a 
novel effective intravenous therapy for VILI. 
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7.3. The role of lung-marginated monocytes and their direct 
contact/interaction with pulmonary endothelium 
Historically, monocytes in the marginated pool were considered to be a transient 
population, which is waiting to return into the systemic circulation, transmigrate into 
the tissues, or maturate and become macrophages or dendritic cells.  In this project, 
we have demonstrated mouse lung contains a surprisingly large marginated pool 
and the lung-marginated monocytes by themselves can play a role in ALI including; 
1) pulmonary oedema; 2) systemic cytokine release; 3) potentially regulation of intra-
alveolar cytokine production.  Lung-marginated monocytes may induce the above 
responses through the soluble mediators and/or direct cellular contact with 
pulmonary endothelium.  Since I already discussed about the soluble mediators 
above, here I focus on the relative importance of neutrophils and monocytes, and the 
role of direct contact-dependent interaction between monocytes and endothelium. 
 
Monocytes vs. neutrophils – which are more important? 
The main focus of leukocyte involvement in ALI has been neutrophils, and this 
project sheds light on the importance of monocytes, in particular lung-marginated 
monocytes.  The patrolling role of Gr-1 low resident monocytes in the marginated 
pool has been shown by Auffray et al. (422), but the role of Gr-1 high inflammatory 
monocytes in the marginated pool has not been well elucidated except for our recent 
studies (219, 446) and my project.  Our results indicated that the lung-marginated 
Gr-1 high ‘inflammatory monocytes’ may play a critical role in ALI.  Although our 
results do not directly disprove the importance of neutrophils in developing ALI, the 
role of monocytes should be more appreciated.  In fact, ALI can develop in 
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neutropenic patients (620) and neutrophils recruitment per se may not be sufficient 
to cause VILI (621). 
The interrelationship between monocytes and neutrophils still remains to be 
elucidated, but there is some emerging evidence about the interaction between the 
two leukocyte subsets.  Using chimeric C-C motif chemokine receptor 2 (CCR2) KO 
mice, Maus et al. showed that Gr-1 high (CCR2 positive) monocytes may facilitate 
the neutrophil transmigration into the lung tissue (569).  Quinn et al. recently showed 
on the other hand that human neutrophil peptides from activated neutrophils 
enhance the monocyte-endothelial interaction (622). 
Although the role of neutrophils should still be considered central in 
developing ALI, the contribution of monocytes should be re-evaluated in light of the 
emerging evidence from this project and others. 
 
What is the significance of monocyte-endothelial interaction? 
In Chapter 6, I have shown the dramatic enhancement of TNF production in the 
donor lung injury model, probably via the monocyte-endothelial interaction.  It has 
been well documented that the arterial regions exposed to reduced shear stress are 
subject to atherosclerosis (623-626) because of enhanced monocyte-endothelial 
interaction (627-630).  Reduced blood flow is considered to decrease NO production 
from endothelium and consequently facilitates monocyte-endothelial interaction and 
the development of atherosclerosis (631).  Recent evidence indicated that 
inflammatory Gr-1 high monocytes may be predominantly involved in this interaction 
(632, 633).  Considering these points, it is likely that the increased number of Gr-1 
high monocytes and cessation of blood flow substantially enhanced the monocyte-
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endothelial interaction in my IPL model, leading to a TNF production and alveolar-
capillary barrier dysfunction. 
To further investigate the mechanism of the interaction, an acquired chimeric 
system should give us some insights.  Bone marrow chimera is often produced by 
total body irradiation to deplete recipient-originated haematopoietic cells followed by 
the transfer of donor bone marrow cells.  This procedure takes several weeks for the 
donor haematopoietic stem cells to normally produce the blood cells, and can affect 
other radiosensitive organs including testis and intestine.  With the IPL, in addition to 
the conventional total body irradiation, temporary (and regional) depletion of lung-
marginated monocytes can be achieved by antibody or pharmacological reagents.  
Therefore, a chimera can be made by combining the depletion techniques with the 
‘leukocyte reconstitution’ within the IPL recirculating circuit.  For instance, after 
depleting the lung-marginated monocytes with clodronate-liposomes or total body 
irradiation, we may be able to replenish them by introducing monocytes into the 
recirculating perfusion system for a certain period.  By utilising monocytes from 
genetically altered animals (e.g. taking the ‘donor’ monocytes from TLR4 KO mice), 
we should be able to achieve the chimeric system (e.g. only lung-marginated 
monocytes are TLR4 negative).  Various ideas can be considered with the chimeric 
system.  Using monocytes from TNF knockout mice should clarify the primary source 
of TNF in perfusate.  Interaction mechanisms can be also investigated by using cells 
from (for example) adhesion molecule knockout donors. 
 
 
	   234	  
7.4. What is the best ventilation strategy – is the open lung 
strategy useful? 
In clinical settings, clinicians sometimes face a controversy to determine the optimal 
ventilation setting because the relative importance of low tidal volume and high 
PEEP is not known (103).  While low tidal volume aims to decrease the end-
inspiratory lung volume, the lower inspiratory pressure may not be sufficient to 
overcome the regional opening pressure, and thus facilitates the atelectasis (634, 
635).  On the other hand, high PEEP aims to increase the end-expiratory lung 
volume, though high PEEP can facilitate excessive end-inspiratory stretch – a 
dilemma exists here (466). 
There is a still ongoing argument about the usefulness of open lung strategy – 
although the open lung strategy is beneficial in animal experiments, clinical trials 
have failed to show the mortality benefit (162, 172-174).  These negative results 
have been often attributed to the technical reasons to determine the optimal PEEP 
and underpowered studies, or adverse effects on cardiac output by the increased 
pleural pressure (636).  However, our results may give an alternative point in this 
discussion.  Patients with ALI often die from MODS and acute respiratory failure 
accounts for only 10-20% of the mortality in these patients (37), while soluble 
mediators are considered to be responsible for the development of biotrauma in 
MODS (240, 538).  In this project, we have demonstrated in Chapter 4 that 
atelectasis does not facilitate systemic cytokine release, and this finding is in line 
with the recent clinical evidence (528, 549).  Those results may provide insights into 
why addition of PEEP to limit atelectasis, has limited clinical outcome benefit in 
ventilated patients with ALI.  This fundamental difference in the inflammatory impact 
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between volutrauma and atelectrauma might be important in the search for a better 
mechanical ventilation strategy. 
With regard to the future plans, the two models of different aetiologies are 
very useful to elucidate the mechanisms behind MODS in ventilated patients.  For 
instance, transferring perfusate onto the cultured extrapulmonary cells (e.g. liver and 
kidney cells) and look at the responses (e.g. apoptosis) may be useful to further 
investigate the biological effects of lung-borne mediators following 
volutrauma/atelectrauma.  The atelectrauma model is also useful to highlight the 
specific molecular mechanisms, because the repetitive opening and collapse theory 
in the development of atelectrauma is still controversial (146).  The investigation of 
individual cellular activation by FACS in the atelectrauma model should be able to 
clarify the pathophysiology in atelectrauma.  Using the macrophage depletion 
technique by intratracheal clodronate-loaded liposome instillation, alveolar 
macrophages have been implicated in high-stretch induced VILI (213, 214).  We can 
take the same approach to investigate the involvement of alveolar macrophages 
specifically in the atelectrauma model. 
 
 
7.5. Further application of IPL model for ALI research 
In this project, we utilised and modified the mouse IPL preparation to develop 
several unique experimental techniques/models.  I believe the application of IPL 
model is even more extensive. 
Recent studies are revealing previously unappreciated functions of 
intravascular immunity (407), but the tools to investigate this area are still developing.  
New imaging approaches, including intravital microscopy (637) and two-photon 
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imaging (638), elucidated the behaviour of immune cells within the vasculature (422, 
443), but these studies were mainly placed in the postcapillary venules in skin, 
intestine, or cremaster muscle due to their accessibility.  Despite the large number of 
marginated cells, lung intravascular immunity has been poorly investigated.  By 
combining the blood-perfused IPL system and these imaging techniques, we should 
be able to visualise how the lung-marginated leukocytes behave. 
IPL is also useful in search of the therapeutic application.  For instance, the 
donor lung injury model is a very useful experimental model to reveal the 
pathophysiological mechanisms behind lung transplantation.  If the monocyte-
endothelial interaction is indeed crucial in this model, we can modify the interaction 
by perfusion with antibodies (e.g. CD18 antibody (639)) without any systemic side 
effects.  In fact, we have previously tested anti-CD18 antibody to intervene the 
monocyte-endothelial interaction in vivo, but resulted in increasing the number of 
lung-marginated leukocytes.  This was probably because the antibody blocked the 
leukocyte-endothelial interaction in the other extrapulmonary organs and the 
demarginated leukocytes were repopulated to the lung.  IPL system should address 
such a technical problem.  Importantly, this technique can be easily applied in the 
clinical setting (i.e. perfusing with antibodies during EVLP), because we do not need 
to administer the antibody to the donor.  As such, similarity between IPL and EVLP 
makes the I/R model very translatable and close to the therapeutic application. 
 Depending on the future direction, further model refinement/characterisation 
may be considered.  For instance, characterisation of glycocalyx may be important in 
this system.  Glycocalyx is similar to a biofilm on the endothelial surface (640), and 
previous literature showed this can also work as a mechanical transduction sensor, 
which eventually induce ROS and/or nitric oxide production (641).  Removal of the 
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glycocalyx layer (e.g. by shedding due to inflammation or enzymatic degradation) 
exposes the adhesion molecules including selectin, hence this may be an important 
step for leukocytes to interact with endothelium and progression of inflammation 
(642).  However, the mechanisms how the glycocalyx comes off have not been well 
elucidated.  One of the difficulties of the investigation of glycolcalyx is ascribed to the 
fact that in vitro endothelial culture system may lack this layer under the normal 
culturing condition (643).  Therefore, if we are able to maintain glycocalyx within the 
IPL system, it will be a good opportunity to investigate its degradation/shedding 
mechanisms and develop a novel therapy, which protects glycocalyx from various 
insults.  Technically, it is possible that the glycocalyx was washed out by the 
perfusion, thus some optimisation might be needed to maintain such a physiological 
structure. 
 
 
7.6. Concluding remarks 
In summary, we have developed a technically very challenging mouse IPL model 
and characterised the kinetics of lung-marginated leukocytes.  We utilised the IPL 
model to develop a ‘pure’ atelectrauma model, which highlighted the distinct 
inflammatory effects in the different aetiologies of VILI and the necessity of 
reappraisal of the current decompartmentalisation paradigm.  My findings also 
revealed that the lung-marginated monocytes are an important factor in developing 
pulmonary oedema and cytokine production in 2 models of ALI (i.e. high-stretch and 
I/R injury). 
My results raise a question to the clinical concept of ALI/ARDS itself.  ARDS 
was originally proposed in 1967 by Ahsbaugh et al. as a clinical syndrome (1), 
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secondary to a collection of variable primary causes.  The AECC definition of 
ALI/ARDS in 1994 (2) has been useful to conduct a large randomised controlled 
trials investigating supportive therapies etc.  However, that definition might have 
promoted a misleading concept as if ALI is a single disease entity.  For instance, 
mesenchymal stem-cell therapies demonstrated some promising results in preclinical 
models and are being considered as a novel therapeutic agent for ALI (644).  
However, when we consider the varied pathophysiologies underlying ALI/ARDS, it is 
probably too naïve to think there are universal therapies.  In this project, I showed 
that lung injury caused by different insults such as atelectasis, high-stretch, and 
ischaemia-reperfusion induces clearly different effects, although the ‘gross’ 
pathophysiological findings of altered respiratory physiology and permeability may at 
first glance look similar.  This fact clearly suggests we should not easily generalise 
new findings gained from a specific experimental model, without careful 
considerations and validations. 
Lung is usually considered to be a respiratory organ, but our findings suggest 
that the lung also works as an important immune organ, where the large number of 
lung-marginated leukocytes sense, respond, and sometimes spread the 
inflammatory responses.  This may explain why ALI is a common complication to 
systemic inflammatory response syndrome (SIRS) (645), and ALI sometimes results 
in increasing plasma cytokines, leading to MODS.  Understanding the function and 
regulation mechanisms of these lung-marginated pools may be crucial to decrease 
the mortality in the ICU. 
The IPL model provides various opportunities to manipulate/analyse the 
specific cellular components, and their resultant immunoregulatory mechanisms.  I 
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strongly believe utilising this model to bridge between the in vivo and in vitro 
experiments will open the ways to develop novel treatments for ALI patients. 
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